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Abstract
Abstract
Xenotransplantation of porcine organs into humans provides a potential solution to the 
current shortage of human donor organs, but raises considerable safety concerns 
including the potential transmission of porcine infectious agents, particularly viruses, to 
humans. Porcine cytomegalovirus (PCMV) is a betaherpesvirus, which causes 
generalised infection in newborn piglets. It is endemic in world pig populations 
including those of high health status, and is transmitted horizontally and in utero. 
PCMV represents a potential risk in xenotransplantation since its human counterpart, 
HCMV, is frequently transmitted from the organ donor and reactivates posttransplant, 
where it is associated with end-organ disease and graft rejection.
Qualitative and quantitative PCR assays were developed in order to investigate the 
quantity and organ distribution of PCMV in pigs being bred for xenograft organs, and to 
investigate when virus is acquired. PCMV was found to be a common infection in 
conventionally-reared CD55 transgenic Large White pigs, with virus detected in 
potential xenograft organs of adult pigs, and widely disseminated in tissues of 3-5 
week-old piglets. Prospective monitoring of piglets from birth showed that virus was 
acquired post-natally, whilst no evidence of in utero infection was found in caesarean- 
derived, barrier-reared piglets. Although these results showed that PCMV could be 
eliminated from pigs being bred for xenograft organs, knowledge of antiviral 
susceptibility is essential as it would provide therapeutic options should clinical trials 
proceed. The effect of antiherpetics on the growth of PCMV in a pig fallopian tube cell 
line was determined by real-time PCR and indirect immunofluorescence (IIF). In this 
cell culture model, ganciclovir and cidofovir were the most effective against PCMV 
replication, however, some cytotoxicity was associated with the highest concentration 
of cidofovir tested. Finally, a recombinant protein-based serological assay for PCMV 
was developed, utilising PCMV glycoprotein B expression in a baculovirus system.
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Chapter 1: General introduction
1.1 Overview to xenotransplantation
1.1.1 Current organ shortages
Experimental transplantation for the treatment of organ failure was performed as early 
as the eighteenth century, although successful graft survival has only been achieved in 
the past 50 years. The first successful kidney and liver transplants were carried out in 
the United States in 1954 and 1967 respectively (Starzl, 2000; Starzl et al, 1963), while 
the first successful heart transplant was performed in South Africa in 1967 (Reitz, 
2002). Following advances in tissue typing and immunosuppression, transplantation has 
become the favoured treatment for the failure of vital organs. In 2003, 25,457 whole- 
organ transplants were carried out in the US, while 2,222 were performed in the UK 
(The US Organ Procurement and Transplantation Network/Scientific Registry of 
Transplant Recipients (OPTN/SRTR) Annual Report, 2003; UK Transplant), with the 
most commonly transplanted organ being the kidney, although heart, liver, lung and 
pancreas transplants are also commonly performed (Figure 1.1). However, the 
increasing success of transplantation has lead to a chronic shortfall in human donor 
organs. This is illustrated in Figures 1.2 and 1.3, which show that the number of people 
awaiting solid-organ transplants in the US and UK has increased dramatically over the 
past 10 years, while the number of transplants being carried out has been limited by the 
number of available donor organs. Such chronic organ shortages mean that patients may 
wait a long time for a transplant, with many dying before a suitable donor organ is 
found. In the US in 2002, more than 6,000 patients were reported to have died while 
waiting for a transplant (The US OPTN/SRTR Annual Report, 2003). Since 
transplantation is becoming increasingly necessary in the treatment of many illnesses, 
this trend is likely to continue unless a solution can be found.
1.1.2 Potential solutions to the human organ shortage
Improvements in modem medicine mean that an increasing proportion of the human 
population is living into old age. With most people dying from cancer and heart disease, 
as well as a reduction in the number of deaths in road traffic accidents, fewer organs are 
becoming available for transplant. In addition, many potential donor organs are wasted 
because of a lack of public awareness of organ donation programmes, issues of consent,
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Kidney 59.2%
P ancreas 0.6%
Pancreas after kidney 1.5% 
K idney-pancreas 3.7%
Liver 20.6%
Intestine 0.2%
Heart 8.6%
Lung 4.2%
Heart-lung 0.1 %
Multi-organ 1.3%
Figure 1.1. Transplants in the US in 2002 by organ type (N=24,544) (The US 
OPTN/SRTR Annual Report, 2003).
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Figure 1.2. US waiting list and transplants 1993-2002 (The US OPTN/SRTR Annual 
Report, 2003).
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Figure 1.3. UK waiting list and transplants 1994-2003 (UK Transplant).
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and problems associated with procurement of organs. While improvements in these 
areas will undoubtedly increase organ availability, in the long-term they are still 
unlikely to provide sufficient organs to meet increasing demand. Even with initiatives to 
promote healthy lifestyles, and vaccination programs, there are many conditions for 
which transplantation is the only option.
Significant improvements in artificial organs such as dialysis and the mechanical heart, 
which are currently used in the short-term treatment for organ failure, will need to be 
made if they are to provide an alternative to transplantation altogether. Bioartificial 
alternatives such as the use of ‘transgenic cloning’ to produce organs from human cells 
provide the most attractive solution in the long run, but limited understanding of the 
control of complex developmental events, means that success in this area is still some 
way in the future. It is clear that an alternative mid-term solution is required, with one 
possibility being xenotransplantation.
1.1.3 Xenotransplantation
Xenotransplantation is defined as any procedure that involves the transplantation, 
implantation, or infusion into a human recipient of either (a), live cells, tissues, or 
organs from a nonhuman animal source or (b), human body fluids, cells, tissues or 
organs that have had ex-vivo contact with live nonhuman animal cells, tissues, or organs 
(Centres for Disease Control and Prevention, 2001). The use of animal organs as an 
alternative to human organs in transplantation has been the subject of intense research 
over the past two decades. The major attraction of this approach is the potential for an 
unlimited supply of fresh and undamaged organs. This means that the transplant can be 
planned in advance, allowing for pre-treatment of the recipient, for example, with 
therapies to prevent rejection. Ischaemia time could be reduced thereby preventing 
inflammation and tissue damage which is thought to contribute to graft rejection. It also 
means that the transplant can be performed as soon as it is needed, rather than making 
the patient wait, while their health deteriorates. One advantage of using animal organs 
over human organs is that they may avoid recurrence of disease in the graft, for 
example, they may be resistant to viruses such as human immunodeficiency virus (HIV) 
or hepatitis B virus (HBV), already present in the recipient. In addition, animal donors 
can be genetically manipulated to improve organ acceptability and biochemical
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functioning within the host, and through breeding techniques it may be possible to 
reduce the risk of transmission of animal pathogens. Although the definition of 
xenotransplantation encompasses a whole range of therapies including cellular 
xenografting and extracorporeal perfusion, the use of solid-organ xenografts is the 
‘Holy Grail’ of xenotransplantation and will therefore be the focus of this thesis.
1.1.4 Experience with clinical solid-organ xenotransplantation
Several attempts at solid-organ xenotransplantation were made early in the 20th century 
using kidneys from various mammals including rabbits, pigs, goats, sheep and 
nonhuman primates (Table 1.1). Although in most of these cases there was no graft 
function, and grafts were lost to thrombosis within hours, patient survival was reported 
up to 16 days (Reemtsma et al, 1964b). Interest in this approach diminished after it 
became clear that both xenografts and allografts were subject to a powerful immune 
response, which resulted in graft failure.
In the 1960s, following demonstration of the effectiveness of immunosuppressive drugs, 
including azathioprine and corticosteroids to prevent rejection, there was renewed 
interest and success with human-to-human allotransplantation. However, problems 
associated with organ procurement and preservation lead to a shortage of human organs, 
and so the possibility of using animal organs was again explored. Hearts, livers and 
kidneys from animals were transplanted into human patients, although the greatest 
success in terms of graft survival was achieved with kidney xenografts. Of note, are the 
attempts by the groups of Reemtsma and Starzl. Reemtsma et al performed a series of 
transplants using kidneys derived from chimpanzees, with grafts surviving on average 
between 11 days to 2 months, with one patient surviving 9 months (Reemtsma et al, 
1964a; Reemtsma et al, 1964b). Starzl et al transplanted kidneys from baboons with 
graft survival ranging from 19-60 days (Starzl et al, 1964). The majority of deaths in all 
cases were related to rejection or infection, often resulting from over­
immunosuppression. The results of these studies suggested that chimpanzees, rather 
than baboons, provided the most suitable source of nonhuman primate donor organs, 
since the increased disparity between baboons and humans meant that their organs were 
rejected more aggressively than those from chimpanzees. Starzl also transplanted 
chimpanzee livers into three patients, but survival was limited to 9 days (Taniguchi &
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Table 1.1. World experience in clinical solid-organ xenotransplantation (Taniguchi & 
Cooper, 1997).
Year Surgeon Donor Number Patient survival
RENAL
1905 Princeteau Rabbit (kidney slices) 1 16 days
1906 Jaboulay Pig 1 3 days
Goat 1 3 days
1910 Unger Monkey 1 2 days
1913 Schonstadt Monkey 1 ?
1923 Neuhof Sheep 1 9 days
1964 Reemtsma Chimpanzee 12 <9 months
Monkey 1 10 days
1964 Hitchcock Baboon 1 5 days
1964 Starzl Baboon 6 <60 days
1964 Hume Chimpanzee 1 1 day
1964 Traeger Chimpanzee 3 <49 days
1965 Goldsmith Chimpanzee 2 <4 months
1966 Cortesini Chimpanzee 1 31 days
HEART
1964 Hardy Chimpanzee 1 <1 day
1968 Cooley Sheep 1 <1 day
1968 Ross Pig 1 <1 day
1969 Marion Chimpanzee 1 <1 day
1977 Barnard Baboon 1 <1 day
Chimpanzee 1 4 days
1984 Bailey Baboon 1 20 days
1992 Religa Pig 1 1 day
LIVER
1966 Starzl Chimpanzee 1 <1 day
1969 Starzl Chimpanzee 2 <2-9 days
1969 Bertoye Baboon 1 <1 day
1970 Lerger Baboon 1 3 days
1970 Marion Baboon 1 <1 day
1971 Poyet Baboon 1 <1 day
1971 Motin Baboon 1 3 days
1974 Starzl Chimpanzee 1 14 days
1992 Starzl Baboon 1 70 days
1993 Starzl Baboon 1 26 days
1993 Makowka Pig 1 <2 days
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Cooper, 1997). In the 1970s, great apes including chimpanzees, were recognised as 
endangered species, limiting their use in xenotransplantation. In addition, at this time, 
alternative therapies such as dialysis and cadaveric transplantation became available, 
and since xenograft rejection could not be controlled by the available 
immunosuppression, the procedure was stopped.
In the past 20 years, since the advent of the immunosuppressive agent cyclosporin A, 
allotransplantation has become increasingly successful. In 1984, cyclosporine therapy 
was given when a baboon heart was transplanted into a 13-day-old patient with 
congenital heart disease (Bailey et al, 1985). The heart functioned for 20 days before the 
organ was rejected, probably, in part, due to ABO blood group incompatibility between 
the donor and recipient. This is currently the longest survival time for a clinical heart 
xenograft. This case was the start of renewed efforts in clinical xenotransplantation 
(Czaplicki et al, 1992; Starzl et al, 1993; Makowka et al, 1994). Having been refused a 
human organ, Starzl et al transplanted a baboon liver into a male patient with HBV and 
HIV infection (Starzl et al, 1993). Although there was little evidence of rejection, the 
patient died after 70 days from an infection resulting from over-immunosuppression. 
Since 1993, no more solid-organ xenotransplantations have been performed.
1.1.5 Experience with clinical cellular, tissue and extracorporeal xenografting
Although there has been little activity with solid-organ xenotransplantation in the past 
decade, throughout this time several hundred patients have participated in clinical trials 
using cellular, tissue or extracorporeal xenografts (Council of Europe, 2000; Groth et al, 
1994; Buchser et al, 1996; Aebischer et al, 1996; Deacon et al, 1997; Schumacher et al, 
2000; Levy et al, 2000; Pascher et al, 2002). The cellular xenografts used in these 
studies have been derived from a variety of animals (Table 1.2), and have been used in 
the treatment of diabetes, Parkinson’s disease, Huntington’s chorea, stroke, pain 
associated with cancer or neurologic pain, spinal injuries, epilepsy, amyotrophic lateral 
sclerosis (ALS), and acquired immune deficiency syndrome (AIDS), while tissue 
xenografts have been used in the treatment of bums. The results of these studies 
demonstrate long-term survival (months) of xenogeneic cells in humans without a 
significant immune response, however, they provide little conclusive data on the 
efficacy of the treatments (Groth et al, 1994; Buchser et al, 1996; Aebischer et al, 1996;
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Table 1.2. World experience in clinical cellular xenografting during the 1990s (Council 
of Europe, 2000).
Graft Indication Number Country
Neonatal bovine Pain >100 Poland, Czech Republic,
cromaffine cells Switzerland & USA
Encapsulated transgenic ALS 6 Switzerland
hamster cells
Foetal porcine neurones Parkinson’s 21 USA
Huntingdon’s 12 USA
Epilepsy 3 USA
Stroke 3 USA
Foetal porcine islets Diabetes 10 Sweden
Neonatal porcine islets Diabetes 6 New Zealand
Foetal rabbit islets Diabetes Several 100 Russia
Baboon bone marrow HIV 1 USA
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Deacon et al, 1997; Schumacher et al, 2000). Extracorporeal perfusion of patient’s 
blood or plasma through bioartificial organs, such as the HepAssist device containing 
porcine hepatocytes, or whole pig organs, has been used in the treatment of liver failure. 
In particular, since 1964, 270 patients with acute, subacute or chronic liver failure have 
been treated with extracorporeal liver perfusion, using livers from six different species, 
with the pig being the most frequently used source (Pascher et al, 2002). Early cases 
were far from successful with long-term survival rates of 20 %, 10 % and 37 % in the 
late 1960s, 1970s and early 1980s, respectively. Long-term survival rates improved in 
the past decade (to 52 %), when the treatment was used for bridging until a suitable 
human organ was available for liver transplantation. In the most recent cases, porcine 
livers, transgenic for human (h) CD59 and hCD55, were used in two patients as a bridge 
to successful liver transplantation (Levy et al, 2000).
1.1.6 Donor animals
As previously described, xenografts have been derived from a variety of animal sources 
including rabbits, goats, and sheep, with the majority being derived from either pigs or 
nonhuman primates. The greatest success was achieved using organs from nonhuman 
primates, and in particular chimpanzees, because they were subject to a less aggressive 
immune response. However, there are significant problems associated with the use of 
nonhuman primate organs rather than those from other species. The close phylogenetic 
proximity of humans and nonhuman primates increases the risk of cross-species 
transmission of infectious agents, particularly viruses, including retroviruses (e.g. 
simian foamy virus and simian T-cell lymphotropic virus) and herpesviruses (Allan, 
1999; Michaels, 2003). In addition, nonhuman primates are expensive and time 
consuming to breed. With great apes including chimpanzees being protected species, 
they can no longer be used in xenotransplantation. Although baboons and several other 
small monkey species are available, it has been suggested that certain organs from these 
animals, such as the heart, would be too small for use in full-grown adult humans, 
which would restrict their use to children and small adults (Taniguchi & Cooper, 1997).
For a variety of practical and ethical reasons the pig has been identified as the most 
suitable potential donor animal for xenotransplantation. They have a high reproductive 
capacity, with a short gestation and large litters, providing a potentially unlimited
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supply of organs. In addition, they are relatively inexpensive to breed and maintain, 
when compared with nonhuman primates, and could be raised to obtain pathogen-free 
herds. Recent studies, to be discussed later, have shown that pigs can be genetically 
modified, for either prevention of rejection or therapeutic benefit. Porcine organs are 
also comparable to the size of human organs, and could therefore be used in both adults 
and children. Finally, the use of porcine organs, compared with those from nonhuman 
primates, is generally considered to be more ethical, since pigs have been farmed by 
humans for thousands of years.
1.1.7 Obstacles to xenotransplantation
In order to provide an adequate alternative to allografts, the xenograft must undergo 
successful engraftment, avoid immune destruction, and be physiologically compatible 
with the recipient. It is also important that the graft does not transmit infectious agents 
to the recipient. Currently, the three main barriers to successful xenotransplantation are 
immune rejection, physiological incompatibilities, and the risk of transmission of 
porcine infectious agents. Each of these obstacles will be discussed further in the 
following sections.
1.2 Immune Rejection
Rejection of transplanted tissues occurs upon revascularisation of the graft, when 
immune components in the circulation of the recipient, recognise and respond to foreign 
antigens expressed on the graft, and is the major hurdle to allotransplantation.
1.2.1 Rejection of allografts
The events involved in transplanting an organ, including tissue excision, transport and 
implantation, result in ischaemia and inevitable tissue damage, which initiate early 
proinflammatory responses. These activities promote immune surveillance, attracting T 
cells, monocytes, neutrophils and macrophages into the graft site, which are 
subsequently involved in the process of rejection (Orosz, 2002). This process comprises 
a series of events, clinically classified according to time frame and histology into; 
hyperacute, acute and chronic rejection.
32
Chapter 1: General introduction
Hyperacute rejection is mediated by pre-formed, circulating, graft-specific antibodies 
which bind to the endothelial lining of blood vessels of the graft, and lead to the 
activation of complement, coagulopathy and graft destruction within minutes to hours of 
reperfusion. These alloantibodies target either ABO blood group proteins, or foreign 
alloantigens which have been encountered previously during pregnancy, blood 
transfusion or a previous transplantation (Goldsby et al, 2000). If hyperacute rejection 
can be avoided, for example, by matching of blood groups, or pre-transplant screening 
of the recipient for the presence of circulating donor-specific antibodies, then the graft is 
susceptible to acute rejection in the weeks to months following transplant, 
predominantly mediated by T lymphocytes. T cells are initially activated by graft 
proteins in the lymph nodes and undergo proliferation, before being released back into 
the circulation where they are restimulated by alloantigens in the graft to secrete 
proinflammatory cytokines and carry out other effector functions (Orosz, 2002). 
Proliferation of B cells to produce graft-specific alloantibodies also contributes to acute 
rejection.
To some extent, donor immunogenicity and thus the degree of acute rejection, can be 
prevented by tissue-matching of the major human leukocyte antigens (HLA) between 
the donor and recipient. However, since a perfect match is not always possible, acute 
rejection is generally controlled by immunosuppressive drugs which inhibit T cell 
responses. The most widely used immunosuppressive agents include azathioprine and 
corticosteroids, both developed in the early 1960s, and cyclosporin A developed in the 
late 1970s (Humar & Matas, 2001). However, these are associated with a number of 
side effects including an increased risk of infection, particularly with viruses which are 
normally controlled by T cells. Depending on the genetic disparity between the donor 
and recipient, and the strength of immunosuppression, rejection can be delayed for 
months to years before the graft is subject to chronic rejection. Chronic rejection is 
characterised by a gradual thickening and blocking of the graft blood vessels, and a 
steady decline in graft function. It is thought to be initiated early posttransplant 
following mechanical, ischaemic (Hauet et al, 2001), immunological and
pharmacological injury, and develop further through prolonged and repeated vascular 
stress, such as high blood pressure. Since there is no therapeutic treatment for chronic 
rejection, a second transplant is usually required.
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1.2.2 Rejection of xenografts
The initial immune response directed against the xenograft is to some extent determined 
by the type of xenograft used and how it derives it’s blood supply. While whole-organ 
xenografts initially induce a strong immune response as soon as the recipient’s blood 
passes through the donor blood vessels, cellular xenografts, which derive their blood 
supply primarily via host vessels, encounter a delayed response, and can additionally be 
protected by encapsulation, or by implantation into privileged sites such as the brain. 
Since the use of whole organs from pigs is the goal of xenotransplantation, immune 
rejection will be discussed in the following sections with reference to solid-organ 
porcine xenografts.
An overview of solid-organ xenograft rejection, as studied in pig-to-nonhuman primate 
models, is shown in Figure 1.4. Briefly, the xenograft is subject to hyperacute rejection 
(HAR) within minutes of reperfusion of the graft, mediated by the binding of pre­
formed xenoreactive antibodies to the porcine vascular endothelium, and resulting in the 
activation of complement and graft destruction within hours (Lawson & Platt, 1996). If 
HAR can be prevented, the xenograft is then subject to acute vascular rejection (AVR), 
characterised by the binding of elicited anti-donor antibodies and endothelial cell (EC) 
activation. If AVR is prevented, for example, through the induction of accommodation, 
then the xenograft will be subject to either cellular rejection, chronic rejection or long­
term xenograft survival.
1.2.3 Hyperacute rejection
In the 1960s, it was demonstrated that vascularised grafts, transplanted between widely 
disparate species, suffered immediate destruction by a humoral immune response, which 
was similar to that seen in hyperacute rejection of ABO-mismatched allografts. 
Hyperacute rejection of xenografts occurs within minutes of revascularisation of the 
graft, and is characterised by extensive intravascular thrombosis and extravascular 
haemorrhage, leading to graft destruction within hours (Auchincloss & Sachs, 1998).
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Figure 1.4. An overview of xenograft rejection, as studied in pig-to-nonhuman primate 
models (Lawson & Platt, 1996). Within minutes of reperfusion, the xenograft is subject 
to hyperacute rejection, mediated by preformed xenoreactive antibodies. If this can be 
prevented, for example, by the transient removal of such antibodies, then the xenograft 
is subject to acute vascular rejection when xenoreactive antibodies return. If acute 
vascular rejection can be prevented, for example, by the induction of accommodation, 
then the xenograft is subject to either cellular or chronic rejection, or long-term 
xenograft survival.
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Initiation of HAR
Hyperacute rejection is initiated by the binding of pre-formed natural antibodies, to 
xenoantigen on the surface of pig cells. These antibodies predominantly recognise a 
single carbohydrate epitope, this being Galal -3Gal(31 -4GlcNAc-R (aGal), expressed 
on the cell-surface of lower mammals as well as many bacteria, viruses and parasites 
(Cramer, 2000), with approximately 107 aGal epitopes present on the surface of pig 
cells (Galili et al, 1988). The aGal epitope is synthesised by the al,3 - 
galactosyltransferase (al,3GT) enzyme (Galili, 2001), which transfers a galactose 
molecule to the terminal N-acetyllactosamine of glycoproteins and glycolipids. 
Although this gene is present in humans, apes and Old World monkeys (those of Asia 
and Africa), it is thought to have been inactivated approximately 20 million years ago 
when apes and monkeys diverged, and is therefore not transcribed (Galili, 2001). 
Antibodies specific for this epitope therefore arise during the first few years of life, 
upon stimulation by the normal bacterial flora of the gut, and comprise approximately 5 
% of circulating IgM antibody (Cramer, 2000; McMorrow et al, 1997).
Pathogenesis of HAR
The binding of xenoreactive antibodies to the aGal epitope results in the activation of 
complement through the classical pathway. The human complement cascade is normally 
regulated by both plasma and membrane-bound complement regulatory proteins 
(CRPs), which prevent autologous damage (Lachmann, 1991). However, since these 
regulatory proteins are species-specific, activation of the complement cascade, leads to 
the rapid assembly of terminal complement complexes on the porcine endothelium, 
resulting in type I endothelial activation, intravascular thrombosis, extravascular 
hemorrhage, edema and loss of the graft (Auchincloss & Sachs, 1998).
1.2.4 Overcoming HAR
Since HAR results from the binding of pre-existing xenoreactive antibodies to the aGal 
epitope and subsequent complement activation, manipulations which interfere with 
these processes could potentially be used to overcome this immune response. 
Approaches to overcome HAR are summarised in Table 1.3. Although temporary
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depletion of xenoreactive antibodies can be achieved by plasmapheresis or 
immunoadsorption (Taniguchi et al, 1996; Xu et al, 1998), and complement activation 
can be prevented to some extent by the administration of cobra venom factor and 
soluble complement receptor type 1 (Candinas et al, 1996), the two main approaches to 
overcome HAR involve genetic manipulation of the donor.
Table 1.3. Approaches to prevent hyperacute rejection (Cascalho & Platt, 2001b).
Approach Method
Depletion of xenoreactive antibodies Column absorption
Inhibition of complement Cobra venom factor, sCRl
Genetic engineering for the expression of DAF, CD59, MCP
complement-regulatory proteins
Genetic engineering to decrease antigen Knockout a-l,3-Galactosyltransferase
expression gene and possibly other genes in pigs
DAF, decay accelerating factor; MCP, membrane cofactor protein; sCRl, soluble 
complement receptor type 1.
Regulation of complement activation
Uncontrolled complement activation can be prevented by the transgenic expression of 
human membrane-bound CRPs on the surface of the porcine vascular endothelium. A 
number of successful attempts have been made to produce pigs transgenic for such 
proteins; including the decay accelerating factor (DAF), CD55 (Cozzi et al, 2000; Bhatti 
et al, 1999), membrane cofactor protein (MCP), CD46 (Diamond et al, 2001; Adams et 
al, 2001), CD59 (Fodor et al, 1994; Diamond et al, 1996) or combinations of these 
(Chen et al, 1999). Organs from these transgenic pigs were not hyperacutely rejected 
when transplanted into nonhuman primates, and have been shown to survive for 
approximately 1 month without evidence of HAR (Diamond et al, 2001; Garcia et al, 
2004). This can be extended to 2.5 months by the administration of soluble aGal 
glycoconjugates, which ‘mop up’ the returning natural antibodies that cause AVR 
(Teranishi et al, 2003; McGregor et al, 2003).
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Removal of xenoantigen
The use of competitive glycosylation, to replace aGal epitopes with other carbohydrate 
moieties, to which humans are immunologically tolerant, is one approach to remove 
xenoantigen. Transgenic expression of a l  ,2-fucosyltransferase (al,2FT), which 
synthesizes the H antigen, has been shown to reduce aGal expression by competing 
with al,3GT for its common substrate lactosamine (Sharma et al, 1996). Other enzymes 
which could be used in this manner to reduce aGal expression include sialyltransferases 
(e.g. a2,3ST) and N-acetylglucosaminyltransferase III (GnT-III) (Galili, 2001).
Complete removal of the aGal epitope using gene knockout techniques to remove the 
al,3GT gene is a more attractive option, and was first demonstrated in mice using 
embryonic stem cell technology (Tearle et al, 1996). Since porcine embryonic stem cell 
lines are not available, nuclear transfer techniques were used instead to clone pigs for 
this purpose (Polejaeva et al, 2000). Heterozygous knockout pigs, where one copy of 
the al,3GT gene was removed, were produced early in 2002 by two groups (Lai et al, 
2002; PPL Therapeutics, 2002), and later that year, homozygous knockout pigs were 
produced (Phelps et al, 2003). Although it is too early to tell if there will be any 
improvement in graft survival, the first in vivo results presented at the International 
Xenotransplantation Association conference in September 2003, showed the survival of 
an al,3GT knockout pig vascularised thymic lobe and kidney xenograft in a baboon for 
68 days without any evidence of HAR or AVR (Yamada et al, 2003). The baboon died 
during an operation to replace an infected catheter and its death was therefore unrelated 
to rejection. In addition, al,3GT knockout pigs expressing human al,2FT have been 
produced (Ramsoondar et al, 2003). Xenografts from these animals may be more 
effective than the null phenotype alone in overcoming humoral rejection.
1.2.5 Acute vascular rejection
If HAR is prevented, the xenograft is subject to rejection within days to weeks by a 
predominantly humoral response called acute vascular rejection (AVR), and sometimes 
referred to as delayed xenograft rejection, or acute humoral xenograft rejection. Since 
HAR is now largely preventable through one or a combination of therapies previously 
described, AVR is currently seen as the major immunological hurdle in pig-to-primate
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xenotransplantation. Beginning within 24 hours of reperfusion of the graft, it is 
characterised by the activation and swelling of endothelial cells lining blood vessels in 
the graft, focal ischaemia and diffuse intravascular coagulation (Cascalho & Platt, 
2001a).
Initiation and pathogenesis of AVR
Increasing evidence suggests that AVR is initiated by elicited anti-graft antibodies 
(primarily directed against aGal), since it is accompanied by an increase in the 
synthesis of xenoreactive antibodies, and can be delayed or prevented by the removal of 
anti-aGal antibodies (Lin et al, 2000). The binding of these xenoreactive antibodies to 
the vascular endothelium of the xenograft is thought to result in either complement- 
dependent or independent EC activation (Dorling, 2003). Complement-dependent EC 
activation is associated with an infiltrate of chronic inflammatory cells, including 
lymphocytes, macrophages and natural killer (NK) cells. EC activation is accompanied 
by interleukin 1 (IL-1) expression (Saadi et al, 2004), and an increased expression of 
pro-inflammatory molecules including intercellular adhesion molecule-1 (ICAM-1), and 
pro-coagulant molecules, such as tissue factor and other regulators of thrombosis, as 
well as the loss of thrombomodulin (Auchincloss & Sachs, 1998). These changes give 
rise to thrombosis and ischaemia, characteristic of AVR.
Molecular incompatibilities involved in AVR
As with HAR, there is evidence of the involvement of underlying molecular 
incompatibilities between species in AVR, which may contribute to disseminated 
intravascular coagulation. The loss of protective anti-coagulation factors normally 
present on the surface of human blood vessels, and the intrinsic failure of porcine 
endothelium to control the human coagulation cascade, is likely to contribute to the 
strength of AVR. The human coagulation cascade is partly regulated by the expression 
of tissue factor pathway inhibitor (TFPI), but the pig equivalent of this molecule fails to 
interact appropriately with the human factor Xa target molecule (Robson et al, 2000).
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1.2.6 Overcoming AVR
A key feature of AVR is the induced xenoreactive antibody response to the aGal 
epitope, and the subsequent activation of the xenograft vascular endothelium. 
Approaches to overcome AVR aim to block these processes and are summarised in 
Table 1.4. Although methods employed to remove the aGal epitope in overcoming 
HAR, such as competitive glycosylation or gene knockout technology, could be used to 
prevent the production of xenoreactive antibody in AVR, it is possible that there may be 
other non-aGal xenoantigens, targeted by xenoreactive antibodies, which contribute to 
HAR and AVR (Macchiarini et al, 1998; Zhu, 2000). Therefore, the most attractive 
approaches to overcome AVR involve the induction of accommodation or 
immunological tolerance to xenoantigen.
Table 1.4. Approaches to prevent acute vascular rejection (Cascalho & Platt, 2001b).
Method Result
Pre-transplant infusion with donor Tolerance to aGal and other xenospecific
haematopoietic cells antigens
Knockout a-l,3-Galactosyltransferase Decreased antigen expression
gene and possibly other genes in pigs
Suppression of pro-coagulant or pro- Inhibition of endothelial cell activation
inflammatory genes
Transient depletion of xenoreactive Induction of accommodation
antibodies
Accommodation, defined as an acquired resistance to humoral-mediated injury, despite 
the presence of anti-donor antibodies and complement, has been demonstrated in 
transgenic pig-to-nonhuman primate xenotransplantation (Lin et al, 2000). Since it is 
thought to be initiated by EC expression of anti-apoptotic genes, stimulated by low 
levels of anti-graft antibodies (Bach et al, 1997; Soares et al, 1999), it may be possible 
to induce a state of accommodation within the xenograft through over-expression of 
such genes (Auchincloss & Sachs, 1998).
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Induction of tolerance could be used to prevent the production of anti-aGal antibodies 
and other potential xenoreactive antibodies by B cells. This could be achieved by 
transplanting porcine bone marrow expressing the aGal epitope into the xenograft 
recipient (Yang et al, 1998; Cooper et al, 2002), or by transducing recipient bone 
marrow with a retroviral vector containing the al,3G T gene. The latter approach has 
been demonstrated in al,3GT knockout mice, to prevent the production of xenoreactive 
antibodies towards aGal (Bracy & Iacomini, 2000).
1.2.7 Cell-mediated and chronic rejection
If the humoral responses in AVR can be overcome, then it is likely that the xenograft 
will be susceptible to cellular immune responses, predominantly from T cells, which 
characterise acute allograft rejection. As yet, the T cell responses involved in pig-to- 
primate xenotransplantation are poorly understood due to the strength and speed of the 
humoral response in HAR and AVR. However, studies have suggested that both CD8+ 
and CD4+ T cells are capable of recognising porcine antigens by direct and indirect 
pathways (Cunningham et al, 1994; Yamada et al, 1995; Olack et al, 2000). Cell- 
mediated rejection of allografts is generally controlled through immunosuppression, but 
this approach is unlikely to overcome cellular rejection of xenografts without resulting 
in increased toxicity and susceptibility to infections. Alternative approaches to 
overcome the cellular response include the induction of T cell tolerance to 
xenoantigens, or genetic manipulation of the donor to down-regulate the cellular 
response. In particular, it may be possible to inhibit the CD8+ T cell response by down- 
regulation of porcine major histocompatibility complex (MHC) class I molecules on the 
surface of pig cells by transgenic expression of viral genes such as herpes simplex vims 
(HSV) ICP47 (Crew & Phanavanh, 2003).
Again, due to the strength of HAR and AVR chronic xenograft rejection is poorly 
characterised, but is likely to occur months posttransplant, and be similar to chronic 
allograft rejection. In theory, the extent of xenograft injury could be reduced by careful 
pre-transplant planning to reduce ischaemia time, however, since xenotransplantation 
has the potential to provide an unlimited supply of organs, a chronically-rejected 
xenograft could be replaced.
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1.3 Anatomical and physiological incompatibilities
Some of the molecular immunological incompatibilities between pigs and humans have 
already been discussed with respect to rejection. Similarly, anatomical and 
physiological incompatibilities may pose problems in the functioning of the graft. 
Indeed, long-term survival is dependent on the ability of the xenograft to function in the 
human body. Since allografts differ only in immunological factors, such as HLA class I 
and II antigens, and are otherwise anatomically, physiologically and biochemically 
identical, this aspect of xenotransplantation poses a novel problem to scientists. There is 
currently little information regarding the impact of anatomical and physiological 
differences following solid-organ xenotransplantation due to short survival times of 
porcine xenografts in humans and nonhuman primates. However, problems associated 
with physiological incompatibilities in baboon-to-human xenografted kidneys and livers 
have been reported (Reemtsma et al, 1964b; Starzl et al, 1993).
1.3.1 Anatomical differences
Anatomical aspects such as the unique upright posture of man, and differences in organ 
size and position of blood vessels, may affect functioning of the xenograft. Posture 
influences blood circulation and the functioning of organs. For example, the size of the 
heart valves varies depending on whether the organ is in an upright or horizontal 
position (Hammer, 1998). Similarly, posture can influence blood pressure in the lung, 
which, along with other species-specific factors such as blood viscosity, size of blood 
cells and haemoglobin, may ultimately affect oxygen supply. The size of the organ can 
also affect homogenous blood pressure, which is essential for parenchymal organs. Both 
over and undersized organs, especially the heart and liver, can be affected (Hammer,
1998). In addition, anatomical differences may make surgery more difficult.
1.3.2 Physiological differences
In addition to anatomical disparity, differences in physiological factors such as blood 
circulation, viscosity and pressure, as well as biochemical elements such as electrolytes, 
serum albumin, hormones and enzymes, may affect proper functioning of the xenograft. 
The activity of hormones and enzymes needs to be carefully controlled, and they may
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only function in a species-specific manner. In this respect, it is likely that the extent of 
physiological incompatibilities may be dependent on which type of organ is 
transplanted. The heart depends on a fairly small number of biochemicals to function; 
electrolyte disturbances will have a major impact, whereas the influences of other 
biochemical elements will be much smaller. This is in contrast to the liver, which is the 
most important metabolic organ of the body, producing 2500 different kinds of enzymes 
(Schraa et al, 1999). As with immunological hurdles, it may be possible to overcome 
some of these physiological incompatibilities through genetic engineering of the donor. 
Although, the true impact of anatomical and physiological incompatibilities is likely to 
remain unclear until the current immunological hurdles have been overcome.
1.4 The risk of transmission of porcine infectious agents to humans in 
xenotransplantation
1.4.1 The risk of zoonosis in xenotransplantation
Zoonosis is the transmission of infectious agents, such as bacteria, fungi, parasites, 
prions and viruses, between species, and can occur through many types of contact 
between humans and animals. In xenotransplantation, the potential for animal infectious 
agents to be transmitted to human xenograft recipients is sometimes referred to as 
xenosis. The clinical xenotransplantation protocol may facilitate this cross-species 
transmission, through intimate contact between species, via connection of the donor 
organ to the systemic circulation of the recipient, by local tissue ischaemia and the 
stimulation of inflammatory cytokines which may activate latent porcine viruses, and by 
the administration of potent immunosuppressive drugs.
Of all the potential infectious agents, which may be transmitted to humans in 
xenotransplantation, it is perhaps the viruses, which will present the greatest threat. 
Viral infections are a significant cause of long-term complications in allotransplantation 
and may be less amenable to therapy. In addition, viruses that are able to remain latent 
or which acquire new characteristics in the new host may be hard to detect. Such 
infectious agents may circulate within the population for some time before new clinical 
syndromes emerge, presenting a risk not only to the human xenograft recipient, but also 
to relatives, medical staff and the general population. Indeed, historic pandemics of
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zoonotic human disease, including the 1918 influenza pandemic, and the current 
HIV/AIDS pandemic, highlight the potential zoonotic risk from xenotransplantation.
1.4.2 The effect of genetic manipulation of the donor on the risk of xenosis
Genetic manipulation of the donor organ to overcome immune rejection by the 
transgenic expression of CRPs and/or knocking-out al,3GT, may increase the risk of 
viral infection. Evidence that some CRPs also act as receptors for human viruses, raises 
the possibility that xenografts from these transgenic animals may be susceptible to 
infection with human viruses. CD55 (DAF) has been shown to be the receptor 
mediating attachment and infection by several echoviruses, coxsackieviruses (Bl, B3 
and B5) and enteroviruses, all of which are human pathogens belonging to the 
picomavirus family (Bergelson et al, 1994; Ward et al, 1994; Shafren et al, 1995; 
Spiller et al, 2002). CD46 (MCP) has been shown to be the cellular receptor for both the 
Edmonston and vaccine strains of measles virus (wild-type strains use the signalling 
lymphocyte-activation molecule (SLAM)), and human herpesvirus (HHV) -6 (Dorig et 
al, 1993; Naniche et al, 1993; Santoro et al, 1999). More recently, CD46 has been 
shown to be a receptor for group B adenoviruses, which are associated with a variety of 
often fatal illnesses in immunocompromised individuals (Gaggar et al, 2003).
Since enveloped viruses such as retroviruses can be inactivated by complement, the 
transgenic expression of human CRPs on porcine cells, and incorporation of these 
proteins into the envelopes of viruses released from these cells, may protect them from 
attack by human complement. Initial studies showed that the transgenic expression of 
human CD59 on porcine cells resulted in incorporation of this protein into porcine 
endogenous retrovirus (PERV) particles produced from these cells, and inhibited 
complement-mediated virolysis (Takefman et al, 2002), but did not compromise the 
protective effects of human serum on the neutralisation of PERV.
Removing the aGal epitope from pig cells by gene-knockout technologies or reducing 
it’s expression, by competitive glycosylation, may also allow enveloped viruses, such as 
gammaretroviruses, produced by these xenografts to evade neutralisation by human 
serum. PERV-B and feline leukaemia virus (FeLV) particles produced from porcine 
endothelial cells transduced with al,2FT, a2,3ST or GnT-III, showed reduced
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sensitivity to human serum (Kurihara et al, 2003). There is also a risk that human 
viruses may infect the xenograft, for example, human cytomegalovirus (HCMV) and 
HSV-1 and -2 have been shown to infect porcine endothelial cells in vitro (Degre et al, 
2001; Leventhal et al, 2001).
1.4.3 Candidate porcine xenosis viruses
Porcine viruses have been categorised into groups according to the risk that they pose in 
xenotransplantation, these being; (i), those of known zoonotic potential, (ii), those 
having the ability to replicate in human cells or having some evidence for zoonotic 
potential, (iii), those with poor replication efficiency in humans but which have the 
potential to be oncogenic, (iv), those currently not defined as zoonotic but which have a 
wide host range, and finally (v), those which would be detrimental to the health of the 
herd or indicate a breakdown in biosecurity (Onions et al, 2000).
Porcine viruses categorised into the first group include; swine hepatitis E virus, swine 
influenza virus, paramyxoviruses such as Nipah virus, and encephalomyocarditis virus. 
Swine hepatitis E virus (HEV) (family calicivirus) is a recently identified virus, 
ubiquitous in >3 month-old pigs in the US (Meng et al, 1997). It was found to share 92 
% nucleotide identity with a virus isolated from two US patients suffering from acute 
viral hepatitis, but only 74 % identity with other strains of human HEV, suggesting that 
swine HEV may have been transmitted to humans and be the cause of disease in these 
patients (Schlauder et al, 1998; Erker et al, 1999). Swine influenza A virus (family 
orthomyxovirus) is thought to be endemic in pigs, with infection commonly causing 
respiratory disease associated with fever, lethargy, coughing, and breathing difficulties 
(Olsen, 2002). Pigs are thought to act as ‘mixing vessels’ for human and avian influenza 
virus assortments that have been the cause of a number of influenza pandemics 
(Webster et al, 1992). However, viral sequences recently isolated from formalin-fixed, 
paraffin-embedded, lung tissue from a victim of the 1918 ‘Spanish’ influenza pandemic, 
were found to be most closely related to early swine influenza strains (Taubenberger et 
al, 1997). More recently, in Malaysia, Nipah virus (family paramyxovirus) was the 
cause of fatal encephalitis among 28 people in close contact with pigs (Chua et al,
1999). Porcine encephalomyocarditis virus (EMCV) (family picornavirus) is endemic in 
many pig populations, causing acute myocarditis and sudden death in pre-weaned pigs,
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and is associated with transplacental transmission resulting in foetal and neonatal 
deaths. EMCV infection, associated with fever, neck stiffness, lethargy, delirium, 
headaches and vomiting has been documented in humans, and the virus has been shown 
to infect human myocardial cells in culture (Brewer et al, 2001). In addition, porcine 
EMCV was transmitted to immunocompetent mice following transplantation of EMC V- 
infected pig islet cells to reverse diabetes, and resulted in acute EMCV disease 5 days 
following transplant (Brewer et al, 2004).
Other viruses, which have no known zoonotic potential but which are pathogenic in 
pigs, include porcine circoviruses (PCV) and coronaviruses. Although, PCVI was first 
identified as a non-cytopathic contaminant of the pig kidney cell line PK15 and is non- 
pathogenic in pigs, PCV2 was identified as the etiologic agent of post-weaning 
multisystemic wasting syndrome in pigs (Nayar et al, 1997). PCV gene expression and 
replication has recently been shown to take place in human cells in vitro, however, 
infection was non-productive (Hattermann et al, 2004). Porcine coronaviruses are 
associated with diarrhoea, and respiratory and neurological syndromes in pigs, but do 
not appear to be zoonotic (Muir & Griffin, 2001).
1.4.4 Lessons from allotransplantation
Allotransplantation provides a useful model for the types of infection that are 
transmitted through organs and tissues, and therefore gives an indication of the types of 
organisms which may be transmitted in xenotransplantation. Micro-organisms such as 
bacteria, fungi, parasites, and viruses (including members of the herpesviruses, hepatitis 
B and C viruses, and HIV) have all been documented in recipients of allografts, and are 
a significant cause of posttransplant morbidity and mortality (Muir & Griffin, 2001). In 
the first month posttransplant, bacterial and fungal infections predominate. While later, 
following sustained immunosuppression, viruses such as HCMV, Epstein-Barr virus 
(EBV), hepatitis B and C viruses, and HSV, are a common cause of post-operative 
complications (Fishman & Rubin, 1998). Herpesviruses in particular, are a significant 
cause of end-organ disease and graft rejection in the posttransplant period, with HCMV 
long recognised as the most important pathogen affecting transplant recipients (Fishman 
& Rubin, 1998).
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1.5 Xenotransplantation regulation and clinical protocols
1.5.1 Regulation of xenotransplantation
Considering the potential zoonotic risks involved, xenotransplantation requires close 
regulation and monitoring. This responsibility is carried out by a number of groups 
appointed in various countries, whose purpose is also to advise the government on 
issues relating to xenotransplantation. The United Kingdom Xenotransplantation 
Interim Regulatory Authority (UKXIRA) regulates xenotransplantation in the UK. Its 
roles are to provide a focal point for xenotransplantation activity and to consider 
applications for clinical trials to be undertaken in the UK. In addition, steering groups 
have been set up to monitor the production of xenografts and the long-term follow-up of 
xenograft recipients. At the time of the last UKXIRA annual report there were no 
clinical trials taking place in the UK (UKXIRA Fifth Annual Report, 2003). In the US, 
xenotransplantation is regulated by the Food and Drug Administration (FDA). In 
addition, guidelines have been drawn up by many health authorities in other countries 
including Canada, Australia, New Zealand, Japan and those of Europe, regarding health 
issues related to xenotransplantation (Sykes et al, 2003).
1.5.2 Guidelines for clinical trials
If xenotransplantation clinical trials are to proceed, protocols are needed regarding the 
generation of source animals, the clinical xenotransplantation site, pre- and post­
xenotransplantation health screening and surveillance plans for source animals and 
xenograft recipients, and informed consent and patient education processes. To this end, 
the US Public Health Service (PHS) has set out guidelines on the infectious disease 
issues in xenotransplantation (Centres for Disease Control and Prevention, 2001). US 
PHS guidelines recommend that precautions to minimise the infection risk should be 
employed in all steps of the production of source animals for xenotransplantation, for 
example, during animal husbandry, procurement, and processing of xenotransplantation 
products. Source animals should be bred in closed herds, preferably using caesarian 
derivation, in facilities with adequate barriers to prevent the introduction and spread of 
infectious agents. These herds should then be actively monitored for infectious agents, 
including the individual source animal and the xenograft product itself. Sites of clinical
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xenotransplantation should have accredited virology and microbiology laboratories 
which have the ability to isolate and identify unusual or newly recognised pathogens of 
human and animal origin.
The process of obtaining informed consent is also an important aspect of clinical trials. 
Relevant information regarding xenotransplantation should be provided to the patient, 
and made available to the family and contacts prior to, and at the time of consent. 
Patients should be informed of the potential for infection with both known and unknown 
zoonotic agents, and the potential for transmission of these agents to the recipient’s 
family or close contacts. Patients additionally need to understand the importance of 
complying with long-term or life-long surveillance and the need for autopsy upon death.
Surveillance programs are important to monitor the introduction and propagation of 
xenogeneic infectious agents in the recipient, with the aim of detecting infection prior to 
dissemination into the general population. US PHS guidelines suggest that post­
xenotransplantation surveillance include surveillance of the recipient(s), selected health 
care workers or other contacts, and the surviving source animal(s). Xenograft recipients 
should be monitored throughout their life-time, with regular evaluation immediately 
following xenotransplantation (i.e. every two weeks), and decreasing in frequency 
thereafter in the absence of any evidence of infection. A number of samples should be 
monitored including; serum, peripheral blood mononuclear cells (PBMCs), tissues and 
other body fluids. It is critical that adequate diagnostic assays and methods for 
surveillance of known infectious agents are available prior to initiation of the clinical 
trial. These assays should be specific, especially when xenogeneic viruses of concern 
have similar human counterparts. Surveillance methods should also be able to detect 
infectious agents known to establish persistent latent infections in the absence of clinical 
symptoms, such as herpesviruses, retroviruses, and papillomaviruses. Depending on the 
degree of immunosuppression, serological assays may or may not be of use in the 
surveillance procedure. All samples recovered during surveillance, or recovered from 
patients as a result of death or rejection of the xenograft, should be archived for 50 years 
beyond the date of xenotransplantation to allow retrospective analysis. In addition to 
surveillance, xenograft recipients and their contacts would be subject to strict 
behavioural procedures, including; refraining from donating body fluids and/or parts for 
use in humans, barrier contraception and refraining from having children.
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1.6 Infection control: breeding pigs for xenograft organs
Experience from allotransplantation allows us to make reasonable predictions about the 
likely candidate viruses which may be transmitted to humans following 
xenotransplantation. As previously mentioned, and described further in section 1.10, the 
transmission of viruses, such as HCMV, within the allograft can have a considerable 
effect on the clinical outcome of the procedure. In allotransplantation, it is not always 
possible to exclude all serious pathogens due to the urgency of transplant, and the short 
supply of donor organs. However, in xenotransplantation, we are potentially able to 
have much greater control over the microbiological status of the donor, and this is 
especially important considering the risk of zoonosis. In light of the risks associated 
with zoonosis, all pigs destined for use as sources of organs for clinical 
xenotransplantation will need to be of an exceptionally high health status and free from 
a long list of porcine infectious agents (Onions et al, 2000). Indeed, the donor organ or 
‘xenograft product’ will need to fulfil all of the safety specifications of a biological 
product. Comprehensive reviews of porcine infectious agents that should be excluded 
from donor pigs have been published (Onions et al, 2000; Muir & Griffin, 2001). Apart 
from the porcine equivalents of those viruses transmitted in human allotransplantation, 
other viruses that should be excluded from xenograft organs include; those which are 
known to be transmitted to and pathogenic in humans, those which are pathogenic in 
pigs, as well as those which have only been recently identified and therefore are poorly 
characterised (Onions et al, 2000). Pigs to be used in xenotransplantation should be bred 
from microbiologically characterised, inbred herds of domestic pigs, and some 
techniques used to control disease in commercial pig herds could be applied to the 
production of pigs for xenograft organs.
1.6.1 Disease control in commercial pig herds
In a commercial setting it is paramount to control infectious disease, since pig farming
is often large-scale and infection can have a major economic impact on productivity.
Infectious disease is most effectively controlled by altering breeding conditions. The
production of high health status pigs often involves removing piglets from the sow and
herd following early weaning, and is termed segregated early weaning (SEW) (Harris &
Alexander, 1999). Piglets are protected from infection immediately after birth with
strong humoral immunity passed to them from the sow’s colostrum and milk. Removing
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piglets from the sow and herd in the following days protects the piglets from infection 
when passive immunity fades. An even more effective, but costly method of producing 
high health status herds involves generating specific-pathogen-ffee (SPF) pigs, by 
caesarian delivery followed by gnotobiotic-rearing (Miniats & Jol, 1978). These SPF 
pigs are free from most infectious agents except those transmitted in utero (Harris & 
Alexander, 1999).
1.6.2 Breeding pigs for xenograft organs
A defined breeding method for the large-scale production of pigs for xenograft organs 
has been proposed by independent members of an advisory board (set up by Novartis 
Pharma AG), charged with advising on the microbiological safety criteria to be met 
before clinical trials of pig organ xenotransplantation (Onions et al, 2000), and is 
intended to maximise the health status and welfare of the herd while minimising cost. 
Similar recommendations for the exclusion of exogenous infectious agents have been 
set out by the US PHS (Centres for Disease Control and Prevention, 2001). Briefly, 
founder lines of transgenic SPF pigs such as those previously described, will be used to 
generate breeding herds. These breeding animals will be delivered by surgical 
techniques, such as hysterotomy or hysterectomy, and raised in gnotobiotic units for the 
first 2-3 weeks of life (Miniats & Jol, 1978), before being transferred to, and maintained 
for several months in high-welfare bioexclusion facilities, designed for the barrier- 
rearing of animals in closed herds. Surgical delivery of breeder animals, followed by 
gnotobiotic-rearing, is essential to exclude those potential infectious organisms 
transmitted peri- and post-natally, although those transmitted in utero, may still be 
passed on. The breeding herd may be maintained over a period of years in a barrier- 
rearing facility, and will be required for the production of subsequent source pigs, from 
which donor organs will be derived. Organ-source animals can either be delivered by 
hysterotomy of the breeding sow, followed by an initial period in isolators under 
gnotobiotic conditions, or can be naturally farrowed from breeding animals. This latter 
approach is preferable for the large-scale production of pigs for xenograft organs since 
it reduces costs and prevents the need to euthanise the sow. Following 5 days, naturally 
farrowed source animals can undergo SEW to minimise the transmission of infectious 
agents.
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Whichever method is chosen for delivery and initial care, source pigs will be barrier- 
reared for several months in cohorts (litters) of approximately 10-20 animals, in strict 
isolation from the breeding herd, before being moved to a separate quarantine room 
approximately 1 month before excision of the organs. In the bioexclusion, barrier- 
rearing facility, breeding or organ-source animals will have no direct contact with pigs 
outside their cohort, but occasional contact with humans. Positive air pressure and high- 
efficiency particulate (HEPA) filtered air should exclude most airborne infectious 
agents, while water and feed will be sterilised, and contain no animal proteins, except 
milk-derived lactose for pre-weaned piglets. Antibiotics should be excluded to reduce 
the risk of selection for antibiotic-resistant bacteria, and vaccination of pigs should be 
avoided as it may be unreliable, may mask the clinical signs of infection and impair the 
ability to diagnose infection by monitoring the antibody response (Onions et al, 2000). 
A standard procedure to prevent microbial contamination during surgical harvest of 
porcine xenografts, equivalent to that used in an operating room for human graft 
retrieval, has also been evaluated (Tucker et al, 2004).
1.6.3 Monitoring the SPF status of source pigs
Although ideal, it would not be feasible to assess the SPF status of organ-source pigs by 
extensive microbiological evaluation of each animal on the day of harvesting organs, 
because of the time taken to perform all of the necessary tests. Therefore, the proposed 
microbial screening of cohorts and individual source animals involves routine 
monitoring, by physical examination and serologic testing, of all pigs in each cohort, 
soon after SEW, on transfer to the barrier-rearing facility, at 2 months of age, and on 
transfer to the final quarantine barrier (Onions et al, 2000). This would involve 
bacteriologic screening of nasal and faecal swabs, as well as virological testing for 
infectious virus, viral antigen, nucleic acid and/or antibodies. In addition, at two months 
of age and prior to the approval of the cohort for human clinical use of the organs, 
sentinel animals, representative of the microbiologic status of the entire cohort, would 
undergo necropsy including extensive bacterial and parasite testing, histopathological 
examination and virological testing of appropriate organs. At the time of organ excision, 
necropsy and sample archiving would allow retrospective confirmation of the SPF 
status of individual source animals.
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The applicability of this system in terms of microbiological safety has been examined 
(Tucker et al, 2002a). The aim of this study was to evaluate the feasibility of producing 
pigs to recommended SPF specifications, and to evaluate the validity of the proposed 
cohort health monitoring programme. In this study, 9 cohorts were delivered by 
caesarian section, and reared for 14 days in isolator tanks under gnotobiotic conditions 
at the Ontario Veterinary College. Gnotobiotic pigs were then transferred to a barrier- 
rearing facility at the Toronto General Hospital and reared in closed herds for 4-5 
months. These breeding techniques were shown to eliminate a wide range of bacterial, 
parasitic, fungal, and viral agents from transgenic pigs being bred for potential use in 
clinical xenotransplantation (Tucker et al, 2002a). In addition, the baseline clinical 
pathology and sizes of potential xenograft organs from these SPF pigs was determined 
(Tucker et al, 2002b). The high health status of these pigs was confirmed by low 
leukocyte counts and serum globulin concentrations, while the growth rates of these 
SPF pigs were shown to be above the targets currently set out for the commercial 
production of conventionally-reared pigs. The results obtained in this study will enable 
estimation and selection of the appropriate organ size prior to transplant (Tucker et al, 
2002b).
1.6.4 Problematic viruses
Experience from allotransplantation has highlighted the porcine equivalents of 
retroviruses, herpesviruses and hepatitis viruses as potential candidate viruses which 
may be transmitted to humans following xenotransplantation (Fishman & Rubin, 1998). 
Retroviruses and herpesviruses in particular, cause latent, persistent infection, and will 
be difficult to eradicate from donor animals using the proposed breeding method 
described above, since they are transmitted in utero or in the germ-line (in the case of 
endogenous retroviruses). Therefore, the following sections will focus on porcine 
viruses of particular concern in xenotransplantation; these being porcine endogenous 
retroviruses and the porcine herpesviruses.
1.7 Porcine endogenous retroviruses
Retroviruses comprise a family of enveloped viruses (Table 1.5), with a unique life 
cycle. Upon entry into the host cell, the single-stranded RNA genome is transcribed into
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double-stranded DNA, and integrated into the host cell chromosomes in the form of a 
provirus, which then serves as a template for viral RNA and protein production (Goff, 
2001). Endogenous retroviruses result from integration of the provirus into the genome 
of germ-line cells, and as a result, are transmitted vertically through generations. The 
majority of endogenous retroviruses are inactive fossil remnants of ancient germ-line 
infections, and have undergone many mutations which render them defective, however 
some, particularly more recent endogenous proviruses can still give rise to infectious 
retroviruses (Patience et al, 1997b). The genomes of all the replication-competent 
retroviruses contain at least three large genes termed; group-specific antigen (gag), 
polymerase (pol) and envelope (env).
Table 1.5. Retrovirus genera (adapted from Goff, 2001).
Name Example
Alpharetrovirus Rous sarcoma virus
Betaretrovirus Mouse mammary tumour virus
Gammaretrovirus Murine leukaemia viruses
Feline leukaemia virus
Gibbon ape leukaemia virus
Deltaretrovirus Human T-lymphotropic virus
Bovine leukaemia virus
Epsilonretrovirus Walleye dermal sarcoma virus
Lentivirus HIV-1, HIV-2
Spumavirus Human foamy virus
Porcine endogenous retroviruses (PERV) are gammaretroviruses that were first 
described in the 1970s as C-type particles released from porcine cell lines. 
Subsequently, two PERV subtypes A and B, capable of infecting human cells, were 
shown to be produced by the porcine cell line PK15 (Patience et al, 1997a). PERV-A 
and -B were shown to be highly homologous (92 % amino acid identity), and closely 
related to gibbon ape, feline, and murine leukaemia viruses (63-66 % amino acid 
identity) (Le Tissier et al, 1997). Sequences from a third subtype, PERV-C (also known 
as PERV-MSL), were then amplified from the lymphocytes of miniature swine
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(Akiyoshi et al, 1998). These three viruses differ in the sequence of their env gene, host 
range and receptor interference (Takeuchi et al, 1998), while the gag and pol genes 
remain highly conserved. PERV-A and -B are found in the genome of all pigs tested so 
far, while PERV-C is only found in certain animals (Akiyoshi et al, 1998). In addition, 
PERV expression has been identified in a variety of pig strains and breeds, including 
SPF pigs and CD55 transgenic pigs, in tissues such as the kidney, lung, liver, heart, skin 
and pancreas (Martin et al, 1998; Clemenceau et al, 1999; Bosch et al, 2000; Langford 
et al, 2001), with PERV-A and -B more prevalent than PERV-C.
1.7.1 PERV tropism
With the revival of xenotransplantation in the 1990s the susceptibility of humans cells 
to PERV infection was examined. PERV-A and -B infection of the 293 human 
embryonic kidney (HEK293) cell line, following incubation with cell-free virus, was 
demonstrated by measurement of reverse transcriptase (RT) activity in supernatant and 
RT-PCR of PERV-specific RNA, while co-cultivation with PK15 cells resulted in a 
broader range of human cell infection (Patience et al, 1997a). In addition, a PERV-A/C 
recombinant (PERV-NIH), produced by mitotic stimulation of PBMCs of miniature 
swine, was found to infect HEK293 and HeLa cell lines (Wilson et al, 1998). 
Importantly, co-cultivation of HEK293 cells with pig primary aortic endothelial cells, 
which will form an interface between the xenograft and recipient, were shown, without 
mitotic stimulation, to result in productive infection of these human cells (Martin et al,
1998). Meanwhile, PERV infection of primary human endothelial cells, vascular 
fibroblasts and mesangial cells, provides further evidence of the risk posed by PERVs in 
xenotransplantation (Martin et al, 2000). Infection of human primary foreskin 
fibroblasts as well as nonhuman primate primary cells and cell lines has also be 
demonstrated (Blusch et al, 2000). Recently, two human PERV-A receptors (HuPAR-1 
and -2) were identified and shown to be expressed on a wide range of human tissues 
including PBMCs (Ericsson et al, 2003).
In vivo experiments of PERV transmission have been limited to date. Cross-species 
transmission of PERV was demonstrated in vivo, following transplantation of porcine 
pancreatic islets cells into severe combined immunodeficiency (SCID) mice (van der 
Laan et al, 2000). The pig islets were shown to release infectious PERV that
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productively infects human epithelial cells in vitro, and following transplantation of the 
islets into SCUD mice, expression of PERV p30 Gag and spliced PERV env mRNA was 
detected. However, to date, no PERV mRNA or PERV-specific immune responses have 
been detected in nonhuman primate recipients of porcine xenografts (Switzer et al,
2001). In this study, 23 nonhuman primates were analysed for PERV infection 
following transplantation of either porcine heart or skin grafts, or encapsulated islet 
cells. All plasma samples tested negative for PERV RNA, and PERV antibodies. 
Similarly, PERV sequences were not detected in PBMC, spleen or lymph node samples 
from these animals.
1.7.2 The potential for PERV infection in xenotransplantation
Although pigs have been estimated to contain approximately 50 copies of PERV-A and 
-B, integrated into the genome (Patience et al, 1997a; Le Tissier et al, 1997), many of 
these are likely to be defective, owing to mutations introduced over many years. 
However, it is possible that mutations, genetic recombination or complementation 
between defective PERV copies, or other related endogenous viruses in xenograft 
recipients could give rise to infectious virus. Such chimeric PERV sequences have been 
detected in pig genomes (Lee et al, 2002; Oldmixon et al, 2002; Klymuik et al, 2003). 
One recombinant, PERV-NIH, containing receptor binding domains of PERV-A, and 
cell fusion domains of PERV-C, was generated by passaging of human-tropic PERV in 
HEK293 cells (Wilson et al, 2000). In addition to the three known envelope subgroups 
of PERV, other novel endogenous beta- and gammaretroviruses have been identified 
(Ericsson et al, 2001; Patience et al, 2001). In the xenotransplantation setting, activation 
of porcine endothelial cells by human cytokines could stimulate the release of PERVs, 
although in vitro, this stimulation was not mirrored by an increase in infectivity towards 
human cells (Cunningham et al, 2004). PERV adaptation or recombination with human 
endogenous retrovirus (HERV) sequences could potentially enhance human-to-human 
transmission, although a recent study suggested that the potential for recombination of 
PERV and HERV sequences was low (Suling et al, 2003).
In addition to the potential for recombination in xenograft recipients, genetic 
modifications of donor pigs and immunosuppression of the xenograft recipient may 
increase the risk of PERV infection. As described in section 1.4.2, the use of pigs
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transgenic for human CRPs, or those which do not express the a-Gal epitope, may 
influence recognition and immune responses to enveloped viruses such as PERVs. In 
contrast to the work by Takefman et al, PERV produced from hDAF transgenic pig 
aortic endothelial cells were protected from inactivation by human serum (Magre et al, 
2004), while PERV produced from al,3G T knockout pigs was found to be resistant to 
inactivation by neutralising antibodies and human serum (Quinn et al, 2004). If 
transmission to humans did occur, PERV infection could result in a range of clinical 
syndromes, such as neoplasia, immunosuppression or autoimmunity, which have been 
associated with other types of endogenous retroviruses (Muir & Griffin, 2001).
1.7.3 Evidence of PERV transmission to human xenograft recipients
Retrospective analysis of human recipients of porcine foetal pancreatic islet and 
mesencephalic cells, skin grafts, and extracorporeal connection to porcine spleens, 
livers and kidneys, as well as bioartificial livers containing porcine hepatocytes, has 
revealed no evidence of transmission of PERV to humans, despite long-term 
microchimerism of up to 8.5 years in some patients (Heneine et al, 1998; Patience et al, 
1998; Paradis et al, 1999; Pitkin & Mullon, 1999; Schumacher et al, 2000; Dinsmore et 
al, 2000; Levy et al, 2000). In the most comprehensive study, PBMC samples were 
collected from 160 patients, up to 12 years following treatment with various porcine 
xenografts (Table 1.6) (Paradis et al, 1999).
Exposure of patients’ to porcine cells varied from minutes in the case of extracorporeal 
perfusion, to over a year in recipients of pancreatic islets. All samples tested negative 
for PERV DNA, RNA and PERV-specific antibodies by PCR, RT-PCR and protein 
immunoblot antibody assays, although samples from 23 patients receiving 
extracorporeal splenic perfusion indicated the presence of microchimerism. However, 
despite the positive results of these findings it is far from conclusive that PERVs will 
not pose a risk in xenotransplantation. The majority of subjects in these studies did not 
receive pharmacological immunosuppression, and those who did, received low doses. In 
most cases, the time that the recipient was exposed to the xenograft was very limited, 
reducing the potential for PERV transmission. In addition, human PBMCs were often 
analysed for evidence of PERV infection, and at present, studies of the susceptibility of 
these cells to PERV infection have yielded conflicting results (Wilson et al, 2000;
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Table 1.6. Results of the Paradis et al study (Paradis et al, 1999), of PERV infection in patients treated with living pig tissue (adapted from
Cunningham et al, 2001).
Patient
numbers
Treatment Exposure PERV infection Microchimerism
present?
PERV RNA PERV antibody 
response (anti-Gag)
1 Extracorporeal liver 
perfusion
4.25 hrs Negative NT Negative Negative
2 Extracorporeal kidney 
perfusion
15 and 65 min Negative NT Negative Negative
28 Bioartificial liver 11.7 hrs average Negative NT Negative 1 positive0 
(preprocedural)
14 Pancreatic islets 1-460 days Negative NT Negative 1 positive 
(preprocedural)
15 Skin grafts 10 days average Negative NT Negative Negative
100 Extracorporeal splenic 
perfusion
50-60 min 96 negative,
1 untested3 
3 uninterpretableb
23 positive, 
1 untested 
76 negative
Negative 2 weak positived (but 
negative for PERV 
DNA)
Microchimerism was present in samples from 23 patients. PCR results from three patients were uninterpretable. All samples were RT-PCR 
negative. Anti-Gag antibodies were found in four cases. These antibodies were considered to be cross-reacting, as all four samples tested 
negative for Env antibodies and in two cases were present prior to exposure to porcine cells (preprocedural). Thus, no evidence of infection with 
PERV was found in these patients. 
a RT-PCR and antibody negative.
b Uninterpretable: the quantity of sample available was insufficient for retesting but patient was RT-PCR and antibody negative. 
c Serum taken within 3 days of treatment, before antibodies could develop, also tested positive.
d Serum was positive at one (of two) testing centres only and PERV DNA or RNA was not detected in samples from these patients.
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Specke et al, 2001). Furthermore, the majority of xenografts used were not derived from 
pigs transgenic for human CRPs, therefore it is not clear whether the expression of these 
proteins on pig cells will reduce the susceptibility of PERVs to inactivation by human 
complement. The only study to use xenografts from transgenic pigs involved 
extracorporeal liver perfusion in two patients for 6.5 and 10 hours, using pig livers 
transgenic for human CD55 (hDAF) and CD59, prior to successful allotransplantation 
(Levy et al, 2000). In this study, serial monthly PBMC samples taken up to 4 and 10 
months following perfusion, tested negative for PERV DNA by PCR.
1.7.4 Overcoming the risk of PERV transmission
In order to prevent the transmission of PERVs to xenograft recipients, it would be ideal 
to create pigs which lack all human-tropic PERVs, i.e. PERV-A and PERV-B. Although 
PERVs are present in multiple copies in pig genomes, many of these are defective 
(Bosch et al, 2000; Herring et al, 2001), and as such it may be possible just to remove 
the critical human-tropic replication-competent (HTRC) PERV loci through selective 
breeding and gene knockout technologies. Indeed, pigs that fail to transmit PERV to 
human cells in vitro have already been reported (Oldmixon et al, 2002). In this study, 
those PERVs that were able to replicate in human cells were recombinants of PERV-A 
and -C, and these HTRC PERV-A/C recombinants were later found to be exogenous 
viruses that were absent from the genome of miniature swine (Wood et al, 2004; Scobie 
et al, 2004).
In addition to removing or inactivating PERV genomes, it may be possible to prevent 
PERV expression through the use of short interfering (si) RNA technology. This 
technology involves expression of siRNA sequences, which activate an innate cellular 
process that results, not only in the degradation of the invading siRNA molecule, but 
other identical single-stranded RNA sequences (Shuey et al, 2002). Synthetic siRNAs 
for the PERV pol region reduced expression of PERV p27 Gag protein in PERV-B- 
infected HEK293 cells by up to 90 % (Karlas et al, 2004). A further study 
demonstrating that porcine endothelial cells expressing siRNA from the gag/pol region 
of PERV, were less infective to HEK293 cells, suggests that siRNA technology could 
be important in reducing the risks posed by PERVs in xenotransplantation (Miyagawa et 
al, 2003).
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If PERV infection did occur, either by direct infection or by recombination, it may be 
possible to inhibit virus with antiretroviral agents. The effect of antiretroviral drugs 
currently licensed for use in the treatment of HIV-1 on PERV has been evaluated (Qari 
et al, 2001; Wilhelm et al, 2002). Although PERV was sensitive to zidovudine (AZT) 
and dideoxyguanosine triphosphate (ddGTP), no activity was detected with the other RT 
and protease inhibitors tested.
1.8 Herpesviruses
1.8.1 Herpesvirus properties and classification
Herpesviridae are a family of large enveloped viruses comprising over 100 members, 
which are well adapted to their hosts, and highly disseminated in nature, infecting a 
wide range of vertebrates and some invertebrates. Although herpesviruses vary greatly 
in pathology and biology, they share four significant biological features. Firstly, they 
encode unique proteins involved in nucleic acid metabolism, DNA synthesis and the 
processing of proteins. Secondly, viral DNA synthesis and assembly of herpesviral 
capsids occurs in the nucleus. Thirdly, the production of progeny virus is invariably 
accompanied by cell death, and finally, they have the ability to establish life-long latent 
infection in specific host cells following primary infection (Roizman & Pellett, 2001).
Herpesviruses were divided into three subfamilies; Alpha-, Beta- and 
Gammaherpesvirinae according to biological properties, and more recent genome 
sequence analysis confirms similarities amongst viruses of the same subfamily. 
Alphaherpesviruses have a variable host range, short growth cycle spreading rapidly in 
culture, and are neurotropic, establishing latency primarily but not exclusively in 
sensory ganglia. Betaherpesviruses in contrast have a restricted host range, long 
reproductive cycle spreading slowly in culture with large infected cells (cytomegaly), 
and establish latency in secretory glands, lymphoreticular cells, kidneys and other 
tissues. Gammaherpesviruses infect lymphoblastoid cells in vitro, being specific for T 
or B lymphocytes, are associated with lymphoproliferative diseases, and establish 
latency in lymphoid tissue (Roizman & Pellett, 2001). All three subfamilies are believed
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to have evolved from a common ancestor more than 200 million years ago (Figure 1.5) 
(Davison & Clements, 1998).
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L- HSV-2 ^
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---------- vzv
 HCMV
.- p; ----------------------------- HHV-6
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■ » » 1  1    —  1
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Figure 1.5. A phylogenetic tree for selected herpesviruses, derived from sequence 
comparisons (Davison & Clements, 1998). Broken lines indicate regions of lower 
confidence.
1.8.2 Porcine herpesviruses
So far, five herpesviruses have been identified in domestic pigs, these being;
pseudorabies virus, porcine cytomegalovirus, and three recently identified lymphotropic 
herpesviruses -1, -2, and -3. Recently, an extensive search for unrecognised
herpesviruses in commercial, experimental, and wild pigs from Germany, Spain, 
Sweden, France and the US, by pan-herpes consensus PCR, failed to identify further 
viruses (Chmielewicz et al, 2003a). Herpesviral DNA polymerase sequences were 
amplified using degenerate, deoxyinosine-containing primers, from blood and a range of 
tissue samples from 294 animals. Sequence analysis attributed all PCR products to the 
known porcine herpesviruses. However, five novel herpesviruses were recently
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identified in suid species (other than the domestic pig, S. scrofa) from Africa and South- 
East Asia (Ehlers & Lowden, 2004). Three of these viruses were closely related to 
known porcine beta- and gammaherpesviruses, while two species were more closely 
related to bovine herpesvirus 4.
1.8.3 Pseudorabies virus
Pseudorabies virus (PRV), sometimes termed suid herpesvirus 1, is an alphaherpesvirus, 
classified alongside Varicella-zoster virus (VZV) in the genus Varicellovirus. It is an 
important veterinary pathogen, causing systemic and often fatal central nervous system 
(CNS) and respiratory disorders (Aujeszky’s disease), in swine (Borie et al, 1998). PRV 
has a world-wide distribution, but has been eradicated from some areas, including the 
UK and Canada (Yoo & Giulivi, 2000; Muir & Griffin, 2001). In adult pigs, infection, 
although usually asymptomatic, can result in fever, growth arrest, as well as CNS, 
respiratory and gastrointestinal disorders. Meanwhile, infection in piglets is associated 
with fever, vomiting, diarrhoea, CNS involvement, and has a high mortality rate with 
death occurring 6-8 days following infection (Sawitzky, 1997). Virus is transmitted via 
oral or nasal routes, replicating in the oropharynx and spreading through the cranial 
nerves in the CNS. In utero transmission is also possible since infection in pregnant 
sows is associated with foetal deaths (Sawitzky, 1997). PRV is neurotropic, establishing 
latency in sensory ganglia, tonsils and lymphoid tissue, with occasional intermittent 
shedding of virus. Like HSV, PRV has a wide host range, infecting a variety of human 
cells in vitro (Sawitzky, 1997). It is also occasionally transmitted from pigs to cattle, 
sheep, goats, horses, dogs, cats, and wild animals (Muir & Griffin, 2001). PRV is 
thought to enter cells using the same cellular receptors as HSV, namely members of the 
nectin family including herpesvirus entry mediator (Hve) -B and -C (Campadelli-Fiume 
et al, 2000). Transmission to humans, resulting from close contact with domestic 
animals, has been reported to be associated with a variety of neurological symptoms, 
but is likely to be rare (Mravak et al, 1987). Since PRV is not common in high health 
status pigs and has been eradicated from pigs in the UK and Canada, it should be 
possible to exclude this virus from pigs being bred for xenotransplantation.
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1.8.4 Porcine lymphotropic herpesviruses
Porcine lymphotropic herpesviruses (PLHV-1 and -2) are gammaherpesviruses 
classified in the genus Rhadinovirus, and were first detected in 1999 in porcine spleen 
and PBMC samples from German and Spanish pigs (Ehlers et al, 1999). The viral DNA 
polymerase sequences amplified from these samples showed highest amino acid identity 
with bovine gammaherpesviruses including alcelaphine herpesvirus 1 (A1HV-1), ovine 
herpesvirus type 2 (OvHV-2), and bovine lymphotropic herpesvirus (BLHV), and were 
prevalent in 87 % of PBMC, and 95 % of spleen samples from German pigs tested. 
Subsequently, the entire DNA polymerase gene of PLHV-1 and -2 was sequenced, and 
found to share 95 % amino acid identity with each other, and 60 % amino acid identity 
with A1HV-1 (Urich et al, 1999). These gammaherpesviruses are not pathogenic in the 
natural host, but cause serious lymphoproliferative disease in other species. In 
particular, A1HV-1 and OvHV-2 are non-pathogenic in their respective hosts, but cause 
malignant catarrhal fever, an often fatal lymphoproliferative and inflammatory disease, 
if transmitted to cattle and other animal species including pigs (Ensser et al, 1997; 
Albini et al, 2003). Both PLHV-1 and particularly PLHV-2 were prevalent in domestic 
and feral swine, suggesting the possibility of viral transfer between feral and domestic 
pig populations (Ulrich et al, 1999). More recently, a third lymphotropic herpesvirus 
PLHV-3 has been identified in blood and lymphoid organ samples from domestic and 
feral pigs from different geographic locations (Chmielewicz et al, 2003b), and is more 
distantly related to PLHV-1 and -2 than they are to each other.
Although PLHV appears not to be pathogenic in pig populations, it has been associated 
with a high incidence of posttransplant lymphoproliferative disease (PTLD) in miniature 
swine undergoing allogeneic haematopoietic cell transplantation (Huang et al, 2001), 
with a high mortality rate in these pigs. This PTLD in swine was morphologically and 
histologically similar to EBV-associated PTLD observed in human allotransplantation. 
PLHV sequences found in swine with PTLD, were later shown to be identical to those 
of PLHV-1 (Goltz et al, 2002), suggesting that PLHV-1 is active during PTLD and may 
be involved in the etiology of the disease. However, activation of PLHV-1 was not 
detected in baboon recipients of porcine thymokidney, kidney, thymus and heart 
xenografts (Mueller et al, 2004).
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Although there is no evidence that PLHVs can infect humans, the fact that other 
gammaherpesviruses can cross the species barrier, and that PLHVs can cause 
lymphoproliferative diseases in the transplant setting, demonstrates that PLHVs will 
have to be eliminated from pigs being bred for xenograft organs.
1.9 Porcine cytomegalovirus
Porcine (P) CMV, sometimes termed suid herpesvirus 2, was first described by Done in 
1955, as large basophilic intranuclear inclusions in cytomegalic cells, and was later 
classified as a betaherpesvirus. Considering that HCMV is frequently transmitted in the 
allograft, where it reactivates and is associated with end-organ disease and graft 
rejection (Fishman & Rubin, 1998), it is believed that the porcine equivalent, PCMV 
may pose a risk to human recipients of porcine xenografts. This risk was highlighted by 
the recent reported transmission of baboon (B) CMV to a human recipient of a baboon 
liver (Michaels et al, 2001). Replication-competent BCMV was isolated from the 
peripheral blood of the patient 4 weeks posttransplantation, and 10 days after 
discontinuation of ganciclovir (GCV) prophylaxis. The presence of BCMV was 
confirmed by BCMV-specific PCR analysis of a CMV-like virus isolated from human 
foreskin fibroblast and MRC5 human foetal lung fibroblast cultures, that had been 
inoculated with the patient’s peripheral blood leukocytes. Replication-competence of 
this BCMV isolate was demonstrated by serial passage for up to five times in human 
foreskin fibroblast and MRC5 cells, and by plaque purification. The absence of BCMV 
in further blood samples from the patient following reinitiation of GCV therapy 
suggested that BCMV was susceptible to GCV. The patient died 70 days following 
xenotransplantation from an acute haemorrhage of the brain, secondary to disseminated 
aspergillus infection. No pathologic evidence of active CMV disease was seen at 
autopsy, and immunity to BCMV was not determined. BCMV is currently the only 
known infectious virus to have been transmitted to humans following 
xenotransplantation.
1.9.1 PCMV DNA sequence analysis
Although PCMV was initially characterised as a cytomegalovirus based on the 
identification of cytomegalic inclusions which are characteristic of CMV infections
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(Mattes et al, 2000), recent sequence analysis of the DNA polymerase, glycoprotein B 
and major capsid protein genes of PCMV show that it is more genetically related to 
HHV-6 and -7, than to HCMV and murine (M) CMV. This was first suggested 
following phylogenetic analysis of partial sequences of the viral DNA polymerase gene 
of PCMV and comparison with other herpesviruses (Widen et al, 1999; Rupasinghe et 
al, 1999). Later, characterisation of the entire DNA polymerase gene of PCMV showed
48.2 % and 48.5 % amino acid sequence identity with HHV-6 and HHV-7 respectively, 
compared with 37 % identity with HCMV (Goltz et al, 2000). In addition, analysis of a 
German isolate and British and Japanese strains showed differences of 0.4-1 % on the 
nucleotide and amino acid level. Characterisation of the major capsid protein gene of 
PCMV showed 53.2 % and 51.9 % amino acid sequence identity with HHV-6 and -7 
respectively, compared with 44.3 % and 46.8 % identity with HCMV and MCMV 
(Rupasinghe et al, 2001). More recently, the sequence of the glycoprotein B gene was 
determined and comparisons were made between different strains of PCMV and 
between other herpesviruses (Widen et al, 2001). Again, the highest amino acid 
sequence identities were found with HHV-6 and -7 (43.4 % and 42.6 % respectively). 
Strain differences of 0.6-1.7 % on a nucleotide level and 3.4 % at the protein level were 
found between five different PCMV strains and isolates from the UK, Germany, Spain, 
Japan and Sweden, indicating intra-species variation.
1.9.2 Epidemiology and transmission
PCMV is endemic in world-wide pig populations including those of high health status, 
with several strains and isolates of PCMV being identified. In the UK, serological 
evidence indicates that over 90 % of herds have been exposed to the virus (Edington, 
1999). Whilst studies carried out in Japan and the Netherlands showed 99.4 % and 93 % 
of pigs were seropositive, respectively (Tajima et al, 1993; Rondhuis et al, 1980). PCR 
analysis of lung tissue and nasal scrapings of Canadian pigs showed that 59 % were 
positive for PCMV (Hamel et al, 1999).
Virus can be recovered from nasal and ocular secretions, urine, cervical fluids from 
primary infections in pregnant sows, and from the testis and epididymis (Edington,
1999). Virus is thought to be transmitted horizontally and in utero, with transmission
64
Chapter 1: General introduction
most commonly occurring via the nasal route (Plowright et al, 1976), but also by saliva 
and contaminated urine.
It has been reported that PCMV appears to be host-specific in vivo and in vitro and that 
the virus has failed to replicate in rabbits, mice, hamsters, chick embryos, and cattle 
(Edington, 1999).
1.9.3 Pathogenesis and clinical manifestations
In commercial pig herds infection occurs between 5 and 8 weeks of age, coinciding with 
the mixing of litters 3 weeks after birth (Plowright et al, 1976). Virus can be recovered 
from nasal secretions from 5 weeks of age, with antibody production detected between 8 
and 11 weeks. Clinical features of PCMV infection vary depending on the age of the 
pig. In adults, infection is predominantly silent, although infected pregnant sows often 
appear anorexic and lethargic (Edington et al, 1977). Infection in foetuses and neonates 
leads to fatal generalised disease, with most piglets either being bom dead or dying soon 
afterbirth (Edington et al, 1976a; Edington et al, 1976b; Edington et al, 1977). In older 
piglets, infection is characterised by rhinitis, respiratory distress and poor weight gain 
(Plowright et al, 1976).
From studies of experimental infections in piglets of varying ages, piglets infected with 
PCMV at less than 2 weeks of age showed clinical symptoms of disease. In one study 
where piglets were infected intranasally at 1 day of age (Edington et al, 1976b), 
viraemia was detected at 5-19 days post-infection (dpi). Three out of 6 piglets died 
within 5 weeks as a result of generalised PCMV infection, while in the remaining 
piglets infection was accompanied by poor growth. Findings were similar in a second 
study where piglets were infected intranasally with PCMV at 1 and 8 days of age 
(Edington et al, 1976a). Symptoms of PCMV infection were detected at 10-18 dpi, and 
most piglets infected at this age died or showed signs of dying as a result of PCMV 
infection. At necropsy there were widespread haemorrhages, particularly in the lungs 
and kidneys. PCMV was detected in many tissues, particularly reticulo-endothelial 
cells; lung macrophages, liver, spleen, lymph nodes, adrenal gland and capillary 
endothelium.
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Where piglets were infected at greater than 2 weeks of age, piglets showed no clinical 
symptoms of disease. In piglets infected at three weeks of age, viraemia was detected at 
14-16 dpi but all piglets remained healthy (Edington et al, 1976b). In addition, no 
clinical abnormalities were observed when piglets were infected at 14 and 16 days of 
age (Edington et al, 1976a). Intranuclear inclusions and cytomegaly were mainly found 
in epithelial cells, for example, in the mucous glands of the nasal mucosa and kidney 
tubule cells. Infection was also observed in the epithelial cells of salivary, lacrimal, and 
Harderian glands, mucous glands of the oesophagus, epithelial lining of the duodenum 
and hepatic cells.
Following these observations, the clinical manifestations of PCMV infection in 
neonates was termed fatal generalised disease, while manifestations in older piglets 
were termed asymptomatic generalised infection (Edington et al, 1976a).
1.9.4 Evidence for in utero infection
PCMV congenital infection was first reported by Raq in 1961, when characteristic 
intranuclear inclusion bodies and cytomegaly were observed in the nasal mucous glands 
of a day-old pig (Edington et al, 1977). Congenital infection has since been 
demonstrated following experimental PCMV infection of pregnant sows, with or 
without the presence of circulating antibody.
Six seronegative sows were intranasally infected with PCMV between 31 and 85 days 
of gestation (Edington et al, 1977). Eighteen out of 60 foetuses died during the gestation 
period, and evidence of PCMV infection was found in stillborn foetuses and other 
piglets, which died within a week of birth. There was no correlation between the stage 
of gestation in which sows were infected, and the number of foetal deaths. In a second 
study, two serologically positive sows were intranasally infected with PCMV at day 69 
of gestation (Edington et al, 1988a). Four out of 24 foetuses died during gestation and 
virus was detected in various foetal tissues either by virus isolation or indirect 
immunofluorescence (IIF). Virus was detected in a further 4 apparently normal piglets. 
This suggests that PCMV can cross the placental barrier in spite of circulating 
antibodies. In a third study, congenital infection resulting from experimental infection 
of the sow, was demonstrated in the early stages of gestation. Nine sows from a SPF
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herd were intranasally infected at day 2 of gestation (Edington et al, 1988b). Sows were 
sacrificed 28-33 dpi and embryos examined for evidence of PCMV infection. Seven out 
of 85 embryos were positive for PCMV by virus isolation and IIF. In utero infection 
seemed to correlate with the time of maternal shedding of the virus. From these results it 
is evident that infection in utero can occur at any stage of gestation, when sows are 
experimentally infected with PCMV. However, it is still unclear how common 
transplacental transmission is in a conventional setting.
1.9.5 Growth in culture
In vitro cultivation of PCMV has proved difficult. The virus has been grown in lung 
macrophages, but because these cells do not replicate, primary cultures must be 
obtained. More recently, PCMV has been shown to replicate in fibroblast- and 
epithelial-like pig fallopian tube (PFT) cell lines, designated 19-PFT-F and 19-PFT-E, 
with 19-PFT-F cells being more susceptible to PCMV (Kawamura et al, 1992). Virus is 
slow growing in these cells, with characteristic cytomegalic cytopathic effect (CPE) 
seen 14 dpi. However, the addition of the mitogen 12-O-tetradecanoylphorbol 13- 
acetate (TPA) to the culture medium was reported to increase the rate of virus 
replication in these cells, with CPE and cytomegaly observed 2 days after inoculation 
(Kawamura & Matsuzaki, 1996).
1.9.6 Detection and prevention
In the 1970s, when the majority of studies into the epidemiology and pathogenesis of 
PCMV infection were performed, PCMV was detected by virus isolation and culture of 
blood and swab samples in porcine lung macrophages, as well as by IIF of serum, and 
histopathology on tissue samples to determine the presence of cytomegalic inclusions 
(Plowright et al, 1976; Edington et al, 1976a; Edington et al, 1976b; Edington et al, 
1977). In commercial pig herds, the presence of PCMV is most often confirmed by 
detecting antibody by IIF (Rondhuis et al, 1980), or enzyme-linked immunosorbent 
assay (ELISA) (Tajima et al, 1993). Recently, PCR assays have been developed to 
detect viral DNA. Primers in these assays have been used to amplify regions of the viral 
DNA polymerase (Widen et al, 1999; Hamel et al, 1999) and major capsid protein 
genes (Rupasinghe et al, 2001) of PCMV. Meanwhile, no specific treatment for PCMV
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infection has been developed or used. This is perhaps because endemic PCMV infection 
does not present major economic problems in well-managed pig herds.
1.9.7 The potential for the transmission of PCMV in xenotransplantation
To assess the likelihood of the transmission of PCMV to humans in xenotransplantation, 
attempts have been made to determine whether PCMV can infect human cells in vitro. 
However, following co-cultivation of human B cells (Raji cells) and HEK293 cells with 
porcine alveolar macrophages infected with PCMV, no PCMV DNA was detected in 
the human cells by PCR (Tucker et al, 1999). To date, these are the only cells in which 
this type of study has been carried out. There are also no data available on human 
exposures to PCMV, since much of the recent research on the transmission of porcine 
viruses to human xenograft recipients has focused on PERVs.
Reactivation of latent PCMV has been demonstrated following administration of 
immunosuppressive agents in pigs. Administration of corticosteroids 56-62 dpi resulted 
in excretion of PCMV from gnotobiotic pigs 70 days following infection with PCMV 
and 38 days since the last detection of PCMV in nasal secretions (Edington et al, 
1976b). In addition, administration of prednisolone in pigs inoculated with PRV 
resulted in reactivation of PCMV, with basophilic inclusion bodies seen in endothelial 
cells (Narita et al, 1985).
1.10 Human betaherpesviruses
At the time of initiating this thesis, PCMV was thought to be most closely related to 
HCMV, however, as previously described (section 1.9.1), recent sequence analysis 
shows the virus to be most closely related to HHV-6 and -7. HCMV (genus 
Cytomegalovirus), together with HHV-6 and -7 (both genus Roseolovirus), make up the 
human betaherpesvirus subfamily. Given the lack of characterisation of the biology of 
PCMV, the following section will describe certain aspects of human betaherpesvirus 
biology, with particular emphasis on HCMV, since this is the prototype member, and 
the most extensively studied of the betaherpesvirus subfamily. HCMV is one of the 
most common viral causes of congenital infection, and a significant cause of disease in 
the immunocompromised, being the most important pathogen affecting transplant
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recipients (Fishman & Rubin, 1998). HHV-6 and -7 are more recently identified 
lymphotropic viruses, and are therefore less well characterised than HCMV. HHV-6 
was first isolated during routine culture in 1986, from the peripheral blood of patients 
with lymphoproliferative disorders and HIV (Salahuddin et al, 1986), while HHV-7 was 
first isolated from CD4+ T cells of a healthy adult in 1990 (Frenkel et al, 1990). As with 
HCMV, both viruses may be reactivated from latency following primary infection, and 
can result in disease in the immunocompromised.
1.10.1 Betaherpesvirus biology 
Virion morphology
Betaherpesvirus morphology is typical of all herpesviruses (Figure 1.6). The HCMV 
virion is 150-200 nm in size, and consists of a linear double-stranded DNA genome, 
encased in an icosahedral capsid, surrounded by an amorphous protein layer called the 
tegument, and a lipid bilayer envelope consisting of cellular polyamines and lipids, and 
viral glycoproteins. The virion capsid is made up of 162 capsomers composed of four 
proteins, all homologous to ones identified in HSV including; the major and minor 
capsid proteins (MCP and mCP), the minor capsid binding protein (mC-BP), and the 
smallest capsid protein (SCP) (Mocarski & Courcelle, 2001). The HCMV virion 
envelope carries three prominent glycoprotein complexes; gCI, gCII and gCIII, 
conserved among herpesviruses. One of these, gCI, is made up of covalently-linked, 
proteolytically-processed, homodimers of glycoprotein (g) B, while gCIII is composed 
of gH, gL and gO. Both are essential for virus entry into cells (Navarro et al, 1993), and 
are important targets for neutralising antibodies. Glycoprotein B is the major heparin 
sulphate proteoglycan-binding protein, and binds to cellular receptors including the 
recently identified epidermal growth factor receptor (EGFR) (Wang et al, 2003). A third 
glycoprotein complex gCII is comprised of gM and gN, and also binds neutralising 
antibodies. At least 25 proteins are located in the tegument layer of the virion; some of 
these, such as ppl50 and pp65 are highly immunogenic, while others function as 
transactivators (Mocarski & Courcelle, 2001). In addition to infectious virions, HCMV- 
infected cells produce dense bodies, consisting of enveloped tegument proteins without 
a nucleocapsid, and noninfectious enveloped particles, which contain capsids but lack a
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A
Figure 1.6. A negatively stained enveloped herpesvirus particle (A) and icosahedral 
capsid (B) (Stannard, 1995). The herpesvirus virion consists of a core containing a 
linear double-stranded DNA genome, surrounded by an icosadeltahedral capsid of 
approximately 100-110 nm in diameter and made up of 162 capsomers. The capsid itself 
is surrounded by an asymmetrical, amorphous protein layer called the tegument, and a 
lipid bilayer envelope consisting of cellular polyamines and lipids, and viral 
glycoproteins.
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DNA core. Neither of these two particles are capable of infection and replication in 
cells.
Viral genome
At 235 kb in size, the HCMV genome is the largest of all the herpesviruses, and is 
comprised of unique long (UL) and short (US) regions, each flanked by direct and 
inverted repeats (TRL/IRL and IRS/TRS) (Dolan et al, 2004). Within these repeat 
sequences are the herpesvirus-conserved elements pac\ and p a d ,  which mediate 
cleavage and packaging of the viral genome. HHV-6 comprises variants A (prototype 
strain U1102) and B (prototype strains HST and Z29), which are approximately 160 kb 
in size and share an overall nucleotide identity of 90 % (Gompels et al, 1995; 
Dominguez et al, 1999; Isegawa et al, 1999). These strains are predicted to contain 119 
(strains U1102 and Z29) and 115 (HST strain) ORFs, 67 % of which, are homologous to 
those of HCMV (Gompels et al, 1995). Meanwhile, isolates JI (145 kb) and RK (153 
kb) of HHV-7 have been completely sequenced (Nicholas, 1996; Megaw et al, 1998). 
HHV-7 strain Jl proteins were found to share 41-75 % nucleotide sequence identity 
with HHV-6 proteins (Nicholas, 1996). The majority of HHV-6 and -7 genes are 
arranged in the unique region (U) of the genome, which is flanked by direct repeat (DR) 
sequences. At present, the structure of the PCMV genome remains undefined.
Virus tropism
Classification of HCMV as a betaherpesvirus was originally based on its slow growth in 
vitro and restricted species specificity. HCMV is poorly adapted to growth in culture; 
with a slow appearance of CPE, primary differentiated human skin or lung fibroblasts 
are the most permissive cell type for replication, and therefore commonly used in 
routine culture (Mocarski & Courcelle, 2001). In contrast, in vivo, HCMV replicates 
dynamically with a doubling time of approximately 1 day during active infection 
(Emery et al, 1999), in most of the major cell types including; fibroblasts, macrophages, 
endothelial cells, epithelial cells, smooth muscle cells, stromal cells, neuronal cells, 
neutrophils and hepatocytes (Sinzger et al, 1995; Sinzger et al, 1999; Jarvis & Nelson,
2002). The presence of HCMV within histopathological samples is routinely determined 
by the visualisation of ‘owl’s eye’ intranuclear inclusions, and are a characteristic
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unique to HCMV infections (Mattes et al, 2000). As described previously, PCMV 
infection is also characterised by the presence of cytomegalic inclusions (Plowright et 
al, 1976; Edington et al, 1976a; Edington et al, 1976b; Edington et al, 1977; Edington 
etal, 1988b).
HHV-6 and -7 are predominantly lymphotropic herpesviruses, replicating in cells of T 
cell lineage, with HHV-7 predominately targeting CD4+ lymphocytes (Takahashi et al, 
1989). In vitro, both HHV-6 and -7 are routinely cultured in continuous T cell lines such 
as Jurkat and SupT-1 cells, inducing CPE characterised by large ballooning cells 
(Gompels, 2004). In vivo, HHV-6 has a wider tropism, including monocytes, and 
epithelial, endothelial and neural cells (Yamanishi, 2001). Interestingly, inclusion 
bodies are not associated with HHV-6 and -7 infection (Mattes et al, 2000).
Virus attachment and penetration
Initial interaction between HCMV and the cell involves the low-affinity binding of gCI 
(gB) and gCII (gM/gN) to heparin sulphate proteoglycans (Compton et al, 1993), which 
are ubiquitously distributed on the cell surface. Following initial attachment, more 
stable interaction is mediated by gB and gH binding to non-heparin cellular receptors. 
One such receptor has been identified as EGFR (Wang et al, 2003). Penetration follows 
fusion of the virion envelope and the cell surface, involving gCIII (gH/gL/gO) and gB 
(Compton, 2004). Nucleocapsids and tegument proteins are released into the cytoplasm, 
and rapidly transported to the nucleus (Landolfo et al, 2003). Viral attachment and 
subsequent activation via cell surface receptors alters host cell gene expression, while 
tegument proteins and regulatory proteins expressed after penetration, regulate cellular 
signalling pathways and gene expression, as infection proceeds (Simmen et al, 2001; 
Song & Stinski, 2002).
The cellular receptor for both variants of HHV-6 is CD46 (Santoro et al, 1999), which 
contributes to its apparent broad tropism in vitro, whereas CD4 is the cellular receptor 
for HHV-7 (Lusso et al, 1994). As with HCMV, HHV-6 and -7 encode homologues of 
glycoproteins gB, gH, gM and gL, which mediate virus attachment and penetration 
(Gompels et al, 1995; Nicholas, 1996). At present, the cellular receptor for PCMV is not 
characterised.
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Gene expression and regulation
As with all herpesviruses, gene expression and replication of the betaherpesviruses 
follows a temporal pattern of expression of different classes of genes termed; immediate 
early (IE), early (E) or late (L) (Figure 1.7), which are transcribed in the nucleus by the 
host cell RNA polymerase II. The expression of many HCMV genes is regulated by 
complex transcriptional elements including enhancers and modulators, which are 
situated upstream of the start site of each gene, and contain dense collections of binding 
sites for various host transcription factors and viral transactivators (Mocarski & 
Courcelle, 2001). These enhancer and modulator elements confer cell tropism and also, 
along with mRNA splicing, allow more than one protein to be produced from the same 
open reading frame (ORF). In permissive human fibroblast cells, transcription of 
HCMV IE genes begins within 1 hour (hr) of infection, with the majority of expression 
arising from the major (M) IE locus, and encoding proteins involved in the regulation of 
E, L and host genes (Mocarski & Courcelle, 2001). E genes are transcribed 4-24 hrs 
postinfection, and encode proteins involved in DNA replication as well as 
immunomodulation, while L genes are transcribed following DNA replication (later 
than 24 hrs postinfection), and encode proteins involved in virion morphogenesis and 
maturation. It is highly likely that PCMV gene expression will follow a similar temporal 
cascade.
DNA replication
HCMV DNA replication takes place within distinct sub-nuclear regions, similar to sites 
of cellular DNA synthesis. The HCMV genome circularises in the nucleus of infected 
human fibroblasts within 4 hrs postinfection, while DNA replication begins at 16 hrs, 
with several thousand copies produced in each infected cell (Mocarski & Courcelle, 
2001). Eleven HCMV gene loci are required for replication (Pari & Anders, 1993). Six 
HSV-1-homologous proteins make up the replication fork; including the DNA 
polymerase, polymerase-associated processivity factor, single-stranded DNA-binding 
protein, and three other proteins which form the helicase-primase complex. The 
polymerase-associated processivity factor prevents dissociation of the polymerase from 
the template DNA, while the single-stranded DNA-binding protein prevents
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Figure 1.7. HCMV gene expression and viral gene product functions during productive 
infection (Landolfo et al, 2003).
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re-annealing of the DNA strands following unwinding by the helicase-primase complex. 
In addition, three viral transactivators, as well as two further proteins, are required for 
optimal replication. Unlike HCMV, HHV-6 and -7 encode an origin-binding protein 
homologue, U73, which is found in alphaherpesviruses (Krug et al, 2001). HCMV 
replication starts from a single origin site (or/Lyt), located within the UL region (Masse 
et al, 1992), and proceeds bi-directionally by a rolling-circle mechanism producing 
concatemeric molecules. Following replication, concatemeric viral DNA molecules 
mature by inversion of both L and S components in the nucleus (McVoy & Adler,
1994), giving rise to the four isoforms of the HCMV genome. Single oriLyt sites have 
also been identified in HHV-6 and -7 (Dewhurst et al, 1993; van Loon et al, 1997), and 
contain binding sites for the HHV-6 and -7 origin-binding proteins.
Encapsidation and egress
The HCMV genome is packaged into pre-formed capsids composed of MCP, mCP, 
mC-BP, SCP and the assembly protein (AP) precursor. The p a d  cleavage/packaging 
signal directs the packaging from the US end into the maturing capsids until no more 
DNA can be inserted (‘headfull’ mechanism), displacing AP (McVoy & Adler, 1994). 
The concatemers are then cleaved into linear, unit lengths.
Accumulation of nucleocapsids within the nucleus form characteristic nuclear owl’s eye 
inclusions that are readily observed by light microscopy. From the nucleus, progeny 
nucleocapsids bud into the perinuclear cistemae, acquiring an initial envelope modified 
with viral glycoproteins. Nucleocapsids then undergo a series of de-envelopment and re­
envelopment processes as they are transported through the cytoplasm, where the 
tegument is added (Mettenleiter, 2002). The virion is then transported in vesicles via the 
Golgi, where envelope glycoproteins are glycosylated, to the cell surface prior to fusion 
with cellular membranes and release beginning at 72 hrs postinfection (Landolfo et al,
2003).
Latency
The HCMV genome is maintained as a covalently closed circle in the nucleus of 
lineage-committed myeloid cells including progenitors of macrophages (monocytes),
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granulocytes, dendritic cells and endothelial cells (Jarvis & Nelson, 2002). In some 
latently infected cells, HCMV latency-associated transcripts (LATs) derived from the 
MIE region and encoding several proteins, have been identified (Kondo & Mocarski,
1995), but are thought to play a minimal role in the regulation of HCMV latency and 
reactivation (Jarvis & Nelson, 2002). In an alternative theory, latency is thought to 
result from the repression of MIE gene expression (Sissons et al, 2002). Subsequent 
reactivation of HCMV and productive infection is thought to result from immune 
activation, in response to pathogenic or allogeneic stimulation, which induces 
proinflammatory cytokine (IL-2 and interferon (IFN) -y) production by T cells, and 
differentiation of latently infected progenitor cells into a permissive cell type which 
supports viral replication (Soderberg-Naucler et al, 1997; Jarvis & Nelson, 2002). In 
immunocompromised individuals reduced immune surveillance leads to uncontrolled 
virus replication, systemic infection and HCMV disease.
HHV-6 and -7 establish latency in cells of the lymphoreticular system. HHV-6 sites of 
latency are thought to include monocytes and early bone marrow progenitor cells 
(Kondo et a\, 1991; Luppi et al, 1999), with viral LATs detected in latently infected 
macrophages (Kondo et al, 2002). Meanwhile, monocytes also provide a possible site 
for HHV-7 latency (Zhang et al, 2001). An alternative form of HHV-6B persistence is 
characterised by high viral loads in blood and integration of the genome into host cell 
chromosomes (Luppi et al, 1993), in particular at the telomeric extremity of the short 
arm of chromosome 17 (Torelli et al, 1995).
Immunomodulation
All betaherpesviruses encode immunomodulatory functions which enable them to evade 
immune responses and persist within the host (Mocarski, 2002). In particular, they 
encode proteins involved in the down-regulation of MHC class I (Jones et al, 1996; 
Gewurz et al, 2001; Shamu et al, 2001; Hewitt et al, 2001; Hudson et al, 2001), and 
class II molecules (Tomazin et al, 1999; Miller et al, 2001), and encode viral 
chemokines (Penfold et al, 1999; Zou et al, 1999), and chemokine receptors (Chee et al, 
1990; Isegawa et al, 1998; Milne et al, 2000; Nakano et al, 2003).
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1.10.2 Virus transmission
There are significant similarities in the transmission routes, and time of acquisition, 
between human betaherpesvirus and PCMV infections. Human betaherpesvirus 
infections are ubiquitous in the human population. Primary infection can occur by 
horizontal and vertical transmission, while recurrent infection may result from either 
reactivation or re-infection with a second virus strain. Horizontal transmission of 
HCMV is thought to occur by close contact between individuals including the transfer 
of saliva, and other body fluids during sexual intercourse. In addition, HCMV is 
frequently transmitted by organ transplantation, with a seropositive organ transmitting 
virus to a seronegative donor in 60-80 % of cases (Griffiths & Emery, 2002).
HCMV can be transmitted vertically from a mother undergoing primary or recurrent 
HCMV infection to her baby either; in utero via the placenta, perinatally through 
ingestion of infected cervical secretions, or post-natally through ingestion of infected 
breast milk. Early publications suggested a relationship between the presence of 
maternal antibodies and congenital infection, with intrauterine infection occurring in 
approximately 30-40 % of pregnancies following primary infection (Stagno et al, 1986), 
and in 1 % of women following recurrent infection (Stagno et al, 1982). However, in a 
recent survey of studies performed between 1977 and 1997, a high seroprevalence was 
associated with a high incidence of congenital infection (Gaytant et al, 2002), 
suggesting that pre-existing maternal immunity is unable to completely prevent 
transmission of virus to the foetus.
Perinatal transmission occurs through exposure to infected maternal genital secretions 
during birth. Approximately 10 % of women are reported to shed HCMV from the 
vagina or cervix, and of these, 50 % are reported to transmit HCMV to the newborn 
(Pass, 2001). The most common route of vertical transmission is through infected breast 
milk, such that in countries where seroprevalence and breastfeeding are common, more 
than 50 % of infants acquire HCMV by the age of 1 year (Pass, 2001).
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1.10.3 Pathogenesis and clinical manifestations
HCMV infection is generally asymptomatic in healthy individuals, and causes disease 
only in the immunologically naive, such the foetus, and in immunocompromised 
individuals, such as AIDS and transplant patients. During the systemic phase of primary 
infection, HCMV disseminates throughout the body by leukocyte-associated viraemia, 
leading to the seeding of ductal epithelia. Following initial infection, HCMV is shed in 
saliva, urine, tears, semen, cervicovaginal fluid and breast milk (Pass, 2001).
Infection in the immunocompromised
HCMV is one of the most common opportunistic infections in the 
immunocompromised, causing a variety of end-organ diseases, ‘HCMV diseases’, as 
well as indirect effects (Table 1.7) (Griffiths, 2002). The most severe infections are seen 
in recipients of bone marrow transplants (BMT) and AIDS patients with low CD4+ T 
cell counts, however, disease is also common following solid-organ transplantation.
The onset of HCMV infection in recipients of solid organ transplants is generally 1-4 
months posttransplant, when the patient is most profoundly immunosuppressed 
(Fishman & Rubin, 1998). HCMV can be reactivated from latency in the recipient or 
donor organ, by inflammatory cytokines, while immunosuppressive agents promote 
persistence and spread of the virus by suppressing host antiviral immune responses, 
leading to uncontrolled viral replication. In general, those without prior immunity are at 
a higher risk of uncontrolled viral replication and disease (Patel & Paya, 1997). Indeed, 
primary infection, viraemia and viral load, have all been identified as risk factors for 
HCMV disease in transplant recipients (Cope et al, 1997b), with a high viral load being 
the primary determinant (Cope et al, 1997a; Hassan-Walker et al, 1999), and primary 
infection and viraemia being secondary to this. Direct end-organ effects are usually seen 
in the transplanted organ, for example, nephritis in kidney recipients, hepatitis in liver 
recipients, myocarditis in heart recipients, and pneumonitis in lung recipients, while 
indirect effects can contribute to acute and chronic graft rejection (Fishman & Rubin, 
1998).
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Table 1.7. HCMV diseases in the immunocompromised (Griffiths, 2002).
Symptom Solid organ 
Transplantation
BMT AIDS
Fever/hepatitis ++ + +
Gastrointestinal + + +
Retinitis + + ++
Pneumonitis + ++
Myelosuppression ++
Encephalopathy +
Polyradiculopathy +
Immunosuppression +
Rej ection/ GVHD + ?
Atherosclerosis +
Death + +
+ clinical problem, ++ major clinical problem, ? controversial 
GVHD, graft vs. host disease
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HHV-6 and -7 infections posttransplantation are common, and are thought to result 
primarily from reactivation because of the high seroprevalence of these viruses. Direct 
clinical effects of HHV-6 infection in BMT and solid-organ transplant recipients 
include pneumonitis (Cone et al, 1993; Singh et al, 1997), encephalitis (Drobyski et al, 
1994; Singh et al, 2000a), hepatitis (Ljungman et al, 2000; Ward et al, 1989) and bone 
marrow suppression (Drobyski et al, 1993; Carrigan & Knox, 1995). While HHV-7 has 
been associated with encephalitis in BMT patients (Chan et al, 1997) and hepatitis in 
liver transplant recipients (Griffiths et al, 1999).
1.10.4 Prevention and treatment of HCMV
In some cases, the use of seronegative or leukocyte-depleted blood products could be 
used to prevent transmission of HCMV to the immunocompromised or pregnant women 
(Ljungman, 2004). However, the use of seronegative donor organs to prevent HCMV 
transmission following solid-organ transplantation is not practicable because of the 
limited supply of donor organs. Studies into the development of a vaccine for at-risk 
groups are underway, with HCMV gB and pp65 being potential components of a 
subunit vaccine (Pass et al, 1999). Meanwhile, antiviral therapy is the mainstay for the 
treatment of life-threatening HCMV disease in the immunocompromised. Since HCMV 
viral load is the primary risk factor for the development of HCMV disease, antiviral 
therapies should be deployed to prevent viral loads from rising above the level 
associated with disease.
Antiviral therapy
Antiviral therapy can be employed through prophylactic or pre-emptive strategies, or by 
the treatment of established disease. In pre-emptive therapy antivirals are administered 
following the detection of systemic infection, i.e. viraemia, while prophylactic antiviral 
therapy is administered prior to the detection of virus. In the case of transplant 
recipients either pre-emptive therapy or prophylaxis are usually employed, although 
there are limitations associated with both approaches (Emery, 2001; Hart & Paya, 
2001). At present, there are five antiviral agents licensed for use in the treatment of life- 
threatening HCMV infections in the immunocompromised; these being, ganciclovir, 
valganciclovir, foscamet, cidofovir and fomivirsen (Figure 1.8) (De Clercq, 2003).
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Figure 1.8. Antiviral agents licensed for use in the treatment of HCMV infection.
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Ganciclovir (GCV)
GCV is the first choice therapy for life-threatening or sight-threatening HCMV 
infections in the immunocompromised (British National Formulary (BNF), 2004). It is a 
competitive acyclic nucleoside analogue inhibitor of the viral DNA polymerase and 
requires initial mono-phosphorylation by the protein kinase encoded by HCMV UL97 
(Figure 1.9). Following initial phosphorylation, GCV-MP is further phosphorylated by 
cellular kinases, and inhibits the viral DNA polymerase by competing with guanosine 
triphosphate (GTP) for incorporation into the DNA chain. Since GCV has a 3’-OH 
group it is not an absolute chain terminator, but because it is acyclic, elongation of the 
viral DNA becomes unstable and terminates.
Both GCV prophylactic and pre-emptive strategies are employed to prevent HCMV 
infection and disease in transplant recipients. Pre-emptive GCV therapy was shown to 
be effective in preventing HCMV disease in liver transplant recipients, with oral GCV 
more effective than intravenous treatment (Singh et al, 2000b), while, in a randomised, 
double-blind, placebo-controlled trial GCV prophylaxis reduced HCMV-induced illness 
in heart recipients (Merigan et al, 1992). Prolonged low-dose GCV prophylaxis 
following heart transplantation reduced HCMV disease following primary infection, but 
only delayed the onset of HCMV disease and reduced morbidity in seropositive 
recipients (Macdonald et al, 1995). In a more recent randomised, placebo-controlled 
study, GCV prophylaxis was found to be a safe and effective method for the prevention 
of HCMV disease after liver transplantation (Gane et al, 1997). In addition, valaciclovir 
prophylaxis was shown to be effective in preventing HCMV disease following renal 
transplantation, and interestingly showed a reduction in biopsy-proven graft rejection in 
those patients at greater risk of HCMV infection (Lowance et al, 1999).
The main side effect of GCV is bone marrow toxicity (myelosuppression), which results 
in neutropenia and thrombocytopenia (Dollery, 1999). In addition, poor oral 
bioavailability means that plasma concentrations are often too low to fully suppress 
HCMV replication, allowing the selection of resistant virus mutants. Mutations, 
including base substitutions, deletions or insertions, within the UL97 gene are the most 
common cause of this resistance, although secondary mutations may arise in the UL54 
gene (Drew et al, 2001).
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Figure 1.9. Mechanisms of action of antiviral agents licensed for use in the treatment of 
HCMV. Nucleotide analogues GCV and VGCV are first activated by HCMV UL97- 
encoded kinase, followed by phosphorylation by cellular kinases. Nucleotide analogue 
HPMPC is phosphorylated only by cellular kinases. These agents inhibit the viral DNA 
polymerase by competing with the native nucleoside triphosphates (dGTP and dCTP). 
PFA inhibits the viral DNA polymerase by competing with pyrophosphate (PPi), while 
fomivirsen inhibits translation of HCMV IE mRNA. MP, monophosphate; DP, 
diphosphate; TP triphosphate; dGTP deoxyguanosine triphosphate; dCTP
deoxycytosine triphosphate.
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Valganciclovir (VGCV)
VGCV is the valine ester, and pro-drug of GCV, and is rapidly metabolised into GCV 
following ingestion (Jung & Dorr, 1999). It has an oral bioavailability that is 10-fold 
higher than that of oral GCV, achieving plasma concentrations that are comparable with 
intravenous GCV (Pescovitz et al, 2000). It may therefore be possible to prevent the 
development of resistance by the use of oral VGCV instead of oral GCV. VGCV is 
licensed for induction and maintenance therapy for HCMV retinitis in AIDS patients 
(BNF, 2004).
Foscarnet (PFA)
PFA is a pyrophosphate analogue, and inhibits the HCMV DNA polymerase by binding 
to it’s pyrophosphate-binding site. This inhibits cleavage of the phosphonate groups 
from deoxynucleotide triphosphates (dNTPs) during chain elongation. PFA is the 
second-line therapy for HCMV infections and is often administered in patients with 
GCV-induced bone marrow toxicity or resistance, but is itself nephrotoxic (Nichols & 
Boeckh, 2000). PFA also suffers from poor bioavailability and must be administered 
three times daily. PFA resistant virus has been documented, with resistance mapped to 
mutations within the UL54 DNA polymerase gene (Baldanti et al, 1996; Chou et al, 
1998).
Cidofovir (HPMPC)
HPMPC is an acyclic nucleotide phosphonate analogue and a competitive inhibitor of 
the HCMV DNA polymerase. Unlike GCV, the presence of the phosphonate group 
means that HPMPC does not require initial phosphorylation by a virus-encoded kinase, 
and is further phosphorylated by cellular kinases (figure 1.9). The three HPMPC 
metabolites; HPMPC phosphate, diphosphate, and phosphate adduct, all have long 
intracellular half-lives of approximately 6, 17, and 48 hrs respectively (Ho et al, 1992), 
which means that the drug can be administered less frequently. The primary indication 
for HPMPC, is the treatment of HCMV retinitis in AIDS patients for whom GCV and 
PFA are inappropriate (BNF, 2004). In addition, primary HPMPC pre-emptive therapy, 
pre-emptive therapy for whom GCV or PFA had failed, and HPMPC treatment of
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established disease, are all effective against HCMV disease in BMT patients (Ljungman 
et al, 2001). Side effects and limitations include nephrotoxicity, the fact that it must be 
administered intravenously, and the development of resistance, which is mapped to the 
UL54 DNA polymerase gene (De Clercq, 2003).
Fomivirsen
Fomivirsen is a phosphorothioate oligonucleotide which inhibits translation of HCMV 
IE proteins by binding to the complementary mRNA sequences (Anderson et al, 1996). 
Although it is specific for HCMV, the technology could be applied to other viruses. It is 
administered by intravitreal injection in salvage therapy for HCMV retinitis in AIDS 
patients, but is associated with ocular adverse effects such as uveitis and retinal 
detachment (Nichols & Boeckh, 2000).
1.10.5 Antiviral therapy for HHV-6 and -7
To date, there have been no controlled trials of antiviral therapy against HHV-6 and -7 
infection in vivo, however, a number of studies have demonstrated the ability of 
currently licensed antiherpetic agents such as GCV, PFA and HPMPC, to suppress 
HHV-6 and -7 replication in vitro (Reymen et al, 1995; Takahashi et al, 1997; De 
Clercq et al, 2001). The U69 gene of HHV-6 is homologous to the UL97 gene of 
HCMV, and was shown to confer GCV susceptibility to a recombinant baculovirus in 
insect cells (Ansari & Emery, 1999). However, the phosphorylation of GCV by the 
HHV-6 U69 gene product appears to be limited, which may account for its modest 
antiviral activity against HHV-6 in certain cell culture systems (De Bolle et al, 2002). In 
vivo, case reports show that GCV and PFA were effective in the treatment of HHV-6 
infection in a BMT patient (Johnston et al, 1999), while GCV also reduced HHV-6 and 
-7 viral loads in liver transplant patients (Mendez et al, 2001). In addition, high-dose 
ACV prophylaxis demonstrated activity against HHV-6 following bone marrow 
transplantation (Wang et al, 1996). Resistance of HHV-6 to antiherpetic agents has been 
mapped to the U38 and U69 genes (Manichanh et al, 2001). Mutations in the U38 DNA 
polymerase gene and the U69 phosophotransferase gene of HHV-6 developed in vitro 
and in vivo, following prolonged exposure to GCV, and resulted in a reduced 
susceptibility to GCV, HPMPC and, to a lesser extent, PFA.
85
Chapter 1: General introduction
1.11 Aims of the thesis
The overall aim of this thesis was to investigate porcine cytomegalovirus issues relevant
to xenotransplantation, and is divided into four objectives:
1. To develop and optimise qualitative and fully quantitative competitive (QC) 
polymerase chain reaction (PCR) assays for PCMV.
2. To determine the prevalence, quantity and organ distribution of PCMV in 
immunocompetent and immunosuppressed pigs being bred for xenograft organs, to 
investigate when virus is acquired, and to examine methods to eliminate PCMV 
from these animals.
3. To clone and express the complete ORF of the glycoprotein B gene of PCMV and a 
truncated version excluding the proposed transmembrane regions, in insect cells, 
using a baculovirus expression system, and to develop a recombinant protein-based 
serological assay for PCMV.
4. To determine the susceptibility of PCMV to established antiherpetic agents in vitro.
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2.1 The development of qualitative and quantitative-competitive (QC) 
PCR assays for PCMV
The methods in this section describe the development of nested qualitative and 
quantitative-competitive (QC) PCR assays to allow both the detection and measurement 
of PCMV DNA loads within porcine samples. The primers used in both of these assays 
amplify a region of the DNA polymerase gene of PCMV (PCMVpol), and were 
designed from a recently published sequence of the gene (Widen et al, 1999). This gene 
was selected as the target in the development of these assays since it is highly conserved 
among different strains of herpesviruses. Both PCMV PCR assays involve two rounds 
of amplification, using nested primers, in order to increase the specificity and yield of 
the product. The first round primers PCMVF1 and PCMVR1 amplify a 236-bp product, 
while primers PCMVF2 and PCMVR2 amplify a 184-bp product, and are shown in 
Table 2.1.
The QC PCR assay for PCMV involves the co-amplification of a PCMVpol control 
sequence alongside sample (wild-type) DNA, and is based on previous fully quantitative 
PCR assays for HCMV, HHV-6, HHV-7, HIV and HHV-8, developed in our 
department (Fox et al, 1992; Clark et al, 1996; Kidd et al, 1996; Atkins et al, 1996; 
Lock et al, 1997). This control sequence is identical to the wild-type target, with respect 
to primer-binding sites, length and G+C content, and differs only by the presence of a 
unique restriction site (Sma I), brought about by a 2-bp change in the PCMVpol 
sequence. This 2-bp alteration was introduced by PCR-mediated site-directed 
mutagenesis, and allows for the separation of wild-type and control amplicons by Sma I 
digestion after PCR amplification. Following the generation of wild-type and control 
PCMVpol sequences and their subsequent cloning into the pGEM-T Easy vector 
(Promega), the PCR parameters were altered to optimise the sensitivity and specificity 
of the PCMV PCR. Finally, the utility of the PCMVpol control sequence to accurately 
quantify PCMV DNA was assessed.
2.1.1 Amplification of the PCMVpol insert
First round primers PCMVF1 and PCMVR1 were used to amplify the 236-bp PCMVpol 
target region (wild-type sequence), from a sample of tissue culture supernatant (TCS) of
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porcine alveolar macrophages infected with PCMV strain B6 (provided by Dr M. 
Banks, Veterinary Laboratories Agency, UK). The PCR mixture contained 100 ng of 
each primer, 2 mM MgCL (Bioline), 200 pM of each dNTP (Promega), 1 U of Taq 
polymerase (Bioline), and either 1 pi, 5 pi, or 10 pi of neat TCS sample of PCMV, in 
(NH4)2SC>4 PCR buffer (Bioline). The cycle parameters used were initial denaturation at 
95 °C for 6 min, followed by 40 cycles of denaturation at 94 °C for 30 s, annealing at 55 
°C for 30 s, and extension at 72 °C for 30 s. The final extension was increased to 10 
min. The PCR was performed on a Hybaid Omnigene thermal cycler.
Table 2.1. PCR primer sequences used in this thesis.
Primer name Primer sequence
PCMVF1 5 ’-CCTATGTTGGCACTGATACTTGAC-3 ’
PCMVR1 5’-CCCTGAAAATCACCGTCTGAGAGA-3’
PCMVF2 5’-AAGCAGCAGCTTGCCCTCAAGGTG-3 ’
PCMVR2 5’-ACTTCTCTGACACGTATTCTCTAG-3’
PCMVFM 5’-TAAGCATGTCCCGGGCTATGCTGG-3’
PCMVRM 5 ’-CCAGCATAGCCCGGGACATGCTTA-3 ’
PCMVFB 5 ’-ACGTGCAATGCGTTTTACGGCTTC-3 ’
PCMVgBF 5’-AACGCGTATGTTTGCGGTCTCTTGTC-3’
PCMVgBR 5’-CACGTCCTCGGTGGATAGCTGCT-3’
PCMVgBT 5 ’-CTCT AACGGCTTT AT ATT AAGGTGGAT A-3 ’
Baculovirus forward 5, t t t a c t g t t t t c g t a a c a g t t t t g -3’
Baculovirus reverse 5 ’ -C AAC AACGC AC AG AAT CT AGC-3 ’
PCMVpolF (Taqman) 5 ’-GCTGCCGTGTCTCCCTCT AG-3 ‘
PCMVpolR (Taqman) 5’-ATTGTTGATAAAGTCACTCGTCTGC-3’
Taqman probe 5 ’ -6F AM-CC ATC ACC AGC AT AGGGCGGG AC-T AMRA-3 ’
2.1.2 Agarose gel electrophoresis
PCR products were analysed by electrophoresis on a 3 % agarose gel in TBE buffer (90 
mM Tris-Borate, pH 8.3; 2 mM EDTA), alongside HyperLadder IV DNA markers
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(Bioline). To prepare the 3 % agarose gel, 3 g of multipurpose agarose (Bioline) were 
added to 100 ml of TBE buffer in a 500 ml sterile Duran bottle, and heated in a 
microwave (850 W) until dissolved. The gel was cooled to -50 °C, before the addition 
of 30 |ig of ethidium bromide (Sigma), and poured into a gel frame containing a comb 
for loading samples. Ten microlitres of PCR product were mixed with 3 pi of loading 
dye (0.25 % bromophenol blue; 0.25 % xylene cyanol; 15 % ficoll type 400 (all Sigma) 
in sterile distilled water (SDW) (Baxter)), and loaded into each well. Gels were 
electrophoresed at 120 V for 30-45 min, and visualised using a UV transilluminator 
(302 nm) with a Baby Imager (Appligene-Oncor) and photographed using a video copy 
processor (Mitsubishi).
2.1.3 Purification of the PCMVpol PCR product and cloning into the pGEM-T 
Easy Vector
The 236-bp PCMVpol product was purified from the PCR mixture by separation on a 2 
% low gelling temperature agarose (Sigma) gel, containing TAE buffer (40 mM Tris- 
acetate; 1 mM EDTA) and ethidium bromide (30 pg), followed by DNA extraction 
using the Wizard PCR Preps DNA Purification System (Promega). Briefly, following 
visualisation on a UV transilluminator, the 236-bp PCMVpol sequence was excised 
from the gel using a clean sterile scalpel. The agarose slice was transferred to a 1.5 ml 
eppendorf and incubated at 70 °C on a heating block until dissolved. One millilitre of 
DNA Purification Resin was added to the melted gel (-300 pi), mixed gently for 20 s, 
and loaded into a 2 ml syringe barrel attached to a Wizard Minicolumn. The syringe 
plunger was inserted slowly to push the mixture through the Minicolumn, which was 
then washed by plunging 2 ml of 80 % isopropanol through the column. The 
Minicolumn was detached from the syringe, placed in a 1.5 ml eppendorf and 
centrifuged at 10,000 xg for 2 min to dry the resin. DNA was eluted by the addition of 
50 pi of SDW and collection of the eluent into a 1.5 ml eppendorf following 
centrifugation at 10,000 xg for 20 s.
The purified PCMVpol PCR product was then cloned into the pGEM-T Easy vector 
(Figure 2.1) to produce the ‘wild-type plasmid’. This is' a high copy number vector, 
which has single 3’-T overhangs at the multiple cloning site. This greatly improves the 
efficiency of ligation of the PCR product by preventing recircularisation of the vector
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Figure 2.1. A diagram of the pGEM-T Easy vector (Promega). The pGEM-T Easy 
vector is a high copy number vector, with a multiple cloning site containing a number of 
restriction sites, located within the a-peptide coding region of the enzyme p- 
galactosidase. The vector has single 3’-T overhangs at the insertion site to allow direct 
cloning of PCR products generated by certain polymerases, and an ampicillin resistance 
gene for selection in E. coli.
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and provides a compatible overhang for PCR products generated by Taq polymerase. 
The vector contains an ampicillin resistance gene and the a-peptide coding region of the 
p-galactosidase gene, allowing for selection and identification of recombinant clones.
The purified PCMVpol PCR product was ligated into the pGEM-T Easy vector 
according to the pGEM-T Easy Vector Systems protocol (Promega). Briefly, the 
PCMVpol PCR product and pGEM-T Easy vector were mixed in a 3:1 and 1:1 molar 
ratio, in a 1.5 ml eppendorf containing; 5 pi of 2* Rapid Ligation Buffer (60 mM Tris- 
HC1, pH 7.8; 20 mM MgCb; 20 mM DTT; 2 mM ATP; 10 % polyethylene glycol), 3 
Weiss units of T4 DNA ligase and SDW to a final volume of 10 pi, and incubated 
overnight at 4 °C. Two microlitres of ligation products were transformed into 50 pi of 
competent JM109 E. coli cells on ice for 20 min, followed by heat-shock at 42 °C for 45 
s. Transformed cells were returned to ice for 2 min, before the addition of 950 pi of 
SOC medium (Invitrogen), and incubation at 37 °C for 1 hr in a shaking incubator 
(~200 rpm). One hundred microlitres of transformed cells were plated onto antibiotic 
selection plates containing 2 % Lima Broth (LB) (Sigma), 1.5 % bacteriological agar 
(Oxoid), 100 pg/ml of ampicillin, 0.5 mM isopropyl-p-D-thiogalactoside (IPTG) and 
100 pg/ml of 5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside (X-Gal) (all Sigma), 
and incubated overnight at 37 °C.
2.1.4 Analysis of recombinant clones
Putative recombinant clones were identified and analysed by picking three single white 
colonies and growing them in 6 ml cultures of 2 % LB containing 50 pg/ml of 
ampicillin. Cultures were incubated for 16 hrs at 37 °C in a shaking incubator (~200 
rpm). Glycerol stocks were prepared from 800 pi of each culture containing 25 % 
glycerol (Sigma), snap frozen in a methanol and dry ice bath, and stored at -80 °C. 
Plasmid DNA was extracted from the remaining culture using the Wizard Plus SV 
Minipreps DNA Purification System (Promega). Each bacterial culture was harvested 
by centrifugation at 2000 xg for 10 min. The pellet was resuspended in 250 pi of Cell 
Resuspension Solution (50 mM Tris-HCl, pH 7.5; 10 mM EDTA; 100 pg/ml RNase A), 
transferred to a clean 1.5 ml eppendorf, and lysed in 250 pi of Cell Lysis Solution (0.2 
M NaOH; 1 % SDS) for 5 min. Lysed cells were incubated with 10 pi of Alkaline
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Protease Solution for 5 min, before the addition of 350 pi of Neutralisation Solution 
(4.09 M guanidine-HCl; 0.759 M potassium acetate; 2.12 M glacial acetic acid; pH 4.2), 
to precipitate cellular proteins. The alkaline protease inactivates endonucleases and 
degrades other proteins. The lysate was cleared by centrifugation (14,000 xg, 10 min), 
loaded onto a Spin Column and centrifuged (14,000 xg) for 1 min. The column was 
washed twice with 750 pi, followed by 250 pi of Column Wash Solution (60 mM 
potassium acetate; 10 mM Tris-HCl, pH 7.5; 60 % ethanol), centrifuging at full speed 
(14,000 xg) for 1 min each time. Plasmid DNA was eluted in 100 pi of Nuclease-Free 
Water (14,000 xg, 1 min) and analysed by nested PCR using primers PCMVF1 and 
PCMVR1 in the first round PCR, and primers PCMVF2 and PCMVR2 in the nested 
round. PCR components and cycle parameters for both rounds were as described in 
section 2.1.1. One microlitre of each first round product was added to the nested round 
PCR. PCR products from both rounds were analysed by electrophoresis on a 3 % 
agarose gel, alongside HyperLadder IV DNA markers (Bioline), as in section 2.1.2.
2.1.5 Generation of the Sma I restriction site
A Sma I restriction endonuclease site was introduced into the 236-bp PCMVpol wild- 
type sequence by site-directed mutagenesis (Figure 2.2), to allow for separation of wild- 
type and control amplicons following PCMV QC PCR. A putative Sma I site was 
identified whereby substitution of two bases would produce the sequence CCCGGG as 
shown below. This site was situated just off-centre in the PCMVpol sequence, to allow 
for the visualisation of both Sma I-digested fragments by polyacrylamide gel 
electrophoresis. Mutagenic primers PCMVFM and PCMVRM were designed with a 2- 
bp mismatch to this region (Table 2.1).
--------------------- PCMVRM-------------------- >
GTCCA TCACC AGCAT AGGGC GGGAC ATGCT TAGGC AGACG
<--------------------PCMVFM---------------------
These mutagenic primers were used in two separate PCRs; primers PCMVF1 and 
PCMVFM were used in one PCR to amplify a 148-bp sequence, while primers 
PCMVR1 and PCMVRM were used in the other, to amplify a 112-bp sequence from 1, 
5, and 10 pi of recombinant plasmid, purified in section 2.1.4. PCR components and
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Figure 2.2. A schematic of the site-directed mutagenesis method used to introduce a 
Sma I restriction enzyme site into the PCMVpol wild-type plasmid to generate the 
PCMVpol control plasmid.
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cycle parameters were as described in section 2.1.1. PCR products were analysed by 
electrophoresis on a 3 % agarose gel, alongside HyperLadder IV DNA markers, as in 
section 2.1.2.
The 148-bp and 112-bp products of these PCRs were purified from the reaction mixture 
using the Wizard PCR Preps DNA Purification System as in section 2.1.3, and the DNA 
concentration determined by UV spectrophotometry at 260 nm (GeneQuantll, 
Pharmacia Biotech). Purified products were mixed in equimolar concentrations of 1 and 
4 pmol, denatured on a 95 °C heating block for 12 min, and annealed together by 
cooling over a 30 min period. Annealed products were then 3’ extended with 200 pM of 
each dNTP, 5 U of DNA polymerase I large (Klenow) fragment in 1x buffer (50 mM 
Tris-HCl, pH 7.2; 10 mM MgSC>4; 0.1 mM DTT) (all Promega), at room temperature 
for 40 min. The reaction was heat-inactivated at 95 °C for 5 min.
The complete PCMVpol control sequence was amplified from the extended sequence 
using primers PCMVF1 and PCMVR1. The PCR components and cycle parameters 
were as described in section 2.1.1. The presence of the Sma I restriction site within the 
PCMVpol control sequence was confirmed by digestion of 10 pi of each PCR product 
with 10 U of Sma I in 1.5 pi of SuRE Cut Buffer H (both Boehringer Mannheim), at 28 
°C for 3 hrs. Digested products were analysed by electrophoresis on a 3 % agarose gel, 
alongside undigested PCR product and HyperLadder IV DNA markers, as in section
2 . 1.2 .
2.1.6 Purification of the control PCMVpol PCR product and cloning into the 
pGEM-T Easy vector
The PCMVpol control sequence was purified from the above PCR, ligated into the 
pGEM-T Easy vector to generate the ‘control plasmid’, and used to transform 
competent JM109 E. coli cells, as in section 2.1.3. Putative recombinant clones were 
identified and analysed by picking five single white colonies and growing them in 6 ml 
cultures as in section 2.1.4. Glycerol stocks were prepared from each overnight culture, 
and plasmid DNA extracted from the remaining culture as previously described (see 
section 2.1.4). The presence of the PCMVpol control sequence within the plasmid was 
confirmed by PCR using primers PCMVF1 and PCMVR1. PCR components and cycle
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parameters were as described in section 1.2.1. The presence of the Sma I restriction site 
within the PCMVpol control sequence was confirmed by restriction enzyme digestion 
of the PCR product as in section 2.1.5. Digested products were analysed by 
electrophoresis on a 3% agarose gel, alongside undigested PCR product and 
HyperLadder IV DNA markers, as in section 2.1.2. The presence of the Sma I site 
within the PCMVpol control sequence was also confirmed by sequence analysis 
(conducted by Oswell Research Products Ltd.).
2.1.7 Large-scale preparation of plasmid DNA
Stocks of wild-type and control PCMVpol plasmids were prepared for use in subsequent 
experiments by the large-scale preparation of plasmid DNA. Recombinant clones 
containing each plasmid were freshly streaked onto selection plates from glycerol 
stocks. Five millilitre starter cultures of LB medium containing 50 pg/ml of ampicillin 
were prepared by picking a single colony from the freshly streaked selection plates, and 
incubated for 8 hrs in a 37 °C shaking incubator (-200 rpm). Two hundred microlitres 
of each starter culture was used to inoculate 100 ml of LB containing 50 pg/ml of 
ampicillin, and incubated for 16 hrs in a 37 °C shaking incubator (-200 rpm). Cultures 
were harvested by centrifugation (6000 xg, 15 min) and plasmid DNA extracted using 
the QIAfilter Plasmid Maxi Kit (Qiagen). Briefly, the cell pellet was resuspended in 10 
ml of Buffer PI (50 mM Tris-HCl, pH 8; 10 mM EDTA; 100 pg/ml RNase A). 
Resuspended cells were mixed thoroughly and lysed in 10 ml of buffer P2 (200 mM 
NaOH; 1 % SDS) at room temperature for 5 min. Ten millilitres of chilled Buffer P3 (3 
M potassium acetate, pH 5.5) were then added to the lysate, mixed gently, and loaded 
into the barrel of a QIAfilter cartridge. Following incubation for 10 min at room 
temperature, the syringe plunger was inserted gently and the cell lysate filtered into a 
previously equilibrated QIAGEN-tip 500. The cleared lysate was allowed to enter the 
resin by gravity flow, before the column was washed twice with 30 ml of Buffer QC (1 
M NaCl; 50 mM MOPS, pH 7; 15 % isopropanol). Plasmid DNA was eluted from the 
column with 15 ml of Buffer QF (1.25 M NaCl; 50 mM Tris-HCl, pH 8.5; 15 % 
isopropanol) and precipitated in 10.5 ml of room temperature isopropanol. Precipitated 
DNA was pelleted by centrifugation at 15,000 xg for 30 min (4 °C). The pellet was 
washed with 5 ml of 70 % ethanol, air-dried, and resuspended in 1 ml of SDW. The 
DNA concentration was determined by UV spectrophotometry at 260 nm.
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The presence of the wild-type and control PCMVpol sequences within the purified 
plasmid DNA was confirmed by restriction enzyme analysis. The presence of the wild- 
type sequence was confirmed by a single digest with Eco RI, while the presence of the 
control sequence was confirmed by a double digest using Sma I and Eco RI. For the Eco 
RI single digest, 10 pi of purified plasmid were digested with 10 U of Eco RI in 1.5 pi 
of SuRE Cut Buffer H (both Boehringer Mannheim), made up to 15 pi with SDW. The 
reaction was incubated at 37 °C for 1.5 hrs. For the Eco RI and Sma I double digest, 10 
pi of purified plasmid were digested with 10 U of Sma I in 1.5 pi of SuRE Cut Buffer A 
in SDW to a final volume of 15 pi for 3 hrs at 28 °C, after which 10 U of Eco RI was 
added and incubated at 37 °C for 1.5 hrs. Digested products were analysed by 
electrophoresis on a 3 % agarose gel, alongside HyperLadder IV DNA markers, as in 
section 2.1.2.
2.1.8 Dilution and aliquoting of wild-type and control PCMVpol plasmids
Wild-type and control plasmids were diluted to 1010 copies/pl for use in subsequent 
experiments where known amounts of plasmid are added to the PCR. The size of both 
wild-type and control plasmids was calculated as follows:
pGEM-T Easy plasmid = 3019 bp (including extra T)
PCMVpol insert = 236 bp
Total = 3255 bp
The number of molecules of plasmid/pg of DNA was then calculated as follows:
As 1 pg of double-stranded DNA of 1-kb is equal to 1.52 pmoles 
Number of pmoles of plasmid/pg of DNA = 4.67 x 10'13
Number of molecules of plasmid/pg = number of pmoles x Avogadro’s constant
of DNA (6.023 xlO23)
= 2.81 xlO11 molecules/pg of DNA
Plasmids prepared and purified in section 2.1.7 were diluted to 1 xlO10 copies/pl in
SDW, aliquoted in 10 pi volumes, and stored at -80 °C until use.
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2.1.9 Optimisation of the PCMV PCR
The annealing temperature, magnesium ion concentration, and cycle number were 
altered to optimise the sensitivity of the PCMV PCR. The specificity of a PCR can also 
be optimised by altering the annealing temperature and magnesium ion concentration.
The magnesium ion concentration and annealing temperature were optimised by nested 
PCR amplification of 50 copies of PCMVpol control plasmid, using either; 1, 1.5, or 2 
mM of MgCl2, at an annealing temperature of either 55 °C or 60 °C in both rounds, and 
performed in triplicate. Since primer PCMVF1 proved to be insensitive, primers 
PCMVF2 and PCMVR1 were used in the first round PCR to amplify a 212-bp 
amplicon, while primers PCMVFB (Table 2.1) and PCMVR2 were used in the nested 
round to amplify a 160-bp product. PCR components and cycle parameters were 
otherwise as previously described (see section 2.1.1). One microlitre of the first round 
PCR product was added to the nested round and amplified for 18 cycles. Nested round 
PCR products were analysed by electrophoresis on a 1 % agarose gel, alongside 
HyperLadder IV DNA markers, as in section 2.1.2. For a 1 % agarose gel, 1 g of 
multipurpose agarose was dissolved in 100 ml of TBE buffer.
The number of cycles to be used in the nested round of the QC PCR was optimised to a 
point where the product resulting from the amplification of 10 copies of PCMVpol 
control plasmid could be easily identified, but distinguished from the products resulting 
from the amplification of 102 and 103 copies of PCMVpol control plasmid, i.e. during 
the exponential phase of the PCR. Between 10 and 103 copies of PCMVpol control 
plasmid were amplified by nested PCR as in sections 2.1.1 and 2.1.4, using the new 
primer sets described above. Nested round PCR tubes were removed from the thermal 
cycler between cycles 10 and 15. PCR products were analysed by electrophoresis on a 1 
% agarose gel, alongside HyperLadder IV DNA markers, as in section 2.1.2.
2.1.10 Investigating the sensitivity of the PCMV PCR
To investigate the sensitivity of the PCMV PCR, the PCMVpol control plasmid was 
diluted from between 103 and 1 copy, and amplified in triplicate by nested PCR using
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the new primer sets described above. PCR components and cycle parameters of both 
rounds were as described in section 2.1.1, however in the first round an annealing 
temperature of 60 °C was used, while in the nested round, the annealing temperature 
was reduced to 55 °C and 15 cycles of amplification were used. One microlitre of first 
round PCR product was added to the nested round PCR. Nested round PCR products 
were analysed by electrophoresis on a 3 % agarose gel, alongside HyperLadder IV DNA 
markers, as in section 2.1.2.
2.1.11 Investigating the specificity of the PCMV PCR
The specificity of the PCMVpol primers was determined by nested PCR amplification 
of viral DNA from other betaherpesviruses; HHV-6, HHV-7, and HCMV, alongside 
PCMV. One microlitre of a TCS or DNA sample of each virus was added to the PCR in 
duplicate and amplified as in section 2.1.10. PCR products from both rounds were 
analysed by electrophoresis on a 3 % agarose gel, alongside HyperLadder IV DNA 
markers, as in section 2.1.2.
2.1.12 Characterisation of the PCMV QC PCR
To assess the utility of the PCMVpol control sequence in the QC PCR, a range of 
known copy numbers of wild-type and control plasmids were co-amplified in triplicate. 
Both plasmids were diluted from between 5 xlO6 and 5 copies in SDW. A single round 
of PCR was performed when 5 xlO6 to 103 copies were used, while a nested PCR was 
performed when 10 to 5 copies of plasmid were used. PCR components and cycle 
parameters were as otherwise described (see section 2.1.10). Following amplification, 
10 pi of PCR product were digested with Sma I (as in section 2.1.5), and analysed on a 
10 % (first round) or 12 % (nested round) polyacrylamide gel electrophoresis (PAGE) 
gel.
10 % PAGE gels were prepared using 2.5 ml of 40 % bis-acrylamide (Scotlab), 1 ml of 
lOx TBE, 70 pi of 10 % ammonium persulphate (APS) and 7 pi of N,N,N’,N’ 
tetramethylethylenediamine (TEMED) (both Sigma) in 6.5 ml of SDW. 12 % PAGE 
gels were prepared using 3 ml of 40 % bis-acrylamide, 1 ml of lOx TBE, 70 pi of 10 % 
APS and 7 pi of TEMED in 6 ml of SDW. Gels were allowed to set at room
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temperature for 20 min. Ten microlitres of each PCR product were mixed with 3 pi of 
loading dye, and loaded into the wells. Gels were electrophoresed at 45 mA for 45 min 
and stained in 50 ml of TBE buffer containing 30 pg of ethidium bromide for 5 min. 
Gels were visualised as in section 2.1.2.
From the photographs of each gel, the intensities of the product bands for wild-type and 
control amplicons were determined using a computer analysis method of quantitation as 
previously described (Kidd et al, 2000). Briefly, QC PCR PAGE gel images were 
scanned at 200 pixels per inch using an Epsom scanner, and imported into the NIH 
Image program (version 1.63). A negative of the photograph was then obtained by 
inverting the image, and the lanes on the gel marked using the gel reading macros 
supplied. Electronic desitometric plots were generated, and the pixel area under each 
peak was calculated. The ratio of wild-type signal to control signal, multiplied by the 
input PCMVpol control sequence copy number, was used to calculate the input copy 
number of wild-type sequence. The range of quantitation for each control sequence 
copy number was 0.5 logunit, for example, with a control plasmid copy number of 100, 
between 50 and 500 copies of wild-type plasmid were tested. The mean result from 
three experiments was plotted against the known input copy numbers of wild-type 
sequence.
100
Chapter 2: Materials and methods
2.2 Investigating the prevalence, quantity and organ distribution of 
PCMV in immunocompetent and immunosuppressed pigs being bred 
for xenograft organs, investigating when virus is acquired, and 
examining methods to eliminate PCMV from these animals.
The qualitative and QC PCR assays developed in section 2.1 were used to detect and 
quantify PCMV DNA in a range of organs and clinical samples from both 
immunocompetent and immunosuppressed pigs being bred for xenograft organs. This 
section describes the methodologies used to extract total DNA from these porcine 
samples, followed by the PCMV PCR assays used to detect and quantify PCMV.
2.2.1 Porcine samples
A range of porcine organs and clinical samples (as shown in Chapter 4, section 4.2) 
were obtained from Imutran Ltd., principally in collaboration with Dr Dan Tucker, and 
were derived from Large White pigs, transgenic for the human decay accelerating factor 
(CD55) (Cozzi & White, 1995). This gene has been cloned into the genome of these 
pigs in order to prevent hyperacute xenograft rejection. Samples were collected using 
individual disposable sets of equipment to minimise the possibility of cross­
contamination of DNA between tissues of the same animal, or between tissues of two 
separate animals. Samples were stored at -80 °C before shipment, on dry ice, to the 
Royal Free and University College Medical School, London, where they were stored at 
-80 °C prior to analysis.
The rearing of animals included in this study and all the associated procedures were 
undertaken according to the requirements of the United Kingdom Home Office Animal 
(Scientific Procedures) Act 1986, or the Ontario (Canada) Animals for Research Act, as 
appropriate.
To investigate the tissue distribution and PCMV viral loads in adult pigs and piglets, a
range of organs and clinical samples were collected from 6 adult and 4 juvenile
conventionally-reared pigs. All adult pigs were aged >15 months while juvenile pigs
were aged between 19 and 34 days at the time of sampling. Animals were not directly
related to each other but were reared identically in a shared airspace.
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To investigate temporal acquisition of PCMV two sows and their litters were 
prospectively monitored from birth. The first litter and their dam (sow P49M), were 
blood sampled (1 ml of EDTA anti-coagulated blood) on days 1, 7, 14, 35, and 49 
following birth. Both sow and litter were euthanised on day 82 when a final blood 
sample and spleen tissue sample was collected from each animal. The second litter and 
their dam (sow G72E) were blood sampled on days 1,7, 17, and 36. All animals were 
reared under conventional farm conditions.
To investigate evidence for transplacental transmission of PCMV, two pregnant sows 
were euthanised at day 86 out of an average full-term gestation of 114 days, and spleen 
samples collected from both sows and their foetuses. The two sows were reared under 
conventional farm conditions.
To investigate the prevalence of PCMV in SPF pigs, spleen samples were collected 
from a total of 9 sows and their hysterotomy-derived, barrier-reared piglets (total of 31 
piglets). The sows were reared under conventional farm conditions. Piglets were derived 
from these sows by caesarean section at day 113 of gestation. Each litter (cohort) was 
raised in a gnotobiotic unit for the first 14 days of life, at the Onterio Veterinary 
College, before being transferred to a bioexclusion facility at the Toronto General 
Hospital. These rearing conditions are further described elsewhere (Tucker et al, 
2002a). Spleen samples were collected from two or three piglets from 7 of the cohorts, 
which were taken as sentinel animals. These piglets had a median age of 9 weeks (range 
4-16 weeks). In the remaining 2 cohorts, spleen samples were collected from all piglets 
(total of 8) which were taken as sentinel animals. These piglets had a median age of 18 
weeks (range 5-21 weeks).
To investigate the effect of immunosuppression on PCMV viral loads, a range of tissue 
samples were collected from three groups of animals reared under different conditions. 
The first group were derived by hysterotomy, reared in a gnotobiotic unit, and aged 58 
days at necropsy. The second group of SEW pigs were naturally farrowed, but weaned 
at 5 days of age, and reared in a gnotobiotic unit. These pigs were aged 57 days at 
necropsy. While the third group of pigs were naturally farrowed, weaned at 5 weeks of 
age, and reared under conventional farm conditions. These pigs were aged 52 days at
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necropsy. All groups consisted of immunosuppressed and control animals. 
Immunosuppressed pigs received a daily regimen of cyclosporine A, azathioprine, and 
prednisolone from 7-12 days of age for a period of approximately 2 months, while 
control pigs did not receive any immunosuppressive treatment. Cyclosporin A was 
administered at 15 mg/kg per os, azathioprine at 1 mg/kg per os, and prednisolone at 1 
mg/kg per os, reducing to 0.5 mg/kg in the second week, 0.25 mg/kg in the third week, 
and to 0.1 mg/kg thereafter.
2.2.2 Extraction of DNA from porcine samples
Extraction of total DNA from tissues samples
All porcine samples were handled in a Class II Microbiological Safety Cabinet. Porcine 
tissue samples were allowed to thaw at room temperature. Once thawed, a section of 
approximately 0.125 cm3 was cut from each tissue sample and cut further into smaller 
pieces using disposable sterile scalpels and forceps. The tissue fragments were digested 
overnight in 500 |il of TNE buffer (55 mM Tris-HCl, pH 8; 110 mM NaCl; 1.1 mM 
EDTA, pH 8; 0.55 % SDS), and 4 pg/ml of Proteinase K (Boehringer Mannheim) at 65 
°C. The proteinase K was inactivated by incubation at 95 °C for 5 min, and DNA 
extracted using phenol and chloroform, followed by ethanol precipitation. Five hundred 
microlitres of phenol (Sigma) were added to each tube and vortexed for 1 min. Samples 
were centrifuged at 13,000 xg for 5 min to separate the lower organic layer from the 
upper aqueous layer containing the DNA. The top aqueous layer was transferred to a 1.5 
ml eppendorf containing 250 pi of phenol and 250 pi of chloroform (BDH). Samples 
were mixed by vortexing and centrifuged at 13,000 xg for 5 min. The top layer was 
again transferred to a 1.5 ml eppendorf containing 50 pi of 3 mM sodium acetate, pH 
5.2, and mixed by vortexing. DNA was precipitated in 1 ml of ice-cold ethanol and 
incubated at -80 °C for 1 hr. The DNA was pelleted by centrifugation at 13,000 xg for 5 
min and washed in 600 pi of 70 % ethanol. The pellet was then air-dried for 10-15 min 
before resuspension in 100 pi of SDW. The concentration of the extracted DNA was 
determined by UV spectrophotometry at 260 nm and 1 pg was analysed by PCR.
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Extraction of total DNA from whole blood and PBMC samples
DNA was extracted from both whole blood and PBMC samples using the Wizard 
Genomic DNA Purification Kit (Promega). DNA was extracted from PBMCs using the 
protocol for the Isolation of Genomic DNA from Tissue Culture Cells and Animal 
Tissue. Briefly, PBMCs were lysed by pipetting in 600 pi of Nuclei Lysis Solution. 
Three microlitres of RNase was added to the nuclear lysate and samples mixed by 
inversion, before incubation at 37 °C for 15-30 min. After cooling to room temperature, 
protein was precipitated by the addition of 200 pi of Protein Precipitation Solution and 
vortexed at high speed for 20 s. Samples were chilled on ice for 5 min to aid protein 
precipitation, before being centrifuged at 13,000 xg for 4 min to pellet the protein. The 
supernatant was transferred to a 1.5 ml eppendorf containing 600 pi of isopropanol and 
mixed by inversion to precipitate the DNA. The DNA was pelleted by centrifugation at
13,000 xg for 1 min and washed in 600 pi of 70 % ethanol. The pellet was air-dried for 
10-15 min and resuspended in 50 pi of SDW.
DNA was extracted from 1 ml of EDTA anti-coagulated whole blood samples using the 
protocol for the Isolation of Genomic DNA from Whole Blood. Briefly, 3X 300 pi of 
each whole blood sample were added to 1.5 ml eppendorfs containing 900 pi of Cell 
Lysis Solution. Samples were mixed by inversion and incubated at room temperature 
for 10 min to lyse the red blood cells. White blood cells were pelleted by centrifugation 
at 13,000 xg for 20 s, and resuspended in 10-20 pi of residual liquid. Cells were lysed 
by the addition of 300 pi of Nuclei Lysis Solution to each tube and pipetted until 
homogeneous. One and a half microlitres of RNase solution were added to samples and 
mixed by inversion, before incubation at 37 °C for 15 min. After cooling to room 
temperature, protein was precipitated by the addition of 100 pi of Protein Precipitation 
Solution and centrifugation at 13,000 xg for 3 min. The supernatant was transferred to a
1.5 ml eppendorf containing 300 pi of isopropanol and mixed by inversion to precipitate 
the DNA. The DNA was pelleted by centrifugation for 1 min at 13,000 xg and washed 
in 300 pi of 70 % ethanol. The pellet was air-dried for 10-15 min and resuspended in 50 
pi of SDW. The concentration of the extracted DNA was determined by UV 
spectrophotometry and 1 pg was analysed by PCR.
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Extraction of total DNA from serum and faeces samples
DNA was extracted from porcine serum and faeces samples using the QIAamp DNA 
Mini Kit (Qiagen). Serum samples were extracted using the Blood and Body Fluid Spin 
Protocol. Briefly, 200 pi of serum was transferred to a 1.5 ml eppendorf containing 20 
pi of QIAGEN Protease (20 mg/ml). Two hundred microlitres of Buffer AL were added 
to each tube, mixed by vortexing, and incubated at 56 °C for 10 min. Two hundred 
microlitres of ethanol were added to each sample, and loaded onto a QIAamp Spin 
Column in a 2 ml collection tube, before centrifugation at 6,000 xg for 1 min. Each 
column was washed with 500 pi of buffer AW1, centrifuging at 6,000 xg for 1 min, 
followed by washing with 500 pi of buffer AW2 and centrifugation at 13,000 xg for 3 
min. DNA was eluted by the addition of 200 pi of SDW and centrifuging at 6,000 xg 
for 1 min.
Approximately 1 ml of each faeces sample was resuspended in 4 ml of 0.89 % NaCl and 
clarified by centrifugation at 4,000 xg for 20 minutes. The supernatant was filtered 
through a 0.2 pm filter (Sartorius), and 200 pi of each filtrate was extracted using the 
Blood and Body Fluid Spin Protocol (as above), without performing the QIAGEN 
Protease step. Five microlitres of each extracted serum and faeces sample were analysed 
directly by PCR.
Extraction of total DNA from nasal and saliva swab samples
Nasal and saliva swabs were transferred to 1.5 ml eppendorf tubes containing 200 pi of 
PBS and incubated at room temperature for 20 min. Swabs were then washed and 
squeezed against the side to the tube to remove excess sample, and discarded. Fifty 
microlitres of each swab sample were transferred to a 0.5 ml eppendorf, held in a 0.5 ml 
eppendorf box (TreffLab), and boiled for 10 min in a boiling water bath. Five 
microlitres of each sample were analysed directly by PCR.
Urine samples
Three microlitres of each urine sample were analysed directly by PCR.
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2.2.3 PCR procedure for clinical samples
In order to prevent contamination of PCR reagents and individual reactions with PCMV 
DNA, the stages in setting up the PCR were performed in separate rooms using different 
sets of pippettes. The PCR mixture was prepared and aliquoted into tubes in a ‘clean 
PCR’ laboratory, following which, tubes were transferred to the ‘PCR set-up’ 
laboratory, where clinical samples were added. The actual PCR and analysis of products 
were performed in separate ‘post-PCR’ laboratories.
2.2.4 Detection of PCMV DNA by qualitative PCR
In the qualitative PCMV PCR, first round primers PCMVF2 and PCMVR1 amplify a 
212-bp amplicon, while nested primers PCMVFB and PCMVR2 amplify a 160-bp 
product. Each PCR mixture contained 100 ng of each primer, 1.5 mM MgCL, 200 pM 
of each dNTP, and 1 U of Taq polymerase, in (NH^SCU PCR buffer. The cycle 
parameters used for both rounds were; initial denaturation at 95 °C for 6 min followed 
by 40 cycles of denaturation at 94 °C for 30 s, annealing at 60 °C for 30 s, and extension 
at 72 °C for 30 s. The final extension was increased to 10 min. In the nested round, the 
annealing temperature was reduced to 55 °C. One microlitre of first round product was 
added to the nested round PCR. Positive and negative controls were amplified by PCR
alongside porcine samples, to ensure accuracy of the results. Positive controls consisted
•>
of 10 copies of PCMVpol control plasmid, while negative controls comprised SDW 
prepared throughout the addition of clinical samples and 1 fig of DNA extracted from 
known negative porcine tissues. Ten microlitres of nested round PCR product were 
analysed on a 3 % agarose gel, alongside HyperLadder IV DNA markers, as in section
2 . 1.2 .
2.2.5 Quantification of PCMV DNA by QC PCR
QC PCR was used to determine the PCMV viral load in samples testing positive by 
qualitative PCR. Sample DNA was amplified alongside varying copy numbers of 
PCMVpol control plasmid. PCR components and cycle parameters were as used in the 
qualitative PCR (section 2.2.4), however, in the nested round the number of cycles of 
amplification was reduced to 15.
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Positive and negative controls were also amplified by QC PCR alongside porcine 
samples, to ensure accuracy of the results. Positive controls consisted of an equivalent 
copy number of PCMVpol control plasmid only, as was used in the testing of samples, 
while negative controls comprised SDW.
Nested round PCR products were digested with Sma I (see section 2.1.5), and analysed 
by PAGE on 10 % (first round) or 12 % (nested round) gel (see section 2.1.12). The gels 
were stained with ethidium bromide and photographed. The intensities of the bands for 
sample (wild-type) and control amplicons were analysed as previously described (Kidd 
et al, 2000). The viral load of the sample was determined from the value where the 
wild-type-to-control-amplicon signal ratio was closest to equivalence. Viral loads below 
the threshold of quantification were given an arbitrary viral load of 1 genome copy/pg 
of DNA.
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2.3 Cloning and expression of PCMV glycoprotein B in insect cells 
using a baculovirus expression system, and the development of a 
recombinant protein-based serological assay for PCMV
This section describes the methodologies used to clone and express the complete ORF 
of PCMV glycoprotein B (gB) in insect cells using a baculovirus expression system. In 
order to ease purification of the recombinant protein, a truncated sequence of 
glycoprotein B (gBT), excluding the proposed transmembrane regions, was amplified 
and cloned using the same system. Both sequences were initially cloned into a 
baculovirus transfer vector, before co-transfection into insect cells alongside 
baculovirus DNA, to generate recombinant baculovirus. Recombinant protein 
production in Sf9 and High Five insect cells was optimised, and used to develop a 
recombinant protein-based serological assay for the detection of PCMV-specific 
antibodies in pig serum.
2J.1 PCR amplification of the complete and truncated PCMV gB gene
Primers PCMVgBF and PCMVgBR were used to amplify the complete ORF of PCMV 
gB, while primers PCMVgBF and PCMVgBT were used to amplify a truncated 
sequence of the gB gene. All primers were designed from the published sequence of the 
PCMV gB gene (Widen et al, 2001), and are shown in Table 2.1. The forward primer 
PCMVgBF, was designed to anneal 30 nucleotides upstream from the ATG initiation 
codon of PCMV gB, and out of frame with the mutated polyhedrin site in the 
baculovirus vector. The reverse primer PCMVgBR, was designed to anneal to the 3’ 
end of the gene, just upstream from the stop codon at amino acid residue 859, and in 
frame with the carboxyl-terminal peptide of the baculovirus transfer vector containing 
the 6x histidine (His) tag, which enables detection and purification of recombinant 
protein in insect cells. The truncated primer PCMVgBT, was designed to anneal 33 
nucleotides downstream from the HCMV AD-1-homologous region at amino acid 
residue 634, 213 nucleotides upstream from the predicted transmembrane regions of 
PCMV gB (Widen et al, 2001), and in frame with the carboxyl-terminal peptide of the 
transfer vector. Complete (2.6-kb) and truncated (1.93-kb) sequences were amplified 
from a TCS sample of porcine alveolar macrophages infected with PCMV strain B6 
(provided by Dr M. Banks, Veterinary Laboratories Agency, UK). The PCR mixture
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contained 100 ng of each primer, 2 mM of MgCh, 200 pM of each dNTP, 2 U of BIO- 
X-ACT DNA polymerase (Bioline), and 1 pi of PCMV TCS sample diluted 1/10 in 
SDW, in PCR Optibuffer (Bioline). BIO-X-ACT DNA polymerase was used to amplify 
PCMV gB and gBT as it has a 3’-5’ proof-reading activity, which prevents the 
misincorporation of nucleotides during primer extension. The cycle parameters used 
were initial denaturation at 95 °C for 2 min, followed by 40 cycles of denaturation at 94 
°C for 1 min, annealing at 65 °C for 1 min, and extension at 72 °C for 2.5 min. The final 
extension was increased to 10 min. PCR products were analysed on a 0.8 % agarose gel 
alongside HyperLadder I DNA markers (Bioline), as in section 2.1.2.
2.3.2 Purification and cloning of the PCMV gB and gBT sequences into the 
baculovirus vector
The PCR amplified complete and truncated PCMV gB sequences were purified from the 
PCR mixture by separation on a 2 % low gelling temperature agarose gel in TAE buffer, 
followed by DNA extraction using the QLAquick Gel Extraction Kit (Qiagen). Briefly, 
the DNA fragment was excised from the gel using a sterile scalpel, and weighed in a 1.5 
ml eppendorf tube. Three hundred microlitres of Buffer QC was added to each 100 mg 
of gel, and incubated at 50 °C for 10 min. One gel volume of isopropanol was then 
added, before the samples were loaded onto a QLAquick spin column in a 2 ml 
collection tube and centrifuged at 13,000 xg for 1 min. The flow-through was discarded 
and 500 pi of Buffer QG were added to the column, before being centrifuged as before. 
The column was washed with 750 pi of Buffer PE, left to stand for 4 min, and again 
centrifuged for 1 min at 13,000 xg. The QLAquick column was then transferred to a 1.5 
ml eppendorf tube. To elute the DNA, 50 pi of SDW were added to the column, left to 
stand for 1 min and centrifuged at 13,000 xg for 1 min.
Purified PCMV gB and gBT sequences were ligated into the baculovirus vector 
pBlueBac4.5/V5-His TOPO TA (Invitrogen) (Figure 2.3), to produce the recombinant 
transfer vector, and used to transform competent DH5a E. coli cells (Invitrogen). Each 
ligation reaction contained 1 pi of purified PCR product, 1 pi of salt solution, 3 pi of 
SDW and 1 pi of baculovirus vector in a 0.5 ml eppendorf tube. Ligation reactions were 
mixed gently and incubated for 30 min at room temperature, before returning to ice.
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&5&S V5 e p i to p e  B S J  6xHis
pBlueBac4.5/ 
V5-His-TOPO
5043 bp
Comments for pBlu#Bac4.5/V5-His-TOPO*
5043 nucleotides
Polyhedrin promoter (Ppm ): bases 7-95 
Multiple cloning site: bases 132-205 
TOPO* Cloning site: bases 187-188 
V5 epitope: bases 212-253 
6xHis tag: bases: 263-280 
SV40 polyadenylation sequence: bases 305-432 
3* end of Ac-PH: bases 436-537 
3* end of ORF 1629: bases 1445-567 (complementary)
Sequence homologous to ORF1629 in Bac-N-Blue DNA: bases 1447-649 (complementary) 
Ampidllin resistance gene: bases 1833-2690 
pUC origin: bases 2838-3511 
5' /ecZ fragment: bases 4741-3629 (complementary)
Sequence homologous to lacZ sequence in Bac-N-Blue DNA: b ases 4514-3629 (complementary) 
Early to late promoter, bases 5043-4742 (complementary)
Figure 2.3. The pBlueBac4.5/V5-His-TOPO vector (Invitrogen), contains a multiple 
cloning site adjacent to the polyhedrin promoter ( P p h ) .  An ampicillin resistance gene 
and the pUC origin allow for selection and replication of the recombinant vector in E. 
coli, while a C-terminal peptide encoding a 6x histidine (His) tag allows for detection 
and purification of recombinant protein in insect cells. The linearised vector also has 
single 3’ thymidine (T) overhangs, which enable direct cloning of PCR products 
amplified using Taq DNA polymerases, such as BIO-X-ACT, which add a single 
deoxyadenosine (A) to the 3’ ends of PCR products.
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Two vials of competent DH5a E. coli cells were thawed on ice, and 50 pi were 
transferred to each of two 1.5 ml eppendorf tubes containing 2  pi of the ligation 
reactions. Samples were incubated on ice for 20 min, before the cells were heat-shocked 
at 42 °C for 20 s, then returned to ice for 2 min. Nine hundred and fifty microlitres of 
SOC medium were added to the transformed cells and incubated for 1 hr in a shaking 
incubator (~200 rpm) at 37 °C. Transformed cells were concentrated by centrifugation 
(70 xg, 10 min), resuspending the pellet in 150 pi of SOC medium, and 50 pi were 
plated onto antibiotic selection plates containing 2 % LB, 1.5 % bacteriological agar, 
and 100 pg/ml of ampicillin. Plates were incubated overnight at 37 °C.
Recombinant clones were picked from overnight plates and used to inoculate 6  ml 
cultures of 2 % LB containing 50 pg/ml of ampicillin. Glycerol stocks were prepared as 
in section 2.1.4, and plasmid DNA was extracted from the remaining overnight culture 
using the QIAprep Spin Miniprep Kit (Qiagen). Briefly, the bacterial cultures were 
harvested by centrifugation at 2000 xg for 10 min, resuspended in 250 pi of Buffer PI 
(50 mM Tris-HCl, pH 8 ; 10 mM EDTA; 100 pg/ml RNase) and transferred to a 1.5 ml 
eppendorf tube. Cells were lysed in 250 pi of Buffer P2 (200 mM NaOH; 1 % SDS) by 
inverting 4-6 times, before the addition of 350 pi of Buffer N3 (3M potassium acetate, 
pH 5.5), and centrifuged at 13,000 xg to pellet cellular protein. The supernatant was 
then applied to a QIAprep spin column in a 2 ml collection tube and centrifuged at
13,000 xg for 1 min. The flow-through was discarded and the column washed with 750 
pi of Buffer PE (Qiagen). To elute the DNA, 100 pi of SDW was added to the column, 
left for 1 min, and centrifuged at 13,000 xg for 1 min. The presence of the PCMV gB 
and gBT sequences within the recombinant baculovirus vector was confirmed by 
digestion with Bam HI and Hind III restriction enzymes. Ten microlitres of purified 
plasmid were digested with 10 U of Bam HI and 10 U of Hind III in 1.5 pi of SuRE Cut 
Buffer B (all Boehringer Mannheim), in SDW to a final volume of 15 pi, for 1 hr 15 
min at 37 °C. Digested products were analysed by electrophoresis on a 1 % agarose gel, 
alongside HyperLadder I DNA markers, as in section 2.1.2. In addition, in order to 
confirm that no mutations had been introduced into the PCMV gB and gBT sequences 
during the PCR, recombinant vector DNA was sent for sequencing at an in house 
facility (Windeyer Institute, UCL).
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2.3.3 Preparation of high quality plasmid DNA for transfection
High quality plasmid DNA was needed for efficient transfection of insect cells. 
Recombinant PCMV gB and gBT clones were streaked onto ampicillin selection plates, 
from glycerol stocks. Five millilitre starter cultures of 2 % LB containing 50 pg/ml of 
ampicillin were prepared by picking a single colony from the freshly streaked selection 
plate, and incubated for 8 hrs in a 37 °C shaking incubator (-200 rpm). Two hundred 
microlitres of each starter culture were used to inoculate 100 ml of 2 % LB containing 
50 pg/ml of ampicillin and incubated for 16 hrs in a 37 °C shaking incubator (-200 
rpm). Cultures were harvested by centrifugation (6000 xg, 15 min) and plasmid DNA 
was extracted using the Endofree Plasmid Maxi Kit (Qiagen). Briefly, the cell pellet 
was resuspended in 10 ml of Buffer PI (50 mM Tris-HCl, pH 8 ; 10 mM EDTA; 100 
pg/ml RNase), and lysed in 10 ml of Buffer P2 (200 mM NaOH; 1 % SDS), inverting 
several times over a 5 min period. Ten millilitres of chilled Buffer P3 (3M potassium 
acetate, pH 5.5) were added to the lysate, mixed by invertion, and then loaded into the 
barrel of a QIAfilter cartridge. Following incubation for 10 min at room temperature, 
the cell lysate was pushed through the column using a plunger, into a 50 ml collection 
tube. Two and a half millilitres of Buffer ER were added to the filtered lysate and 
incubated on ice for 30 min. Meanwhile, a QIAGEN-tip 500 was equilibrated by 
applying 10 ml of Buffer QBT (750 mM NaCl; 50 mM MOPS, pH 7; 15 % isopropanol; 
0.15 % Triton X-100). The filtered lysate was then applied to the column, allowed to 
enter the resin by gravity flow, and the flow-through was discarded. The column was 
washed twice with 30 ml of Buffer QC (1 M NaCl; 50 mM MOPS, pH 7; 15 % 
isopropanol), and plasmid DNA eluted with 15 ml of Buffer QN (1.6 M NaCl; 50 mM 
MOPS, pH 7; 15 % isopropanol). DNA was precipitated by the addition of 10.5 ml of 
isopropanol, mixed and centrifuged at 15,000 xg for 30 min (4 °C), to pellet the DNA. 
The DNA pellet was washed with 5 ml of endotoxin-free 70 % ethanol, air-dried, and 
resuspended in 100 pi of endotoxin-free Buffer TE (10 mM Tris-Cl, pH 8 ; 1 mM 
EDTA). The DNA concentration of the purified plasmid DNA was determined by UV 
spectrophotometry at 260 nm.
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2.3.4 Insect cell culture
Sf9 insect cells derived from Spodoptera Jrugiperda and High Five (Tn5) insect cells 
derived from Trichoplusia ni were used throughout this investigation. Sf9 insect cells 
were used for the transfection, plaque purification and the generation of high-titre virus 
stocks, since their regular size makes them ideal for the formation of monolayers and 
plaques. High Five insect cells were investigated for the expression of recombinant 
PCMV gBT since they have been reported to increase the yield of certain secreted 
proteins (Wickham & Nemerow, 1993).
Sf9 insect cells were maintained in Sf-900II SFM medium (Invitrogen), supplemented 
with 100 U/ml of penicillin, 100 pg/ml of streptomycin (both Sigma) and 10 % FCS 
(Labtech International), at 28 °C, and split at a ratio of 1:3, every 2-3 days. High Five 
insect cells were maintained in Express Five medium (Invitrogen), supplemented with 
20 U/ml of penicillin, 20 pg/ml of streptomycin and 17 mM of L-Glutamine 
(Invitrogen), at 28 °C, and split at a ratio of 1:4, every 2-3 days.
2.3.5 Transfection of Sf9 insect cells
Transfection of recombinant baculovirus into insect cells was carried out using the Bac- 
N-Blue Transfection Kit (Invitrogen), according to the manufacturer’s instructions. Sf9 
insect cells (2 xlO6) were seeded in two 60 mm cell culture dishes in 4 ml of serum-free 
Sf-900II medium, and allowed to attach at room temperature for 30 min. Meanwhile, 4 
p,l (4 pg) of endoffee-purified recombinant transfer vector, 20 pi of Cellfectin reagent 
(Invitrogen) and 1 ml of serum-free Sf-900II medium were added to a 1.5 ml tube 
containing 10 pi (0.5 pg) of Bac-N-Blue DNA (Invitrogen), and mixed gently by 
flicking. Once the insect cells had attached to the cell culture dishes, medium was 
removed from the cells, and the transfection mixture was added drop-wise onto one 60 
mm dish, while 1 ml of serum-free Sf-900II media was added to the other dish as a 
cells-only control. Cell culture dishes were then incubated at room temperature for 4 hrs 
with gentle rocking, before the serum-free medium was replaced with complete Sf-900II 
medium, and returned to the 28 °C incubator. Culture medium was harvested 72 hrs 
posttransfection by centrifugation (400 xg, 6  min) and labelled as transfection virus
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stock, while the cells were incubated at 28 °C for a further 4-7 days for visual 
confirmation of successful transfection by light microscopy.
2.3.6 Purification of recombinant virus by plaque assay
Purification of recombinant virus from uncut or non-recombinant (wild-type) 
baculovirus DNA was important to prevent dilution of recombinant virus, since wild- 
type virus replicates more efficiently than recombinant virus (Bac-N-Blue Transfection 
and Expression Guide, 2002). Recombinant virus was purified by plaque assay
1 oaccording to the Bac-N-Blue Transfection Kit. Briefly, 1 ml dilutions of 10 ', 10' and 
10' 3 of transfection virus stock (see section 2.3.5), harvested 72 hrs posttransfection, 
were prepared and used to infect a monolayer of 5 xlO6 Sf9 insect cells seeded in 100 
mm cell culture dishes. Infected cells were incubated for 1 hr at room temperature with 
gentle rocking. The cells were then covered with 10 ml of an overlay of complete Sf- 
900II medium containing 0.625 % low gelling temperature agarose, and incubated at 28 
°C on paper towels dampened with 5 mM EDTA, in a sealed plastic bag. Five days 
postinfection, 1 ml of complete Sf-900II medium containing 75 pg/ml of X-Gal was 
added to each plate and incubated overnight at 28 °C. Cells were screened for the 
formation of viral plaques 6  dpi. Viral plaques appeared as areas of lysed cells and were 
identified as distinct blue spots on a clear background of cells. Plaques were cut out of 
the agarose overlay using a wide-ended pastette and stored in 1.5 ml eppendorfs 
containing 1 ml of complete Sf-900II medium at 4 °C.
2.3.7 PCR analysis of recombinant virus
The presence of recombinant virus was confirmed by PCR analysis of each viral plaque. 
Four hundred microlitres of complete Sf-900II medium containing each recombinant 
virus agarose plug was used to infect 5 xlO6 Sf9 insect cells in 25 cm2 cell culture 
flasks, and incubated at 28 °C for 6  days. Infected cells were harvested and separated 
from the culture medium by centrifugation (400 xg, 6  min). The supernatant was 
labelled as PI virus stock and stored at 4 °C, while viral DNA was isolated from the cell 
pellet using the Puregene DNA Extraction Kit (Gentra). Briefly, the cell pellet was 
lysed in 600 pi of Cell Lysis Solution and transferred to a 1.5 ml eppendorf tube. Two 
hundred microlitres of Protein Precipitation Solution were added to samples, mixed by
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vortexing and centrifuged at 13,000 xg for 5 min. The supernatant was transferred to a 
1.5 ml eppendorf tube containing 600 pi of isopropanol, inverted ~50 times, and 
incubated on ice for 3-4 min to aid DNA precipitation. The DNA was pelleted by 
centrifugation (13,000 xg, 5 min), washed with 600 pi of 70 % ethanol, and air-dried for 
20 s. The DNA pellet was resuspended in 200 pi of DNA Rehydration Solution and 
incubated at 65 °C for 5 min to aid resuspension.
Both PCMV gB- and baculovirus-specific primers (Table 2.1), were used to amplify 
recombinant viral DNA from the extracted insect cells. A positive control comprising of 
recombinant transfer vector, and negative controls comprising wild-type baculovirus 
(provided by Dr Hassan-Walker, Centre for Virology, UCL), DNA extracted from 
uninfected Sf9 insect cells, and SDW, were also amplified by PCR. Each PCR mixture 
using baculovirus primers contained 100 ng of each primer, 1.5 mM of MgCh, 200 pM 
of each dNTP, 2.5 U of HotStarTaq polymerase (Qiagen), and 1 pg of extracted DNA, 
in PCR Buffer (Qiagen), to a final volume of 50 pi. The cycle parameters used were 
initial denaturation at 95 °C for 15 min, followed by 30 cycles of denaturation at 94 °C 
for 1 min, annealing at 60 °C for 2 min, and extension at 72 °C for 3 min. The final 
extension was increased to 10 min. The PCR mixture using PCMV gB-specific primers 
contained 100 ng of each primer, 2 mM of MgCb, 200 pM of each dNTP, 2 U of BIO- 
X-ACT polymerase, and 1 pg of extracted DNA, in PCR Optibuffer, to a final volume 
of 50 pi. The cycle parameters used were initial denaturation at 95 °C for 2 min, 
followed by 41 cycles of denaturation at 94 °C for 1 min, annealing at 65 °C for 1 min, 
and extension at 72 °C for 2.5 min. The final extension was increased to 10 min. PCR 
products were analysed by electrophoresis on a 1 % agarose gel, alongside HyperLadder 
I DNA markers, as in section 2.1.2.
2.3.8 Preparation of high-titre virus stocks and determination of virus titre
High-titre virus stocks of recombinant PCMV gB and gBT baculoviruses were prepared 
for the production of recombinant proteins. Sf9 insect cells (2 x 106), seeded in 25 cm2 
cell culture flasks, were infected with 2 0  pi of the PI virus stock harvested in section 
2.3.7, and incubated at 28 °C for 7 days. The culture medium was harvested by 
centrifugation (400 xg, 6  min) 7 dpi, and the supernatant labelled as P2 virus stock. Two
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hundred microlitres of this P2 stock were used to infect 1.5 xlO7 Sf9 insect cells in 175 
cm2 cell culture flasks. The culture medium from these infected cells was harvested by 
centrifugation (400 xg, 6  min) 6  dpi and the supernatant labelled as P3 virus stock.
The titre of the P3 virus stock was determined by plaque assay. Sf9 insect cells (5 xlO6) 
were seeded in 10 0  mm cell culture dishes, and infected with 1 ml of 10 '5, 1 0 '6 and 1 0 '7 
dilutions of the P3 virus stock, in triplicate. Infected cells were covered with an overlay 
as in section 2.3.6. Six days postinfection plates were covered with 1.5 ml of a second 
overlay of complete Sf-900II medium containing 0.41 % low gelling temperature 
agarose and 0.25 mg/ml of Neutral Red Solution (Sigma), and incubated overnight at 
room temperature. Plaques were identified as pale pink spots on a red background of 
cells and counted on each of the dilution plates. Virus titre, measured in plaque forming 
units per ml (pfu/ml), was determined from the plate containing 50-100 plaques, 
according to the formula:
pfu/ml = (1/dilution) x number of plaques
23.9 Determining optimal recombinant protein expression
Time-course for recombinant protein expression in High Five insect cells
High Five insect cells (2.5 xlO6) were seeded in 25 cm2 cell culture flasks, and infected 
with 500 pi of recombinant PCMV gB and gBT baculovirus P3 stocks at a multiplicity 
of infection (MOI) of 10. Cultures were harvested 1, 2, 3, and 4 dpi, by sloughing and 
centrifugation (400 xg, 6  min). Cell pellets were washed twice in 5 ml of sterile PBS, 
resuspended in 750 pi of sterile PBS, and stored at -80 °C for further analysis.
Comparison of Sf9 vs. High Five insect cells for the expression of recombinant 
protein
Sf9 and High Five insect cells (2.5 xlO6) were each seeded in 25 cm2 cell culture flasks, 
and infected with 500 pi of recombinant PCMV gB and gBT baculovirus P3 stocks at 
an MOI of 10. Cultures were harvested 2 dpi, by sloughing and centrifugation (400 xg,
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6  min). Cell pellets were washed twice in 5 ml of sterile PBS, resuspended in 750 pi of 
sterile PBS, and stored at -80 °C for further analysis.
Investigating the secretion of recombinant PCMV gBT in the culture supernatant 
of High Five insect cells 2 and 3 dpi
High Five insect cells (5 xlO6) were seeded in 75 cm2 cell culture flasks, and infected 
with 1 ml of recombinant PCMV gBT baculovirus P3 stock at an MOI of 10. Cultures 
were harvested 2 and 3 dpi, by sloughing and centrifugation (400 xg, 6  min). An aliquot 
of the centrifuged culture supernatant was stored at -80 °C for further analysis. 
Meanwhile, cell pellets were washed twice in 10 ml of sterile PBS, resuspended in 150 
pi of sterile PBS, and stored at -80 °C for further analysis.
Investigating the secretion of recombinant PCMV gBT in the culture supernatant 
of Sf9 and High Five insect cells 4 dpi
Sf9 and High Five insect cells (5 xlO6) were each seeded in 75 cm2 cell culture flasks, 
and infected with 1 ml of recombinant PCMV gBT baculovirus P3 stock at an MOI of 
10. Cultures were harvested 4 dpi, by sloughing and centrifugation (400 xg, 6  min). The 
centrifuged culture supernatants were concentrated using Amicon Ultra-15 Centrifugal 
Filter Devices (Millipore) with a 10-kDa molecular weight cut-off. Briefly, 15 ml of 
culture supernatant was centrifuged at 4000 xg in a swinging bucket rotor for 20 min. 
The retentate was stored at -80 °C for further analysis. Meanwhile, cell pellets were 
washed twice in 10 ml of sterile PBS, resuspended in 150 pi of sterile PBS, and stored 
at -80 °C for further analysis.
2.3.10 Analysis of recombinant protein by SDS-PAGE
PCMV gB- and gBT-infected and uninfected cell pellet samples were lysed in 4x 
NuPAGE LDS Sample Buffer (Invitrogen). Culture supernatant samples were also 
diluted in 4x NuPAGE LDS Sample Buffer. All samples were heated to 70 °C for 10 
min and 20 pi of each sample were loaded into the wells of each of two 4-12% 
NuPAGE Novex Bis-Tris gels (Invitrogen), alongside 10 pi of RPN 756 Rainbow
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markers (Amersham Pharmacia) and 5 |il of 6 xHis Protein Ladder (Qiagen). Gels were 
run in lx  NuPAGE MOPS SDS Running Buffer (Invitrogen) at 200 V for ~50 min.
2.3.11 Coomassie staining of SDS-PAGE gels
Following SDS-PAGE, one gel was soaked in 100 ml of fixing solution (70 % (v/v) 
deionised (d) H2O; 20 % (v/v) methanol; 10 % (v/v) glacial acetic acid (both BDH)) for 
5-10 min, and stained in 100 ml of Coomassie staining solution (50 % (v/v) dt^O; 40 % 
(v/v) methanol; 10 % (v/v) glacial acetic acid; 0.05 % (w/v) Coomassie Brilliant Blue 
R-250 (Sigma)), for 2.5 hrs, on a rocking platform. Gels were then rinsed in several 
changes of destain (50 % (v/v) dt^O; 40 % (v/v) methanol; 10 % (v/v) glacial acetic 
acid) until no more colour was removed.
2.3.12 Western blot analysis of recombinant protein
Recombinant proteins were transferred from the second SDS-PAGE gel to a 
polyvinylidene difluoride (PVDF) membrane by western blot. Filter paper, blotting pads 
and the Hybond-P PVDF Transfer Membrane (Amersham Pharmacia) were cut to the 
size of the gel and assembled as in Figure 2.4. The PVDF membrane was pre-soaked in 
methanol for 30 s, rinsed with dF^O, and then soaked in lx  NuPAGE Transfer Buffer 
(Invitrogen) for 5 min. The blotting pads and filter paper were also soaked in lx  
NuPAGE Transfer Buffer for 5 min before assembly of the blot. Proteins were 
transferred using a Trans-Blot SD Semi-dry transfer cell (Biorad), at 30 V for 1 hr.
Following the transfer of proteins, the PVDF membrane was washed twice in 100 ml of 
TBS buffer (10 mM Tris-HCl; 150 mM NaCl; pH 7.5) for 10 min each on a rocking 
platform. The remaining protein-free sites on the membrane were blocked in 20 ml of 
Anti-His horseradish peroxidase (HRP) Conjugate blocking buffer (Qiagen), for 1 hr on 
a rocking platform. Following blocking, the membrane was washed twice in 100 ml of 
TBS-Tween/Triton Buffer (20 mM Tris-HCl; 500 mM NaCl; 0.05 % (v/v) Tween 20; 
0.2 % (v/v) Triton X-100; pH 7.5), and once in 100 ml of TBS buffer (10 min each), on 
a rocking platform. Hybridised 6 xHis-tagged proteins were detected by incubation with 
Penta-His HRP conjugate mouse IgGl antibodies, diluted 1/2000 in 10 ml of Anti-His 
HRP Conjugate blocking buffer (both Qiagen), on a rocking platform for 1 hr.
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Transfer of 
proteins -es>
Cathode ( - )  
Blotting pads
SDS-PAGE gel
PVDF membrane 
Filter paper
Anode (+)
Figure 2.4. Assembly of the western blot. The PVDF membrane was pre-soaked in 
methanol for 30 s and rinsed with dH20. The membrane, blotting pads, and filter paper 
were then soaked in lx NuPAGE Transfer Buffer for 5 min before assembly of the blot. 
SDS-coated, negatively charged proteins were transferred from the SDS-PAGE gel to 
the PVDF membrane using a Trans-Blot SD Semi-dry transfer cell, at 30 V for 1 hr.
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The membrane was washed as before, and incubated in 3,3’-diaminobenzidine (DAB) 
substrate (6  drops of Buffer Stock Solution; 12 drops of DAB Stock Solution; 6  drops of 
Hydrogen Peroxide Solution; 6  drops of Nickel Solution in 15 ml of SDW) (Vector 
Laboratories), for 15 min without shaking. Finally, the membrane was rinsed in (IH2O 
for 5 min and air-dried.
2.3.13 IIF using porcine serum and visualisation of recombinant protein
High Five insect cells (5 xlO6) were seeded in 75 cm2 cell culture flasks, and infected 
with 1 ml of recombinant PCMV gB and gBT baculovirus P3 stocks at an MOI of 10. 
Cultures were harvested 2 dpi, by sloughing and centrifugation (400 xg, 6  min). Cells 
were washed twice in 10 ml of sterile PBS, and counted using a haemocytometer. Cells 
(1.5 x104) were spotted onto each well of a polytetrafluoroethylene-coated slide 
(Hendley). Negative control wells were prepared using uninfected cells. Slides were 
then air-dried and fixed in ice-cold 100 % acetone for 10 min at -20 °C.
Porcine serum samples from adult pigs and piglets (see section 2.2.1) were diluted 1/20 
and 1/40 in sterile PBS, and 10 jxl of each dilution were spotted onto the slides prepared 
above, and incubated in a humidified chamber at 37 °C for 40 min. PBS was added to 
wells containing infected and uninfected cells as a negative control. Slides were then 
washed, once in 400 ml of PBS containing 1 % BSA (Sigma), and twice in 400 ml of 
PBS alone for 5 min each. Non-well areas of the slides were dried, and 10 pi of 
fluorescein isothiocyanate isomer 1 (FITC)-Conjugated Rabbit Anti-Swine IgG 
Antibody (Dako-Cytomation), diluted 1/40 in sterile PBS, were added to each well and 
incubated at 37 °C for 40 min. Following incubation, slides were washed and dried as 
before, mounted in Vectashield fluorescence preservative (Vector Laboratories), and 
visualised under an Olympus BX60 fluorescence microscope. Photographs were taken 
using an Olympus DPII digital camera.
Cross-reactivity of mouse anti-HCMV gB monoclonal antibodies with recombinant 
PCMV gB, and PCMV-seropositive serum with recombinant HCMV gB was 
investigated. Porcine serum from a PCMV-seropositive and seronegative pig, was 
diluted 1/20 in sterile PBS, while mouse anti-HCMV gB monoclonal antibodies 
(provided by K Lawson, Centre for Virology, UCL) were diluted 1/10 in sterile PBS.
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Ten microlitres of each dilution were spotted onto slides prepared from Sf9 insect cells 
infected at an MOI of 10 with either recombinant PCMV gB or HCMV gB (provided by 
K Lawson) baculovirus, and incubated in a humidified chamber at 37 °C for 40 min. 
Slides were washed and dried as before, and incubated with 10 pi of either FITC- 
Conjugated Rabbit Anti-Swine IgG Antibody (Dako-Cytomation), diluted 1/40 in sterile 
PBS, or FITC-Conjugated Goat Anti-Mouse IgG Antibody (Dako-Cytomation), diluted 
1/100 in sterile PBS, at 37 °C for 40 min. Following incubation, slides were washed, 
dried, mounted, and visualised as before.
2.3.14 Analysis of cell lysis methods for the preparation of recombinant protein for 
use in a PCMV ELISA
Cell pellets from PCMV gBT-infected High Five insect cells harvested 2 dpi (see 
section 2.3.9), were lysed in 1 ml of TNE buffer (10 mM Tris-HCl pH 7.2; 100 mM 
NaCl; 1 mM EDTA; 1 % NP40) with or without the addition of 10 pi of General Use 
Protease Inhibitor Cocktail (Sigma), followed by four freeze-thaw cycles in a dry ice 
and methanol bath, and a 37 °C water bath. Cell lysates were clarified by centrifugation 
at 13,000 xg for 30 min (4 °C) and the supernatant was transferred to a 1.5 ml 
eppendorf tube. In addition, PCMV gBT-infected High Five insect cells were lysed in 1 
ml of TNE buffer followed by sonication, at a peak-to-peak power of 8 , 10 and 12 
microns for 10-20 s. The effectiveness of each method for the preparation of ELISA 
antigen was determined by SDS-PAGE and western blot as in sections 2.3.10-2.3.12.
2.3.15 Preparation of ELISA antigen and determination of protein concentration
Cell lysates were prepared from PCMV gBT-infected and uninfected High Five insect 
cells 2 dpi (see section 2.3.9), by lysis in 1 ml of TNE buffer containing 10 pi of 
General Use Protease Inhibitor Cocktail, followed by sonication, twice, at a peak-to- 
peak power of 10 microns for 10 s each time. Five hundred microlitres of each lysate 
sample was filtered through a 0.8 pm filter (Sartorius) to, in part, clarify the sample.
The protein concentration of each filtered and non-filtered lysate sample was 
determined using the BCA Protein Assay Reagent Kit (Pierce). Briefly, the BSA 
standard supplied with the kit was serially diluted from 0-250 pg/ml in TNE buffer,
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while each protein lysate was diluted 1/5 and 1/10 in TNE buffer. BCA Working 
Reagent (WR) was prepared by mixing BCA Reagents A and B, at a ratio of 50:1. One 
millilitre of WR was added to 1.5 ml eppendorf tubes containing 50 pi of each BSA or 
lysate dilution, and mixed by vortexing. The reactions were then incubated in a 60 °C 
water bath for 30 min, before cooling to room temperature, and measuring the 
absorbance at 562 nm using a UV spectrophotometer (Camspec). A standard curve of 
the absorbance measurements of the BSA standard dilution reactions, plotted against 
their concentration, was used to determine the protein concentration of each unknown 
lysate sample.
2 .3.16 Adsorption of protein onto 96-well plates and preliminary PCMV ELISA
Filtered and non-filtered protein lysate samples from PCMV gBT-infected and 
uninfected (control) High Five insect cells were diluted to 5 pg/ml in 0.1 M carbonate- 
bicarbonate buffer, pH 9.6 (Sigma), and 100 pi were used to coat each well of a 96-well 
Maxisorp immuno-plate (Nalge Nunc International) at 37 °C for 2 hrs. Negative control 
wells were comprised of 100 pi of 0.1 M carbonate-bicarbonate buffer only. Following 
washing of each well, with six volumes of 200 pi of sterile PBS using an ELx50 Auto 
Strip plate washer (Bio-Tek Instruments Inc.), wells were incubated overnight at 4 °C, 
with 200 pi of blocking buffer (2.5 % BSA; 0.01 % Tween in PBS). One hundred 
microlitres of PCMV-positive and negative pooled porcine serum samples, serially 
diluted to 1/50, 1/100 and 1/1000 in sterile PBS, were added to each well and incubated 
at room temperature for 1 hr. High-titre HCMV-positive and negative pooled human 
serum, diluted 1/5000 in sterile PBS, were used as negative controls. After washing 
three times with 200 pi of 0.05 % Tween in PBS, each well was incubated with 200 pi 
of HRP-Conjugated Rabbit Anti-Swine IgG Antibody (Dako-Cytomation), diluted 
1/7000 in sterile PBS, at 37 °C for 1 hr. Wells were washed four times with 200 pi of 
0.05 % Tween in PBS, before incubating with 100 pi of 3,3’,5,5’-tetramethylbenzidine 
(TMB) substrate (Sigma) for 30 min. The reaction was stopped by the addition of 50 pi 
of 2M H2SO4 and the absorbance measured at 450 and 630 nm using an ELX800 plate 
reader (Bio-Tek Instruments Inc.).
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2.3.17 Optimisation of the PCMV ELISA
The concentrations of the protein lysate antigen and HRP-conjugated antibody, and the 
washing procedure were altered to optimise the sensitivity and reduce non-specific 
reactions in the PCMV ELISA. To optimise the protein lysate concentration, lysate 
samples diluted to 20, 10, 1, 0.5 and 0.1 pg/ml were added to each well of a 96-well 
plate. Porcine serum was tested at dilutions of 1/50, 1/100, 1/500 and 1/1000, while 
HRP-conjugated antibody was used at a dilution of 1/7000. To optimise the HRP 
conjugate concentration, 0.1  fig/ml of each protein lysate was added to each well, and 
incubated with porcine serum diluted to 1/50, 1/100, 1/500 and 1/1000. HRP-conjugated 
antibody was tested at dilutions of 1/5000, 1/10000 and 1/15000. To optimise the 
washing procedure, again 0.1  jig/ml of each protein lysate was added to each well, and, 
following incubation with porcine serum diluted to 1/50, 1/100, 1/500 and 1/1000, wells 
were washed either three or six times with either 0.05 % or 0.1 % Tween in PBS. In this 
experiment, HRP-conjugated antibody was used at a dilution of 1/10000. The remaining 
assay conditions in the PCMV ELISA were as otherwise described in section 2.3.16.
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2.4 The susceptibility of PCMV to established antiherpetic agents in 
vitro
This section describes the methodologies used to investigate the in vitro susceptibility of 
PCMV to antiviral agents, currently licensed for use in the prophylaxis and/or treatment 
of human herpesvirus infections. PCMV infection was established and characterised in 
pig fallopian tube (PFT) cells, an adherent, fibroblast-like cell line, although a porcine T 
cell line, L45, was also investigated for susceptibility to PCMV infection. The antiviral 
inhibition of PCMV in chronically-infected PFT cells was subsequently determined by 
real-time PCR and IIF.
2.4.1 PFT cell culture
PFT cells (kindly provided by Dr Clive Patience, Immerge BioTherapeutics Inc.) were 
maintained in minimum essential medium (MEM) (Invitrogen), supplemented with 100 
U/ml of penicillin, 100 fig/ml of streptomycin and 10 % FCS, in a 5 % CO2 humidified 
incubator at 37 °C. Once confluent, cells were passaged every 5-6 days at a ratio of 1:4. 
On these days medium was removed and the cells washed with 5 ml of versene 
(Invitrogen), and removed from the flask by incubation in 4 ml of trypsin (Invitrogen) at 
37 °C for no more than 5 min.
2.4.2 Establishing PCMV infection in PFT cells
PCMV-infected PFT cells (kindly provided by Dr Clive Patience, Immerge 
BioTherapeutics Inc.) were mixed with 1 ml of freshly trypsinised uninfected PFT cells 
in 8 ml of complete MEM and seeded in a 25 cm2 cell culture flask (day 0). An aliquot 
of TCS was harvested from the culture at 3, 4, 7 and 8 days following mixing of cells, 
and stored at -80 °C for PCR analysis, prior to total medium replacement. The cells 
were passaged at a ratio of 1:3 into three 25 cm2 flasks on day 4. Productive infection in 
the PFT-PCMV culture was confirmed by nested qualitative PCMV PCR of TCS 
harvested on days 3,4, 7, and 8 , by RT PCR of RNA extracted from one 25 cm2 flask at 
day 8 , and by PCMV IIF assay using slides prepared from a second 25 cm2 flask of 
PFT-PCMV cells at day 10, following mixing of cells. The remaining 25 cm2 flask of 
PFT-PCMV cells was maintained at 37 °C.
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2.4.3 Extraction of RNA from PFT-PCMV cells
Following removal of the culture medium, 2.5 ml of TRIzol (Invitrogen) was added to 
one 25 cm2 flask of PFT-PCMV cells 8  dpi, and pipetted up and down to dislodge and 
lyse the cells. Lysed cells were transferred to a 15 ml tube on ice. Five hundred 
microlitres of chloroform was added, mixed for 15 s and incubated at room temperature 
for 2-3 min. Cells were centrifuged at 2000 xg for 15 min and the upper, clear layer 
transferred to a clean 15 ml tube. The RNA was precipitated in 1.25 ml of isopropanol 
at room temperature for 10  min and pelleted by centrifugation at 2 0 0 0  xg for 10  min. 
The RNA pellet was washed with 2.5 ml of 75 % ethanol, air-dried, and resuspended in 
50 j l l I  of RNase-free water (Promega). The concentration of the RNA was determined by 
UV spectrophotometry at 260 nm. Extracted RNA was then treated with RNase-Free 
DNase (Promega) to remove contaminating DNA. Three microlitres of lOx DNase 
Reaction Buffer, 6 .6  pi of RNase-Free DNase and 16.5 pi (0.4 pg/pl) of RNA, were 
added to 3.9 pi of RNase-free water (all Promega) in a 1.5 ml RNase-free tube, and 
incubated on a 37 °C heating block for 30 min. The reaction was stopped by incubation 
with 3 pi of DNase Stop Solution at 65 °C for 10 min.
2.4.4 Confirmation of PCMV productive infection by RT and qualitative PCMV 
PCR
An RT PCR for PCMV was performed on 10 pi of DNase-treated RNA extracted from 
PFT-PCMV cells 8 dpi, using the Omniscript Reverse Transcriptase Kit (Qiagen). The 
RT reaction was prepared on ice and contained; 0.5 mM of each dNTP (Qiagen), 1 pM 
of Oligo-dT primer (Roche), 10 U of RNase inhibitor (Roche), 4 U of Omniscript 
Reverse Transcriptase (Qiagen) and 10 pi of DNase-treated RNA, in RT Buffer 
(Qiagen) in a 0.5 ml RNase-free tube. The RT reaction was incubated for 60 min on a 
PCR block at 37 °C, and inactivated by heating to 93 °C for 5 min. Ten microlitres of 
cDNA, 5 pi of DNase-treated RNA, and 2 pi of each TCS sample harvested from PFT- 
PCMV cells 3, 4, 7, and 8 dpi, were amplified by nested qualitative PCMV PCR as in 
section 2.2.4. One thousand copies of PCMVpol control plasmid were amplified as a 
positive control, while SDW was used as a negative control.
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2.4.5 Confirmation of PCMV productive infection in PFT cells by IIF assay 
PCMV infection was also confirmed by IIF of PFT-PCMV cells harvested 10 dpi. Cells
•j
were harvested from one 25 cm flask using trypsin, transferred to a 15 ml tube 
containing 6  ml of complete MEM, and pelleted at 400 xg for 6  min. The cell pellet was 
washed twice in 5 ml of sterile PBS, centrifuging at 400 xg for 6  min each time, and 
resuspended in 1 ml of sterile PBS. An aliquot of cells was counted in 20 % 
paraformaldehyde using a haemocytometer and diluted to 1 x io6 cells/ml in sterile PBS. 
IIF slides were then prepared as in section 2.3.13. Uninfected PFT cells were added to 
slides as a negative control. The IIF assay was performed using serum from PCMV 
seropositive pigs, diluted 1/20 and 1/40 in sterile PBS. In addition, sterile PBS was 
added to control wells.
2.4.6 The effect of TPA on the growth of PCMV in PFT cells
The effect of TPA on the growth of PCMV in PFT cells in vitro was determined by 
monitoring PFT-PCMV cells 3, 7, and 11 days following incubation either with or 
without 5 ng/ml of TPA (Sigma). Immunofluorescence slides were prepared from PFT- 
PCMV cells incubated with and without TPA as in section 2.3.13, and the IIF assay was 
performed using serum from PCMV-seropositive pigs, diluted 1/20 and 1/40 in sterile 
PBS. Sterile PBS was added to control wells. In addition, the effect of TPA on 
uninfected PFT cells was determined by comparing cultures under a light microscope, 3 
days following incubation either with or without 0, 1, 2, or 5 ng/ml of TPA.
2.4.7 Preparation of PCMV inoculum
In order to determine the optimum method of infecting PFT cells with PCMV, two 
inoculums derived from TCS and lysed cells were prepared from a flask of PFT-PCMV 
cells. A TCS inoculum was prepared by harvesting TCS, followed by centrifugation at 
400 xg for 6  min to remove floating cells, and filtering through a 0.45 pm filter 
(Sartorius). Meanwhile, cells were harvested from the flask by trypsinisation, pelleted 
(400 xg, 6  min), resuspended in 1 ml of complete MEM, and lysed by three cycles of 
freeze-thawing for 1 min in liquid nitrogen followed by 5 min in a 37 °C water bath. 
The cell lysate was clarified by centrifugation at 14,000 xg for 5 min. One millilitre of
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each inoculum was used to infect semi-confluent PFT cells in two 25 cm cell culture 
flasks in a 37 °C incubator for 1 hr, rocking occasionally. Following infection, the 
inoculum was replaced with 8 ml of complete MEM, with or without 5 ng/ml of TPA, 
and returned to the 37 °C incubator. An IIF assay was performed using slides prepared 
from PFT cells 21 dpi with each PCMV inoculum as in section 2.3.13. The PCMV 
DNA load of each inoculum was also determined by QC PCR as in section 2.2.5, with 2 
pi of neat inoculum, and inoculum diluted to 1/10 and 1/100, added to each PCR.
The virus titre of each PCMV inoculum was assessed by plaque assay using the method 
previously described by Kawamura et al (Kawamura et al, 1992). Approximately 8 xlO5 
PFT cells were seeded in each well of a 6 -well plate and incubated overnight at 37 °C in 
a 5 % CO2 humidified incubator. Serial tenfold dilutions (10' 2 to 10'5) of TCS and cell 
lysate inoculums were prepared in complete MEM. Once PFT cells were 80-90 % 
confluent, 200 pi of each virus inoculum dilution were used to infect PFT cells in 
triplicate. Following virus adsorption at 37 °C for 1 hr, the inoculum was removed and 
each monolayer was overlaid with 2.5 ml of 0.8 % bacteriological agar in complete 
MEM, and returned to the humidified incubator. Fresh overlay was added to plates 
every 5 dpi. Following 10 and 15 days of culture an overlay containing 0.005 % Neutral 
Red Solution was added to each well. Plaques were observed up to 20 dpi under a light 
microscope.
The virus titre of TCS and cell lysate inoculums were also assessed using an alternative 
plaque assay method using a methyl cellulose overlay. PFT cells (5 xlO4) were seeded 
in each well of a 48-well plate and incubated overnight at 37 °C. Serial tenfold dilutions 
(10' 2 5 to 10' 5 5) of TCS and cell lysate inoculum were prepared in complete MEM 
medium. Once PFT cells were 80-90 % confluent, 100 pi of each virus inoculum 
dilution were used to infect PFT cells in triplicate. Meanwhile, 100 ml of methyl 
cellulose overlay were prepared by adding 10 ml of 1 Ox MEM, 30 ml of Leibovitz’s L- 
15 medium (both Invitrogen), 5 ml of FCS and 3 ml of 7.5 % sodium bicarbonate 
(Invitrogen), supplemented with 100 U/ml of penicillin and 100 pg/ml of streptomycin, 
to 51 ml of 2 % methyl cellulose. Following virus adsorption at 37 °C for 1 hr, the 
inoculum was removed and each monolayer was overlaid with 0.5 ml of methyl 
cellulose overlay and returned to the humidified incubator. Thirteen days postinfection, 
1 ml of formal saline (140 mM NaCl; 10 % formaldehyde (37 %) (both Sigma)) was
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added to each well and incubated at room temperature for 45 min. Plates were washed 
ten times in (IH2O, dried, and incubated with 0.5 ml of 0.03 % methylene blue 
(Sigma)/well for 45 min. Wells were washed and dried as before and observed under a 
light microscope.
In addition, the effect of using freshly harvested PCMV TCS vs. TCS which had been 
stored at -80 °C, on the resulting PCMV infection in PFT cells was investigated. TCS 
was harvested from chronically-infected PFT-PCMV cells, centrifuged (400 xg, 6 min) 
to remove floating cells and filtered through a 0.45 pm filter. TCS was then either 
stored at -80 °C overnight or used directly to infect PFT cells. One millilitre of each 
TCS inoculum was used to infect semi-confluent PFT cells in two 25 cm2 cell culture 
flasks for 1 hr in a 37 °C incubator. Following virus adsorption, the inoculum was 
removed and replaced with 8 ml of complete MEM. The effect of freezing TCS 
inoculum on PCMV virus titre was then determined by observing the development of 
CPE under a light microscope, and by the preparation of IIF slides from cultures 17 and 
27 dpi. The IIF assay was performed as in section 2.3.13. In addition, the PCMV DNA 
load of each inoculum was determined by QC PCR as in section 2.2.5, with 2 pi of neat 
inoculum, and inoculum diluted to 1/10 and 1/100, added to each PCR.
2.4.8 Investigating the use of 70 % sorbitol to preserve virus titre during freezing
The effect of using 70 % sorbitol to preserve PCMV virus titre when freezing PCMV 
TCS inoculum was assessed. TCS was harvested from chronically-infected PFT-PCMV 
cells, centrifuged (400 xg, 6 min) to remove floating cells and filtered through a 0.45 
pm filter. TCS was then stored at -80 °C overnight in either, an equal volume of 70 % 
sorbitol (BDH), an equal volume of complete MEM, or undiluted. One millilitre of each 
inoculum was then used to infect semi-confluent PFT cells in three 25 cm2 cell culture 
flasks for 1 hr in a 37 °C incubator. Following virus adsorption, the inoculum was 
removed and replaced with 8 ml of complete MEM. The effect of using 70 % sorbitol to 
preserve PCMV virus titre was determined by observing the development of CPE under 
a light microscope, and by the preparation of IIF slides from cultures 14 dpi. The IIF 
assay was performed 21s in section 2.3.13.
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2.4.9 Establishing PCMV infection in L45 cells
In order to investigate alternative cell lines in which to determine PCMV antiviral 
susceptibility, a suspension porcine T cell line, L45, was infected with TCS inoculum 
from PFT-PCMV cells. A growing culture of L45 cells (purchased from the European 
Collection of Cell Cultures) was maintained in 8 ml of RPMI medium (Invitrogen), 
supplemented with 100 U/ml of penicillin, 100 pg/ml of streptomycin, 1 mM of sodium 
pyruvate, 0.05 mM of 2-mercaptoethanol (both Invitrogen), and 10 % FCS, in 25 cm2 
cell culture flasks at 37 °C (5 % CO2). TCS was harvested from chronically-infected 
PFT-PCMV cells, centrifuged (400 xg, 6 min) to remove floating cells and filtered 
through a 0.45 pm filter. Two millilitres of L45 cells were incubated with 1 ml of 
PCMV TCS inoculum for 1 hr prior to the addition of 7 ml of complete RPMI medium. 
Cultures were then incubated at 37 °C and passaged at a ratio of 1:5 every 5 days. IIF 
slides were prepared from L45-PCMV cells harvested 10, 20 and 30 dpi, and an IIF 
assay was performed as in section 2.3.13.
2.4.10 Establishing chronically-infected PFT-PCMV cultures to investigate 
antiviral susceptibility
Chronic PCMV infection of PFT cells was established by limiting passaging of cells. 
PFT cells (1 xlO6) were seeded in 25 cm2 cell culture flasks. Following incubation 
overnight (37 °C, 5 % CO2), sub-confluent (90 %) PFT cells were inoculated with 1 ml 
of fresh PCMV TCS (filtered, 0.45 pm) harvested from PFT-PCMV cells, for 1 hr, 
rocking occasionally. Following virus adsorption at 37 °C for 1 hr, the inoculum was 
removed and replaced with 8 ml of complete MEM. Following the appearance of CPE 
approximately 5-10 dpi, cultures were transferred to 75 cm2 cell culture flasks at 14 dpi, 
and incubated for a further 7 days, with the culture medium replaced weekly. The 
development of CPE was additionally recorded in PFT-PCMV cultures incubated up to 
20 dpi without passaging, and photographed using an Olympus DPII digital camera 
attached to a light microscope.
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2.4.11 Visualisation of PCMV virus particles by electron microscopy
PCMV TCS was harvested from chronically-infected PFT-PCMV cells and 
ultracentrifuged at 40,000 rpm in a Beckman L-80 Ultracentrifuge (SW60 rotor) for 30 
min. The viral pellet was resuspended in 3 % phototungstic acid, pH 6.3, EM stain. 
Visualisation of virus particles using the electron microscope was then performed by a 
member of the diagnostic staff in the department, and photographs were developed on 
site.
2.4.12 Investigating antiviral susceptibility in TCS and PFT-PCMV cells
Chronically-infected PFT-PCMV cells were divided between four 25 cm2 cell culture 
flasks; one flask for each of three concentrations of antiviral drug tested, and one 
control flask containing no antiviral drug (day -2). Unattached cells were removed from 
cultures after 2 days by total medium replacement (day 0), and real-time PCMV PCR 
(see section 2.4.13) of the culture supernatant, harvested on day 2, was used to confirm 
that equal numbers of PFT-PCMV cells were present in each flask. The effect of each 
antiviral drug on PCMV replication was investigated by monitoring PCMV viral load in 
the supernatant every two days from day 2 (the first day that antiviral drug was added) 
until day 14. On these days, the supernatant was collected prior to total medium 
replacement including the appropriate antiviral drug concentration. Ganciclovir (Roche) 
and cidofovir (Moravek Biochemicals) were diluted to a final concentration of 1, 5 and 
10 pg/ml, while foscamet (AstraZeneca) was diluted to a final concentration of 25, 50 
and 100 pg/ml. Aciclovir (Foulding) was diluted to a final concentration of 5, 10 and 25 
pg/ml. Supernatant at each time point was centrifuged (400 xg, 6 min), to remove 
detached cells and 5 pi of cell-free supernatant was tested by real-time PCR. On day 14, 
all cultures were harvested for the preparation of IIF slides (as in section 2.3.13) and 
DNA extraction. Following IIF, the average number of fluorescing, PFT-PCMV cells, 
in each well of the IIF slide was calculated by counting the total number of cells in each 
of four wells on the IIF slide. DNA was extracted from cells using the Wizard Genomic 
DNA Purification Kit, using the protocol for the Isolation of Genomic DNA from 
Tissues Culture Cells and Animal Tissue (see section 2.2.2). One hundred nanograms of 
DNA were analysed by real-time PCR, with uninfected PFT cellular DNA tested as a 
negative control.
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2.4.13 Real-time PCR for PCMV DNA
PCMV target sequences were quantified by real-time PCR using an ABI PRISM 7700 
Sequence Detection System (Applied Biosystems). Primers PCMVpolF and 
PCMVpolR, and Taqman probe (table 2.1), were designed using Primer Express 
software (Applied Biosystems), from a region of the DNA polymerase gene of PCMV 
(Widen et al, 1999). The sensitivity of each primer to amplify the wild-type PCMVpol 
plasmid (generated in sections 2.1.1-2.1.4) was initially assessed by testing 106-0.1 
copies of wild-type plasmid per reaction. Wild-type PCMVpol plasmid was diluted in 
10 mM Tris buffer (pH 8.5), containing 150 ng/pl of salmon sperm DNA (both Sigma) 
as a carrier. Each reaction contained 100 ng of each primer, 5 pmol of probe, 200 pM of 
each dNTP, 2.5 U of HotStarTaq and target DNA, in PCR buffer (containing 1.5 mM 
MgCl2) (Qiagen), in a final volume of 25 pi. Reagents were aliquoted into each well of 
a 96-well optical reaction plate (Applied Biosystems). Cycle parameters were; an initial 
cycle of 50 °C for 2 min and 95 °C for 10 min, followed by 40 cycles of 95 °C 
denaturation for 15 s and 60 °C annealing/extension for 1 min. Real-time PCR products 
were analysed using Taqman software and additionally run on a 3 % agarose gel to 
visualise results. Subsequently, target sequences were amplified alongside 10-10 
copies of PCMV standard (wild-type PCMVpol plasmid), with all samples being tested 
in triplicate. The threshold cycle values for the PCR amplification of the standards were 
used to generate a standard curve for the quantitation of target DNA, and the mean of 
three viral loads was calculated.
2.4.14 Determining the cytotoxicity of antiviral agents
The cytotoxic effect of each antiviral on PFT-PCMV cells was determined by counting 
the total number of remaining adherent cells, harvested from each culture at day 14, 
following removal of culture supernatant. An aliquot of cells was diluted in an equal 
volume of 0.4 % trypan blue (Sigma) and 37 % formaldehyde (1:1), and counted using a 
haemocytometer. In a parallel study to that in section 2.4.12, cytotoxicity was 
determined using cellular DNA extracted at day 14 from uninfected adherent cells, 
cultured with each concentration of drug, as a marker of the total cell count. In addition, 
DNA was extracted from detached cells removed in the culture supernatant over the 14
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day period. DNA was extracted from uninfected cells using the Wizard Genomic DNA 
Purification Kit, using the protocol for the Isolation of Genomic DNA from Tissues 
Culture Cells and Animal Tissue (see section 2.2.2), and the DNA concentration was 
determined by UV spectrophotometry at 260 nm.
2.4.15 Investigating the dynamics of PCMV replication in vivo
In order to estimate the doubling time of PCMV replication in vivo, PCMV viral loads 
were determined in PCMV-positive blood samples from piglets derived from sow 
P49M, which had been prospectively monitored from birth (see section 2.2.1). DNA 
(0.5 pg) extracted from whole blood samples in section 2.2.2 was analysed by real-time 
PCR as in section 2.4.13. Each sample was tested in triplicate and the mean of each 
result was calculated.
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Chapter 3: The development of qualitative and 
quantitative competitive (QC) PCR assays for
PCMV
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3.1 Introduction
Evidence of PCMV infection is most often detected by IIF or ELISA of porcine sera, or 
by the presence of intranuclear inclusions within infected cells (Edington, 1999). 
However, these methods are time consuming and suffer from limited sensitivity. More 
recently, PCR assays for the detection of PCMV DNA have been developed (Hamel et 
al, 1999; Widen et al, 1999). Both of these assays are qualitative, thereby detecting the 
presence or absence of the virus within a sample, and use primers specific for the DNA 
polymerase gene of PCMV.
PCR is a powerful diagnostic tool, which has revolutionised the detection of many 
viruses. Advantages of PCR are that it is reliable, fast, versatile, cost effective, and 
sensitive. Specificity is brought about by primers which are designed to bind only to a 
specific target sequence under stringent conditions. The choice of target gene also 
influences the specificity of the PCR. The DNA polymerase gene is a common target 
for the detection of herpesviral DNA by PCR, since the gene is highly conserved. 
Specificity and sensitivity can be further increased by performing two rounds of 
amplification using nested primers, which bind internally to the first round primers.
Viral load measurements are important in understanding the pathogenesis of viruses, 
and have significant prognostic implications (Mellors et al, 1996; Spector et al, 1998). 
In particular, in renal transplant recipients, the quantity of HCMV DNA detected in 
urine, was significantly increased in those patients with clinically apparent disease. In 
fact, high viral load has been identified as the primary risk factor for the development of 
HCMV disease in transplant recipients (Cope et al, 1997a; Hassan-Walker et al, 1999). 
There are currently no methods available to quantify PCMV DNA.
At the time of conducting this work, the main PCR methods of quantifying viral DNA 
within clinical samples include co-amplification of the sample with genes such as (3- 
globin (Pang et al, 1990), and limiting dilution of the sample, followed by qualitative 
PCR (Simmonds et al, 1990), however, the latter method is very time-consuming and 
inappropriate for the analysis of a large number of samples. At the Centre for Virology, 
at the Royal Free and University College Medical School, an alternative approach has 
been developed, and used to accurately quantify viruses including HCMV, HHV-6, -7,
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and -8, and HIV (Fox et al, 1992; Clark et al, 1996; Kidd et al, 1996; Lock et al, 1997; 
Atkins et al, 1996). These methods are based on the co-amplification of ‘wild-type’ 
DNA extracted from a clinical sample alongside a control sequence of known copy 
number. This control sequence is identical, in length, primer binding sequences and 
G+C content, to the actual wild-type sequence apart from the presence of a unique 
restriction endonuclease site, which allows for the separation of control and wild-type 
amplicons following PCR (Figure 3.1). Comparison of wild-type and control amplicons 
by electrophoresis and densitometric analysis, allows for the calculation of the number 
of wild-type molecules within the original sample (Kidd et al, 2000). Advantages of this 
method are that it compensates for local variation between PCRs, and controls for the 
presence of inhibitory substances within specific clinical samples, since the control 
sequence is added with the sample DNA. In addition, since both wild-type and control 
sequences are identical in size, base composition, and possess identical primer binding 
sites, the kinetics of the amplification of both sequences is the same. A nested QC PCR 
is used to quantify viral DNA present in low copy numbers.
The following chapter describes the development and optimisation of a qualitative and 
QC PCR assay for PCMV, using primers specific for a region of the viral DNA 
polymerase gene PCMVpol. The target PCMVpol region was initially amplified and 
cloned into the pGEM-T Easy vector to generate the PCMVpol wild-type plasmid. A 
Sma I restriction endonuclease site was then introduced into the PCMVpol region by 
PCR-mediated, site-directed mutagenesis (Fox et al, 1992), to produce the PCMVpol 
control sequence. The sensitivity of the PCMV PCR was optimised by altering the PCR 
conditions. The utility of the PCMVpol control plasmid to accurately quantify 
PCMVpol wild-type DNA was then determined in a series of co-amplification 
experiments.
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Co-amplify sample with known copy 
number of control sequence
Nested PCR
Wild-type amplicon
Control amplicon 
(restriction enzyme 
s i t e B H  )
Digestion of PCR product with 
restriction enzyme, followed by 
PAGE
wild-type
control
bands
Scanning, densitometry
Figure 3.1. Quantitative competitive (QC) PCR. Following co-amplification of sample 
DNA with a known copy number of control sequence, control amplicons are digested 
with a restriction enzyme and separated from wild-type amplicons by PAGE. 
Comparison of wild-type and control amplicons by densitometric analysis, allows for 
the calculation of the number of wild-type molecules within the original sample.
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3.2 Results
3.2.1 Generation of the PCMVpol control plasmid as an internal standard for the 
QC PCR
Nested PCR primers were designed from a 520-bp published sequence of the DNA 
polymerase gene of PCMV (Widen et al, 1999). First round primers were initially used 
to amplify a 236-bp region of the PCMV DNA polymerase gene from a TCS sample of 
porcine alveolar macrophages infected with PCMV strain B6 (Figure 3.2). The 236-bp 
PCR product was purified and cloned into the pGEM-T Easy vector. The presence of 
the 236-bp PCMVpol sequence within the pGEM-T Easy vector was confirmed by 
nested PCR analysis of three recombinant clones (Figure 3.3). First round primers 
amplified a 236-bp PCR product, while a 184-bp product was amplified by nested round 
primers.
PCR-mediated, site-directed mutagenesis, similar to the method described by Fox et al 
(Fox et al, 1992), was used to create a Sma I restriction endonuclease site within the 
PCMVpol sequence. Two complementary mutagenic primers, each with a 2-bp 
mismatch to the target sequence, were used in two separate PCRs. The products of these 
PCR experiments (Figure 3.4) were purified, mixed in equimolar amounts, and annealed 
together. The annealed products were 3’ extended to produce the PCMVpol control 
sequence, and used as the template for amplification with first round PCMV PCR 
primers. The presence of the Sma I site within the control sequence was confirmed by 
restriction enzyme digestion of the PCR product (Figure 3.5). The PCMVpol control 
sequence was then cloned into the pGEM-T Easy vector, and used to transform 
competent E. coli cells. Five recombinant clones were analysed for the presence of the 
PCMVpol control sequence by PCMV PCR and Sma I digestion (Figure 3.6). The 
presence of the Sma I restriction site was also confirmed by sequence analysis of the 
PCMVpol control plasmid (Figure 3.7). Stocks of wild-type and control plasmids were 
produced by large-scale plasmid preparation, diluted to 1010 copies/pl, and stored at -80 
°C.
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Lane 1 2 3 4 5 6
«-----  236-bp
Figure 3.2. PCR amplification of the 236-bp PCMVpol sequence from 1 pi (lane 2), 5 
pi (lane 3), and 10 pi (lane 4) of TCS from alveolar lung macrophages infected with 
PCMV, strain B6. SDW was added to the PCR as a negative control (lanes 5 & 6). PCR 
products were electrophoresed on a 3 % agarose gel alongside HyperLadder IV DNA 
markers (lane 1).
Lane 1 2 3 4 5 6 7 8 9  10 11
 <-----  236-bp
 <-----  184-bp
First round Nested round
Figure 3.3. Nested PCR analysis of three recombinant clones (lanes 2-4 & 7-9), 
following cloning of the 236-bp PCMVpol sequence into the pGEM-T Easy vector and 
transformation of competent E. coli. SDW was added to the PCR as a negative control 
(lanes 5,6,10 & 11). PCR products were electrophoresed on a 3 % agarose gel alongside 
HyperLadder IV DNA markers (lane 1).
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Lane 1 2 3 4 5 6 7 8 9  10 11
148-bp
112-bp
Figure 3.4. Site-directed mutagenesis products generated by PCR. A 148-bp sequence 
was amplified from 1, 5, and 10 pi of recombinant plasmid, using primers PCMVF1 and 
PCMVFM in one PCR (lanes 2-4). In a separate PCR, a 112-bp sequence was amplified 
from 1, 5 and 10 pi of recombinant plasmid, using primers PCMVR1 and PCMVRM 
(lanes 7-9). SDW was added to each PCR as a negative control (lanes 5, 6, 10 & 11). 
PCR products were electrophoresed on a 3 % agarose gel alongside HyperLadder IV 
DNA markers (lane 1).
Figure 3.5. Sma I digestion of the PCMVpol control sequence. The PCMVpol control 
sequence (lanes 2-5) was PCR-amplified from the Klenow-filled mutated PCMVpol 
sequence using primers PCMVF1 and PCMVR1. SDW was added to the PCR as a 
negative control (lanes 6 & 7). The presence of the Sma I restriction enzyme site was 
confirmed by Sma I digestion of PCR products (lanes 8-13). All samples were run on a 
3 % agarose gel alongside HyperLadder IV DNA markers (lane 1).
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13
236-bp
^ ----- 100-bp
,4___ 136-bp
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Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
236-bp.
.136-bp 
100-bp
Figure 3.6. PCR analysis of five PCMVpol control plasmid recombinant clones (lanes 
2-6). SDW was added to the PCR as a negative control (lanes 7 & 8). The presence of 
the Sma I restriction enzyme site was confirmed by Sma I digestion of PCR products 
(lanes 9-15). All samples were run on a 3 % agarose gel alongside HyperLadder IV 
DNA markers (lanes 1 & 16).
□GTC CATCAC CAGCAT
1 8 0  1 9 0
AC ATOC T TAG GCAGACGA 
2 0 0  2 1 0
B
3CGTC CATCAC CAQCATAGfccCGQG^CATQCTTAGQCAGACQA 
1 9 0  2 0 0  2 1 0  2 2 0
Figure 3.7. Sequence analysis of wild-type and control PCMVpol plasmids. Panel A 
shows a section of the wild-type PCMVpol sequence, showing the putative Sma I 
restriction site. Panel B shows a section of the control PCMVpol sequence, showing the 
introduced Sma I restriction enzyme site.
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3.2.2 Optimisation of qualitative and QC PCR assays
The magnesium ion concentration and annealing temperature were optimised to 
maximise the sensitivity and specificity of the PCMV PCR assays. Since primer 
PCMVF1 proved insensitive, primers PCMVF2 and PCMVR1 were used in the first 
round PCR to amplify a 212-bp amplicon, while primers PCMVFB and PCMVR2 were 
used in the nested round to amplify a 160-bp product. The magnesium ion concentration 
was varied between 1 mM and 2 mM, while an annealing temperature of either 55 °C or 
60 °C was used. The results in Figure 3.8 show that increasing the magnesium ion 
concentration from 1 mM to 1.5 mM increased the yield of the PCMV PCR product, 
while increasing the magnesium ion concentration to 2 mM did not lead to any further 
increase in yield of the PCMV PCR product. At a magnesium ion concentration of 1 
mM the yield of the PCMV PCR product was greater when an annealing temperature of 
55 °C was used. Whilst at a magnesium ion concentration of 1.5 mM, there was no 
difference in yield of the PCMV PCR product at either annealing temperature. 
Following these findings 1.5 mM of MgCl2 was added to the PCMV PCR. An annealing 
temperature of 60 °C was used to increase specificity in the first round of the PCMV 
PCR, while in the nested round, the annealing temperature was reduced to 55 °C to 
increase sensitivity.
The number of cycles used in the nested round of the PCMV PCR were optimised by 
amplifying 103, 102 and 10 copies of the PCMVpol control plasmid by nested PCR, and 
removing tubes from the thermal cycler during the nested round following 10 to 15 
cycles of amplification. When 103 copies of the PCMVpol control plasmid were used, 
there was little increase in PCMV PCR product between cycles 10 and 15, suggesting 
that amplification had reached a plateau (Figure 3.9). When 102 and 10 copies were 
used, PCMV PCR product increased exponentially between cycles 10 and 15. Since 
following 15 cycles of amplification it was still possible to distinguish between PCMV 
PCR products amplified from 102 and 10 copies of PCMVpol control plasmid, 15 cycles 
of nested round amplification were performed in the QC PCR.
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Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
55 °C 60 °C 55 °C 60 °C 55 °C 60 °C
V w J y w J K w Jy y  y
1 mM MgCl2 1.5 mM MgCl2 2 mM MgCl2
Figure 3.8. Optimisation of magnesium ion concentration and annealing temperature in 
the PCMV PCR. Fifty copies of PCMVpol control plasmid were amplified by nested 
PCR, using either; 1, 1.5, or 1 mM of MgCl2, at an annealing temperature of either 55 
°C or 60 °C. One microlitre of each first round PCR product was added to the nested 
round and amplified for 18 cycles. Nested round products were run on a 1 % agarose gel 
alongside HyperLadder IV DNA markers (lane 1).
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Cycle no. 10 11 12 13 14 15 10 11 12 13 14 15 10 11 12 13 14 15
V_______   yVs_______   J K_______   J
Y Y
« 710 copies control plasmid 10 copies control plasmid 10 copies control plasmid
Figure 3.9. Optimisation of the nested round cycle number in the PCMV PCR. Between 
10 and 103 copies of PCMVpol control plasmid were amplified by nested PCR. Nested 
round PCR tubes were removed from the thermal cycler between cycles 10 and 15 and 
PCR products were electrophoresed on a 1 % agarose gel alongside HyperLadder IV 
DNA markers (lane 1).
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3.2.3 Investigating the sensitivity and specificity of the PCMV PCR assays
The sensitivity of the PCMV PCR was investigated by diluting PCMVpol control 
plasmid from 103 to 1 copy. Control plasmid dilutions were amplified in triplicate by 
nested qualitative PCR. The results show that 103, 102, 10, and 5 copies of PCMVpol 
control plasmid were consistently amplified, while 1 copy of input plasmid was not 
amplified (Figure 3.10). This shows that the sensitivity of this qualitative PCR for the 
detection of PCMV is < 5 genome copies/reaction.
The specificity of the PCMV PCR assay was tested by amplifying DNA from other 
betaherpesviruses; HHV-6, HHV-7, and HCMV alongside PCMV. Figure 3.11 shows 
that none of these samples yielded detectable amplification products.
3.2.4 Characterisation of the PCMV QC PCR
To assess the utility of the PCMVpol control sequence in the QC PCR, a range of 
known copy numbers of wild-type and control plasmids were co-amplified. A single 
round PCR was performed when 5 xlO6 to 103 input copies were used, while a nested 
PCR of 15 second round cycles was performed when 103 to 5 input copies were used. 
Following nested PCMV PCR, control amplicons were separated from wild-type 
amplicons by Sma I digestion and PAGE. Gels were stained with ethidium bromide and 
the input wild-type plasmid copy number calculated as previously described (Kidd et al, 
2000) (Figure 3.12). Figure 3.13 shows a calibration curve where the mean result from 
three experiments was plotted against the known wild-type input copy number. It shows 
that the calculated and actual copy numbers of PCMV were highly correlated (R = 
0.998, P < 0.0001 for a linear fit curve), demonstrating that the QC PCR assay is highly 
reproducible over a broad dynamic range and could be used to accurately quantify 
PCMV DNA.
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Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Ml 60-bp
103 102 1 0 5
Figure 3.10. Sensitivity of the PCMV PCR. One thousand (lanes 2-4), 102 (lanes 5-7), 
10 (lanes 8-10), 5 (lanes 11-13), and 1 (lanes 14-16) copy of PCMVpol control plasmid 
were amplified by nested PCR in triplicate, and 10 pi of nested products were 
electrophoresed on a 3 % agarose gel, alongside HyperLadder IV DNA markers (lane 
1). SDW was used added to the PCR as a negative control (lanes 17-20).
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Figure 3.11. Specificity of the PCMV PCR. Viral DNA from HHV-6 (lanes 2, 3, 11 & 
12), HHV-7 (lanes 4, 5, 13 & 14), and HCMV (lanes 6, 7, 15 & 16), was not amplified 
by nested PCMV PCR. PCMV (lanes 8, 9, 17 & 18), and SDW (lanes 10 & 19), were 
used as positive and negative controls respectively. First round (lanes 2-10) and nested 
round (lanes 11-19) PCR products were electrophoresed on a 3 % agarose gel, alongside 
HyperLadder IV DNA markers (lane 1).
M212-bp
Ml 60-bp
First round Nested round
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Figure 3.12. An example of the densitometric analysis performed in the PCMV QC 
PCR. QC PCR PAGE images (A) were scanned at 200 pixels per inch using an Epsom 
scanner. The scanned image was imported into the NIH Image program (version 1.63), 
for densitometric analysis (B). The scanned image was inverted (screen window A), and 
the lanes were marked using the gel reading macros supplied. Electronic densitometric 
plots were generated (screen window B), and the pixel area under each peak was 
calculated (screen window C).
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R = 0.998 
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Input wild-type PCMV copy number (log10)
Figure 3.13. Characterisation of the PCMV QC PCR. Known copy numbers of the 
PCMVpol wild-type plasmid, ranging from 5 to 5 xlO6 were co-amplified with known 
copy numbers of the PCMVpol control plasmid (ranging from 10-106). Calculated wild- 
type copy numbers were plotted against actual input wild-type copy numbers. Each 
point represents the mean of triplicate determinations, with standard errors shown in 
error bars. R = correlation coefficient.
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3.3 Discussion
This chapter describes the development of qualitative and fully quantitative competitive 
PCR assays for PCMV (Fryer et al, 2001). Although there have been reports of 
qualitative PCR assays for the detection of PCMV DNA (Widen et al, 1999; Hamel et 
al, 1999), this was the first quantitative PCR for PCMV to be published. As previously 
described, viral load measurements can provide information on the pathogenesis of viral 
infections, are important for the diagnosis of disease in patients such as transplant 
recipients, and are therefore useful in the treatment of these patients (Manez et al, 1996; 
Mutimer et al, 1997). In the context of xenotransplantation, it will be equally important 
to be able to measure PCMV viral loads in pigs being bred for xenograft organs, and 
also potentially in human xenograft recipients should clinical trials proceed.
The QC PCR method developed for PCMV is based on that previously used in our 
department to accurately and efficiently measure viral loads within clinical samples 
(Fox et al, 1992; Clark et al, 1996; Kidd et al, 1996; Lock et al, 1997; Atkins et al, 
1996). Compared with other quantitative methods, it controls for sample-to-sample and 
sample-to-well variations, since target and identical control sequences are amplified 
within the same tube. At the time of starting this thesis, QC PCR was the method of 
choice for the quantification of viral loads. However, in later stages, key developments 
in PCR quantification facilitated the change from this relatively time-consuming 
method to a more rapid real-time PCR assay (Chapter 6).
The qualitative PCR for PCMV was developed using primers specific for a region of the 
DNA polymerase gene of PCMV. Since initially one of the first round primers proved 
insensitive, primers pairs were changed to increase sensitivity. These primers were 
shown by BLAST analysis to share 100 % identity with sequence data for the DNA 
polymerase gene of all three strains of PCMV; B6, OF-1, and 55b, suggesting their 
ability to amplify different isolates. In addition, results obtained in this chapter show 
that these primers do not amplify HCMV, HHV-6 or HHV-7 DNA sequences, and are 
sensitive to < 5 PCMV genome copies/PCR reaction. The same primers were used to 
develop a QC PCR assay for the quantification of PCMV DNA. This assay was shown 
to be accurate and reproducible over a broad dynamic range (5-5x106 PCMV genome 
copies).
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The PCMV PCR assays developed in this chapter will be useful in further studying the 
pathogenesis of PCMV, and will enable the detection and accurate quantification of 
PCMV in porcine organs and tissues from pigs being bred for use in xenotransplantation 
(Chapter 4).
148
Chapter 4: PCMV in pigs being bred for xenografts
Chapter 4: Investigating the prevalence, quantity 
and organ distribution of PCMV in 
immunocompetent and immunosuppressed pigs 
being bred for xenograft organs, investigating 
when virus is acquired, and examining methods 
to eliminate PCMV from these animals
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4.1 Introduction
Xenotransplantation raises considerable safety issues including the potential 
transmission of porcine infectious agents, particularly viruses, to humans (Murphy, 
1996; Brown et al, 1998). Experience from human allotransplantation indicates that 
members of the retrovirus and herpesvirus families may be transmitted in the graft 
(Fishman & Rubin, 1998). In particular, since HCMV is frequently transmitted to 
human allograft recipients, where it reactivates and is associated with end-organ disease 
and graft rejection, the porcine equivalent, PCMV, may pose a risk to human recipients 
of porcine xenografts. This is highlighted by the fact that BCMV is the only virus to 
date, which has been transmitted to humans following xenotransplantation (Michaels et 
al, 2001).
Serological evidence indicates that approximately 90 % of pig herds in the UK are 
infected with PCMV (Edington, 1999). A high seroprevalence of PCMV has also been 
reported in pigs from the Netherlands and Japan (93 % and 99.4 % respectively) 
(Rondhuis et al, 1980; Tajima et al, 1993). The prevalence of PCMV in lung tissue and 
nasal scrapings from Canadian pigs, as detected by PCR, was lower (59 % of pigs tested 
PCMV PCR-positive) (Hamel et al, 1999).
PCMV infection is characterised by rhinitis, pneumonia and poor weight gain in young 
pigs, and is associated with a significant loss of newborn piglets, while infection in 
adults is generally silent (Edington, 1999). In commercial pig herds, infection occurs 
between 5 and 8 weeks of age, coinciding with the mixing of litters in the early post- 
weaning period (Plowright et al, 1976). PCMV causes fatal generalised disease, 
characterised by piglet death and poor weight gain, in young piglets of less than two 
weeks of age, with viraemia detected 5-19 dpi (Edington et al, 1976b), and 
characteristic PCMV intranuclear inclusion bodies detected in many tissues including 
lung macrophages, liver, spleen, lymph nodes, and adrenal glands (Edington et al, 
1976a). In older piglets, PCMV causes asymptomatic generalised infection, with 
viraemia detected 14-16 dpi (Edington et al, 1976b), and inclusion bodies detected 
primarily in epithelial cells of the nasal mucosa and kidney tubules (Edington et al, 
1976a). Virus is most commonly transmitted via nasal secretions (Plowright et al, 
1976), but also through saliva and contaminated urine. In utero infection has been
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demonstrated following experimental infection of pregnant sows at various stages of 
gestation, resulting in significant losses of foetuses and neonates (Edington et al, 1977; 
Edington et al, 1988a; Edington et al, 1988b). However, the frequency of in utero 
infection in a conventional setting has yet to be reported.
As pigs are the most likely source for organs in xenotransplantation, it is important to 
gain a greater understanding of the pathogenesis of PCMV infection, and to investigate 
whether transmission of virus can be interrupted. In previous epidemiological studies, 
evidence of PCMV infection was detected by serology, virus isolation or by the 
identification of inclusion bodies. These methods are generally not sufficiently sensitive 
for the detection of low-level viral infection, in particular, high HCMV loads are 
required before inclusion bodies can be visualised in histopathological samples (Mattes 
et al, 2000). In the era of PCR, it is now possible to re-examine the prevalence of 
PCMV, it’s organ distribution and temporal acquisition.
Since xenograft recipients are likely to be subject to immunosuppressive treatment to 
prevent rejection, it is also important to investigate the effect that this 
immunosuppression might have on PCMV replication. As a herpesvirus, PCMV has the 
ability to remain life-long in the host following primary infection, including a latent 
phase, and may reactivate periodically to produce infectious virus and potentially cause 
disease. Herpesviruses, such as HCMV are frequently reactivated from latency 
following human allotransplantation (Fishman & Rubin, 1998). Meanwhile, reactivation 
of PCMV has been reported following the administration of corticosteroids (Edington et 
al, 1976b; Narita et al, 1985). PCMV reactivation in pigs can otherwise occur when 
new breeding stock is introduced or when routine is disturbed (Edington, 1999).
The following chapter describes the use of qualitative and QC PCR assays, developed in 
Chapter 3, to investigate the prevalence, quantity and organ distribution of PCMV in 
immunocompetent and immunosuppressed pigs being bred for xenotransplantation. The 
chapter also describes the investigations carried out to determine the temporal 
acquisition of virus and methods for it’s control (Clark et al, 2003). Porcine samples 
were obtained from Imutran Ltd., and were derived from Large White pigs (Figure 4.1), 
transgenic for the human decay accelerating factor (CD55). The expression of this 
protein on porcine xenografts used in non-human primate models of xenotransplantation
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has been shown to prevent HAR (Bhatti et al, 1999; Cozzi et al, 2000; Schuurman et al,
2002).
Figure 4.1. Large White pig (source JSR Healthbreed).
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4.2 Results
4.2.1 Tissue distribution and PCMV viral loads in adult pigs and piglets
PCMV DNA was detected in a range of organs and clinical samples from six adult and 
four juvenile pigs by qualitative PCR, and viral loads of PCR-positive samples were 
determined by QC PCR (Tables 4.1 and 4.2). All pigs had been conventionally reared.
All six adult pigs tested positive for PCMV DNA in at least one tissue (median of 4 
tissues, range 1-6). The spleen tested positive in all adult pigs, with a median viral load 
of 27 PCMV genomes/pg of DNA (range 1-151). Of potential xenograft organs, three 
liver samples and one heart and kidney sample tested positive. In general, viral loads 
were low (median of 6 PCMV genomes/pg of DNA, range 1-151), indicating either 
latent or low-level active infection. No excretion of virus was detected in urine, faeces, 
or nasal and saliva swab samples.
In contrast to the adult pigs, PCMV was widely disseminated in 3-5 week-old weaned 
piglets, with a median of 13 PCR-positive tissues (range 12-15). This was significantly 
increased compared to adult pigs (Mann Whitney U test, P < 0.05). In addition, viral 
loads in the piglets (median of 667 genomes/pg of DNA, range 1-5.5 xlO6) were 
significantly higher than those of adult pigs (Mann Whitney U test, P  < 0.0001). These 
results suggest either recent or ongoing active PCMV infection in the piglets. Only 3 out 
of the 4 piglets tested positive for PCMV by PCR, although all were reared identically. 
In addition, there was evidence for excretion of virus in the urine, nasal and saliva swab 
samples of one of the piglets, with high viral loads detected in these samples.
4.2.2 Investigating the temporal acquisition of PCMV
To investigate when virus is acquired, two sows and their respective litters were 
prospectively monitored in blood, from the time of birth (day 1), for a period of 82 and 
36 days. In the first litter examined, both sow and piglets tested PCR-negative for 
PCMV in blood for the first 14 days (Table 4.3). At day 35, five of the ten surviving 
piglets tested positive for PCMV DNA by PCR. By day 49, all piglets tested PCMV- 
positive and remained positive at day 82. Significantly, at day 28, the piglets were
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Table 4.1. Tissue distribution and PCMV viral loads in adult pigs (aged >15 months). Numerical values represent PCMV 
viral load (genomes/pg of DNA). Viral loads below the threshold of quantitation were given an arbitrary viral load of 1 
genome copy/pg of DNA.
D681 a 1 1 - - - - - 8 - - 6 - - - -
E765 - - - - - - - - 8 - - - - - - -
F800 - - - - - - - - 1 - - 1 - - - -
F894 28 - 5 - 1 147 - 6 86 - - nt - - - -
F934 - - - - 1 15 - - 45 - - 1 - - - -
G473 - - - 4 1 40 - - 151 - - - - - - -
a samples tested negative by qualitative PCMV PCR. 
nt = sample not tested owing to insufficient DNA.
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Table 4.2. Tissue distribution and PCMV viral loads in 3-5 week old piglets. Numerical values represent PCMV viral load 
(genomes/|ig of DNA). Viral loads below the threshold of quantitation were given an arbitrary viral load of 1 genome copy/|ig of
DNA.
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Table 4.3. Temporal acquisition of PCMV in sow P49M and litter. At day 28 the piglets were moved to a building 
for weaning with shared airspace but no direct contact with other pigs.
Sow Piglets
Day P49M J443 J444 J445 J446 J447 J448 J449* J450 J451 J452 J453
1 a - - - - - - - - - - -
7 - - - - - - - na - - - -
14 - - - - - - - na - - - -
35 na +b - - + + + na + - - -
49 na + + + + + + na + + + +
82 na + + + nt + nt na nt + + +
Spleen1 na 969 439 3518 7346 107 110 na 3329 1653 4671 9205
a blood samples tested negative by qualitative PCMV PCR,b samples tested positive by qualitative PCMV PCR. 
1 PCMV viral load (genomes/jig of DNA) in spleen harvested at day 82.
na = sample not available, nt = sample not tested owing to insufficient DNA, * piglet died at day 1.
Chapter 4: PCMV 
in pigs being 
bred for xenografts
Chapter 4: PCMV in pigs being bred fo r  xenografts
moved to a building for weaning, with shared airspace but no direct contact with other 
pigs. These results indicate horizontal transmission of the virus, which may have 
occurred after mixing of the litter with other pigs at day 28. In addition, spleen samples 
harvested from the litter at day 82 all tested PCMV-positive by PCR with a median viral 
load of 2491 genomes/pg of DNA (range 107-9205) (Table 4.3).
In the second litter examined, both sow and piglets tested PCR-negative for PCMV 
during the first 7 days (Table 4.4). At day 17, one out of eleven piglets tested positive 
for PCMV, and by day 36 all twelve piglets tested PCMV positive by PCR. These 
results again indicate horizontal transmission of the virus.
Our results in both adult pigs and piglets suggest the spleen is an appropriate tissue to 
sample for PCR analysis of PCMV DNA.
4.2.3 Investigating transplacental transmission of PCMV
In order to investigate whether PCMV is transmitted in utero, spleen samples were 
tested from two conventionally-reared sows and their corresponding foetuses (total of 
22), at day 86 from an average full-term gestation time of 114 days. Both sows tested 
PCR-positive for PCMV in the spleen, with viral loads of 61 and 75 genomes/pg of 
DNA. Meanwhile, all 22 foetuses tested PCR-negative for PCMV in the spleen, even 
after re-testing using 2.5 pg of input DNA in the PCR. These results show that no 
transplacental transmission of PCMV had taken place in the first three-quarters of full- 
term gestation.
In addition, spleen samples were tested from nine sows and their hysterotomy-derived, 
barrier-reared piglets. The rearing of these piglets is further described in chapter 2, 
section 2.2.1. Piglets comprised two or three sentinel piglets from seven sows, and all 
piglets from two further sows. All sows were conventionally reared. Six of the nine 
sows tested positive for PCMV using 1 pg of input DNA in the PCR (median viral load 
of 34 PCMV genomes/pg of DNA, range 9-81) (Table 4.5). On re-testing with 2.5 pg of 
input DNA in the PCR, two further sows tested PCMV-positive. One sow remained 
PCMV-negative even after re-testing with 5 pg of input DNA in the PCR. Meanwhile, 
all 31 hysterotomy-derived, barrier reared piglets (median age of 15 weeks, range 4-21),
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Table 4.4. Temporal acquisition of PCMV in sow G72E and litter. At day 28 the piglets were moved to a building for
weaning with shared airspace but no direct contact with other pigs.
Day
Sow
G72E
Piglets
J479 J480 J481 J482 J483 J484 J485 J486 J487 J488 J489 J490
1 a - - - - - - - - - - nt -
7 na - - - - - - - - - - - -
17 na - - - - - - - nt - + - -
36 na +b + + + + + + + + + + +
a blood samples tested negative by qualitative PCMV PCR,b samples tested positive by qualitative PCMV PCR. 
na = sample not available, nt = sample not tested owing to insufficient DNA.
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Table 4.5. Prevalence of PCMV in spleen samples from SPF piglets and sows.
Sow Sow spleen PCMV viral 
load/pg DNA
Number of piglets PCR 
positive/total tested
593A 81 0/2
671A +a 0/2
004A _b 0/2
45704 9 0/8
476B 37 0/8
616A 36 0/2
423B + 0/2
744A 32 0/3
595A 12 0/2
No. positive/Total 8/9 0/31
a indicates positive for PCMV DNA by PCR when 2.5 pg of DNA were used, negative 
at ljig of DNA input.
b indicates PCR negative when tested at 1,2.5, and 5 pg of DNA input.
159
Chapter 4: PCMV in pigs being bred for xenografts
tested PCR-negative for PCMV, even after re-testing with 2.5 pg of input DNA in the 
PCR. These results show that piglets delivered by caesarean section and subsequently 
barrier-reared did not acquire PCMV. In addition, despite eight of the sows testing 
PCMV-positive in the spleen, there was no transplacental or perinatal transmission of 
PCMV to their offspring.
4.2.4 Prevalence of PCMV and viral loads in immunosuppressed pigs
Qualitative and QC PCR assays were used to detect and quantify PCMV DNA in a 
range of organs from three groups of pigs comprising immunosuppressed and control 
animals. Pigs in group 1 (aged 58 days at necropsy), were delivered by caesarean 
section and reared in a gnotobiotic unit. Pigs in group 2 (aged 57 days at necropsy), 
were weaned at 5 days of age and reared in a gnotobiotic unit. While pigs in group 3 
(aged 52 days at necropsy), were weaned from 5 weeks of age and reared under 
conventional farm conditions. Immunosuppressed pigs received a daily regimen of 
cyclosporin A, azathioprine and prednisolone, from 7-12 days of age, for a period of 
approximately 2 months, while control pigs received no treatment.
In group 1, all tissue samples from both immunosuppressed and control pigs tested 
PCMV-negative by qualitative PCR (Table 4.6). It was therefore not possible to 
compare the effect of immunosuppression on PCMV viral load in these gnotobiotic 
pigs. Meanwhile, all tissues from the conventionally-reared sow, from which these 
group 1 pigs were derived, tested PCMV-positive by PCR (median viral load of 160 
genomes/pg of DNA, range 57-284). These results further support the findings obtained 
in section 4.3.3, that piglets delivered by caesarean section and subsequently barrier- 
reared do not acquire PCMV.
In group 2, again, all tissue samples from both immunosuppressed and control pigs 
tested PCMV-negative by qualitative PCR (Table 4.7). As with results obtained in 
group 1 pigs, it was not possible to compare the effect of immunosuppression on PCMV 
in this group of piglets.
In group 3, both immunosuppressed and control piglets tested PCMV-positive by 
qualitative PCR (median 5 tissues, range 3-5) (Table 4.8). Viral loads varied between
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Table 4.6. Group 1: Prevalence of PCMV in immunosuppressed and control gnotobiotic 
pigs.
Immunosuppressed pigs Control pigs
Sample 192 193 194 195 191 196 197 Sow
Heart a - - - - - - 160
Kidney - - - - - - - 57
Liver - - - - - - - 104
Lung - - - - - - - 218
Spleen - - - - - - - 284
a DNA extracted from each tissue sample tested negative by qualitative PCMV PCR. 
Numerical values represent PCMV viral load (genomes/pg of DNA).
Table 4.7. Group 2: Prevalence of PCMV in immunosuppressed and control SEW pigs.
Immunosuppressed pigs Control pigs
Sample 253 239 244 270 275 238 243 271
Heart
Kidney _ _ _ _ _  
Liver _ _ _ _ _  
Lung _ _ _ _ _  
Spleen -
-
a DNA extracted from each tissue sample tested negative by qualitative PCMV PCR.
Table 4.8. Group 3: Prevalence of PCMV in immunosuppressed and control 
conventionally-reared pigs.
Sample
Immunosuppressed pigs Control pigs
F312 F314 F315 F321 F313 F324
Heart 153 11277 770 a 344 4164
Kidney 378 7 26 - 77 9881
Liver 261 29 23 25 57 28
Lung 290 883 2407 202 94 597
Spleen 7953 984 2870 32 2676 3986
a DNA extracted from each tissue sample tested negative by qualitative PCMV PCR. 
Numerical values represent PCMV viral load (genomes/pg of DNA).
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different tissues in each piglet, and between different piglets in the group. There was 
however, no noticeable difference in the viral loads between immunosuppressed and 
control pigs (median viral load of 276 genomes/jig of DNA in immunosuppressed pigs 
(range 7-11277) vs. median viral load of 471 genomes/|ig of DNA in control pigs (range 
28-9881)). Therefore, immunosuppression did not appear to affect the PCMV viral load 
in these pigs.
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4.3 Discussion
The use of pig organs in xenotransplantation is associated with a risk of transmission of 
porcine infectious agents, particularly viruses, to the xenograft recipient. Since in 
human allotransplantation, HCMV is frequently transmitted via the donor organ, where 
it reactivates and is associated with end-organ disease and graft rejection (Fishman & 
Rubin, 1998), there is a possibility that the porcine equivalent, PCMV, may be 
transmitted to and cause disease in human xenograft recipients.
The aim of this study was therefore to gain a greater understanding of the epidemiology 
of PCMV, to investigate how virus is acquired, and to investigate whether PCMV 
transmission could be interrupted. Qualitative and QC PCR assays developed in chapter 
3, were used to detect and quantify PCMV in transgenic pigs being bred for xenograft 
organs.
This is the first molecular study examining PCMV prevalence, organ distribution, 
temporal acquisition and methods to control its transmission (Clark et al, 2003). The 
results obtained in this study confirm that PCMV is a common infection in transgenic 
pigs reared under conventional farm conditions. The virus was widely disseminated in 
young 3-5 week-old piglets, which is consistent with previous serological findings of 
the epidemiology of PCMV in commercial pig herds (Plowright et al, 1976). Virus 
persisted in adult pigs (aged >15 months) in potential xenograft organs including the 
heart, liver and kidney. The spleen was consistently positive, and in fact tested positive 
in all but one of the adult pigs tested throughout the whole study. This important finding 
highlights the potential for this organ to be monitored for the PCMV status of the donor 
or sentinel animal, if clinical trials proceed. Viral loads in the piglets were significantly 
higher than in the adult pigs (P < 0.0001), indicative of recent or ongoing active 
infection in the piglets.
In a previous PCR analysis of porcine blood and tissue samples from four European 
countries, 50-100 % of lung and spleen samples from domestic pigs of Germany (total 
of 54 samples), Great Britain (total of 8 samples) and Spain (total of 9 samples), tested 
PCMV-positive, while only 4-23 % of PBMC samples from domestic pigs of Germany
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(total of 52 samples) and the Netherlands (total of 34 samples), tested PCMV-positive 
(Goltz et al, 2000).
Prospective monitoring of piglets from birth showed that virus was acquired in the first 
few weeks of life. This is again consistent with previous findings in commercial pig 
herds (Plowright et al, 1976). Although the exact source of virus was not determined, it 
is likely that virus was transmitted horizontally, perhaps from other piglets during the 
post-weaning mixing of litters.
In the context of xenotransplantation, it is essential to determine how PCMV is 
transmitted, and whether it can be eliminated from pigs being bred for xenograft organs. 
Previous studies have shown that in utero infection can occur following experimental 
infection of pregnant sows (Edington et al, 1977; Edington et al, 1988a; Edington et al, 
1988b), however, the frequency of in utero transmission in a conventional setting has 
not been reported. Results obtained in this study only identified post-natal transmission 
of virus. In utero infection was not detected in either of two foetal litters, in the first 
three-quarters of full-term gestation, suggesting that it may be uncommon.
The absence of in utero infection in this investigation may have been a result of the 
immune status of the sows studied. Although transplacental transmission of PCMV has 
been shown to take place despite the presence of pre-existing immunity, following 
experimental infection of pregnant sows, it occurred more frequently as a result of 
primary infection in the pregnant sow; 56.6 % congenital infection in seronegative sows 
(Edington et al, 1977) vs. 33.3 % in seropositive sows (Edington et al, 1988a). HCMV 
congenital infection occurs by primary infection or reactivation, with the latter being 
more common (Griffiths, 2004).
Although transplacental transmission of PCMV is common following experimental 
infection of pregnant sows, it may be much rarer in a conventional setting. In humans, 
epidemiological evidence suggests that in utero infection with HCMV occurs in 30-40% 
of pregnant women with primary infection and in 1 % of seropositive women (Stagno et 
al, 1982; Stagno et al, 1986). In pigs this incidence may in fact be much lower due to 
differences in placental structure between humans and pigs. In particular, the 
epitheliochorial structure of the pig placenta may provide a more protective barrier
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against in utero infection than the hemomonochorial human placenta, by preventing 
invasion of infected trophoblast cells (Leiser & Kaufmann, 1994).
Until recently, pig-to-nonhuman primate models of xenotransplantation were not 
examined for the presence of PCMV, and to date PCMV has not been excluded from 
pig xenografts used in these studies. Reactivation of PCMV and associated disease has 
since been demonstrated following pig-to-baboon xenotransplantation (Mueller et al,
2002). Six baboons received pig thymokidney grafts and underwent intense 
immunosuppression. Activation of PCMV, as measured by quantitative PCR, was 
demonstrated in 5/6 xenografts, and was associated with ureteric necrosis in one case. 
This xenograft did not show evidence of graft rejection suggesting that PCMV infection 
was indeed the cause of disease. In addition, BCMV reactivation was demonstrated in 
3/6 baboons resulting in CMV disease in one animal. In both cases, reactivation of virus 
and disease was restricted to the native host species of the virus. However, low levels of 
PCMV were detected in baboon tissue and vice verse, and were most likely a result of 
microchimerism. In a further study by the same group, activation of PCMV was 
detected in 6/7 pig kidney-to-baboon, 2/3 pig thymus-to-baboon, and 3/6 pig heart-to- 
baboon xenografts (Mueller et al, 2004).
PCMV reactivation in non-human primate models of xenotransplantation has also been 
associated with consumptive coagulopathy seen in these animals (Gollackner et al,
2003). Consumptive coagulopathy (CC) is defined as defective blood clotting, caused 
by decreasing levels of fibrinogen and platelets, which leads to increased haemorrhage. 
CC and thrombotic microangiopathy have been described in human allograft recipients 
with disseminated primary HCMV infection (Jeejeebhoy & Zaltzman, 1998). It is 
frequently observed in pig-to-baboon renal xenografts, in particular in 5/9 baboon 
recipients of PCMV-infected pig kidney xenografts (Gollackner et al, 2003), and is 
potentially fatal unless the xenograft is removed. The cause is not definitively known, 
but it may be initiated by endothelial activation, immunologic injury, infection or 
molecular incompatibilities. These recent findings highlight the risks of PCMV in 
xenotransplantation; not only that it may be transmitted to the xenograft recipient, but 
that it could reactivate and result in graft rejection or direct damage to the organ.
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The most significant finding of our study was that there was no transmission of virus to 
hysterotomy-derived barrier-reared piglets, suggesting that this approach could be used 
to eliminate PCMV from pigs being bred for xenograft organs. These piglets were 
delivered by caesarean section and reared for two weeks in isolator tanks under 
gnotobiotic conditions (Miniats & Jol, 1978). Gnotobiotic pigs were then transferred to 
a bioexclusion, barrier-rearing facility, in which all air, water and feed was sterilised 
(Tucker et al, 2002a). Such SPF breeding stocks could potentially be established using 
a l  ,3GT knock-out animals, and the SPF status quality controlled by monitoring saliva 
or urine from the herd, and by testing the spleen from individual donor animals. 
Transmission of PCMV to xenograft recipients should then be preventable, first in non­
human primate models, and also in humans should clinical trials proceed.
Since xenograft recipients are likely to be subject to immunosuppressive therapy to 
prevent rejection, the effect of immunosuppression on PCMV viral load in pigs was 
investigated. This immunosuppressive treatment was based on that used to prevent 
allograft rejection. Corticosteroids such as prednisolone have previously been shown to 
reactivate PCMV (Edington et al, 1976b; Narita et al, 1985). However, in this study, 
immunosuppression did not appear to affect viral load of PCMV in tissues from 
conventionally-reared pigs. In future investigations, it would be useful to look at a 
greater number of pigs and to prospectively monitor them during the period of 
immunosuppression, since in this study, any reactivation of PCMV may have occurred 
within the two month period before pigs were euthanised and samples collected. 
However, the results from the gnotobiotic group examined support the findings earlier 
in the study that PCMV can be eliminated by SPF breeding.
In summary, PCMV is a common infection in pigs being bred for xenograft organs and 
is acquired in the first few weeks of life, most probably following mixing of litters in 
the early post-weaning period. In contrast with previous experimental results, 
transplacental transmission was not common. Importantly, animals that were 
hysterotomy-derived and barrier-reared did not acquire PCMV, suggesting that this 
approach could be used to generate PCMV-ffee pigs for use in xenotransplantation. 
Finally, these results show that the PCMV-ffee status of these pigs could be quality 
controlled by monitoring the saliva or urine from the herd, and by testing the spleen 
from individual sentinel animals.
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Chapter 5: Cloning and expression of PCMV 
glycoprotein B in insect cells using a baculovirus 
expression system and the development of a 
recombinant protein-based serological assay for
PCMV
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5.1 Introduction
If pigs are to be used as source animals in xenotransplantation they will need to be free 
from a wide range of porcine infectious agents. The results obtained in Chapter 4 show 
that PCMV can be eliminated from pigs being bred for xenograft organs by caesarian 
delivery and barrier-rearing. Pigs bred using these methods will need to be 
comprehensively screened to ensure that they are free from potential zoonotic agents, 
and to achieve this, reliable and sensitive diagnostic tests are needed. The results 
obtained in chapter 4 suggest that the PCMV status of pig herds being bred for 
xenograft organs can be monitored by testing spleen samples from sentinel or individual 
donor animals by PCMV PCR, since this organ tested consistently PCMV DNA 
positive in infected animals. However, the results also showed that PCMV DNA was 
not always detected in readily available samples, such as blood or serum, from pigs with 
latent or low-level active infection, highlighting the importance of a serological assay 
for this virus. Serological assays such as IIF and ELISA, are important tools for the 
detection of prior exposure to a virus. Serological assays that have previously been 
described for PCMV are time consuming, since they require in vitro culturing of PCMV 
(Plowright et al, 1976; Rondhuis et al, 1980; Tajima et al, 1993). In the IIF assay 
described by Rondhuis et al, antigen is prepared by in vitro culturing of PCMV in 
porcine lung macrophages for 10-12 days. Since lung macrophages do not replicate, 
primary cultures must be used. These are difficult to obtain and potentially 
compromised by other infectious agents. In addition, different batches of macrophages 
can vary considerably in their quality and sensitivity to detect virus (Plowright et al, 
1976). In the ELISA described by Tajima et al, antigen was prepared from 19-PFT-F 
cells 2-10 dpi with PCMV (Tajima et al, 1993).
Problems associated with in vitro cultivation systems might be overcome by using 
immunogenic PCMV proteins produced using a recombinant expression system. 
Glycoprotein B (gB) (UL55) is the major antigenic protein of HCMV, and has been 
shown to be a common target of neutralising antibodies (Britt et al, 1990), with 40-70 % 
of total serum neutralising antibodies being directed against this protein. The UL55 
ORF of HCMV encodes a 906-907 amino acid protein (Figure 5.1 A) (Mocarski & 
Courcelle, 2001). The HCMV gB precursor (105 kDa) is modified to a protein of 150 
kDa by N-linked glycosylation in the endoplasmic reticulum (ER), and is further
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glycosylated to a 165-170 kDa glycoprotein as it is transported through the Golgi 
network (Britt & Vugler, 1989). The cellular endoprotease furin cleaves the mature 
HCMV gB in the Golgi (Vey et al, 1995), into a 116 kDa amino-terminal fragment and 
a 55 kDa carboxyl-terminal fragment, which associate on the virion envelope as a 
disulphide-linked heterodimer (Britt & Vugler, 1989). A phosphorylation site, situated 
at the carboxyl-terminus (Norais et al, 1996), is thought to determine the cellular 
distribution of HCMV gB (Fish et al, 1998). HCMV gB contains two distinct antigenic 
domains containing neutralising epitopes including AD-1, located in the gp55 
component (amino acids 552-635), and AD-2 located in the gp ll6  component (amino 
acids 68-77) (Griffiths & Emery, 2002). However, the major neutralising domain maps 
to the AD-1 region within the carboxyl-terminal end of the protein (Banks et al, 1989).
Glycoprotein B is one of the herpesvirus core genes and is highly conserved across all 
subfamilies of herpesviruses (Roizman & Pellet, 2001). The gB genes of five PCMV 
strains and isolates were recently identified and sequenced by genome walking (Widen 
et al, 2001). The gB gene of PCMV strain B6 and isolate #55 (Spanish isolate) were 
found to have an ORF of 2580 nucleotides, encoding a protein of 860 amino acids. The 
Japanese strain OF-1 and isolates #489 (German isolate) and #1469 (Swedish isolate) 
have an ORF of 2583 nucleotides encoding a protein of 861 amino acids. The amino 
acid sequences of these proteins showed highest identities with the corresponding 
sequences of the betaherpesviruses, in particular HHV-6 & -7 (43.5 % and 42 % 
identity, respectively), and less so with HCMV (35.1 % identity). They also showed 
sequence similarity with members of the gammaherpesvirus subfamily including rhesus 
rhadinovirus (32.4 % identity), bovine herpesvirus 4 and HHV-8 (both 31.1 % identity), 
and EBV (30.4 % identity). The deduced protein sequence of PCMV gB shows 
positional conservation of 10/11 cysteine residues and 4-5/15 N-linked glycosylation 
motifs, with HHV-6 and -7 gB proteins. A potential cleavage site (residues 439-441), 
signal peptide sequence (residues 7-19) and transmembrane anchor sequences (residues 
706-726 and 730-747) were also identified (Figure 5.IB). In addition, the region 
between residues 521 and 623 was found to be 45.6 % identical to the immunodominant 
AD-1 region of HCMV gB strain Ad 169, suggesting that this protein could be used as a 
source of viral antigen in IIF or an ELISA. The five strains and isolates of PCMV gB 
exhibited pair differences of 0.6-1.7 % on the nucleotide level and 3.4 % on the amino 
acid level, with most of these differences attributed to the UK strain B6.
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1I-25 68-77 460 552-635 752-772 907
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V > t
gp116 gp55
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1 7-19 439-442 521-623 706-726 730-747 860
H2N 1 1 COOH
PCMVgBF PCMVgBT PCMVgBR
Signal peptide sequence --3 Immunodominant domain H  Transmembrane anchor sequence
Figure 5.1. A schematic of HCMV gB (A) and PCMV gB (B) proteins (Griffiths & 
Emery, 2002; Widen et al, 2001). Numbers represent amino acid codons. The furin 
protease cleavage site is located at amino acid residue 460 in HCMV gB, and between 
residues 439-442 in PCMV gB. Primers PCMVgBF and PCMVgBR were used to 
amplify the complete PCMV gB sequence, while primers PCMVgBF and PCMVgBT 
were used to amplify a truncated sequence.
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The following chapter describes the expression of PCMV gB in insect cells, using a 
baculovirus expression system, for the development of a recombinant protein-based 
serological assay for PCMV. The baculovirus expression system was developed by 
Summers and colleagues, and first used to produce recombinant human beta interferon 
(Smith et al, 1983). Insect cells are commonly used to express human and other 
eukaryotic proteins since they introduce near-authentic posttranslational modifications 
(van Oers & Vlak, 2000) including phosphorylation (Hoss et al, 1990), acylation (Kloc 
et al, 1991) and glycosylation (Davidson & Castellino, 1991), which preserves the 
protein structure and function. Insect cells are also able to recognise most vertebrate 
protein targeting sequences and can therefore express a wide range of cytoplasmic, 
nuclear, membrane-spanning and secreted proteins (QIAexpressionist, 2002).
The baculovirus Autographa califomica multiple nuclear polyhedrosis virus 
(AcMNPV), has a large (134-kb) double-stranded DNA genome and is commonly used 
to clone and express foreign genes in insect cells (van Oers & Vlak, 2000). It is a lytic 
virus that infects lepidopterans (moths and butterflies). During the late phase of 
baculovirus infection occluded virus particles encased in polyhedrin aggregate form 
intranuclear inclusions (Kidd & Emery, 1993). This polyhedrin protein is the most 
abundant protein produced by baculoviruses, making up 30-50 % of the total cell 
protein (Ansari & Emery, 1998). The baculovirus expression system takes advantage of 
the fact that this protein is expressed at very high levels and is dispensable for growth in 
cell culture, such that the polyhedrin gene is replaced with a foreign gene. To generate a 
recombinant baculovirus the gene of interest is initially cloned into an appropriate 
transfer vector, under the control of the polyhedrin promoter, and flanked by 
baculovirus-derived sequences. This is then co-transfected into insect cells with 
baculovirus DNA using cationic liposomes. Site-specific recombination between the 
viral DNA and the transfer vector, results in insertion of the gene of interest into the 
baculovirus genome (van Oers & Vlak, 2000). Recombinant virus can then be isolated 
and amplified for large-scale recombinant protein production.
Important applications of the baculovirus expression system include the production of 
antigens for use in serological assays (Brown et al, 1991), and the development of 
subunit vaccines, for example, against classical swine fever virus (Hulst et al, 1993). 
The baculovirus production of recombinant glycoproteins from human and animal
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herpesviruses, and their use in serological assays and vaccines, has previously been 
described (Wells et al, 1990; Abdelmagid et al, 1998; Schleiss & Jensen, 2003). In 
addition, baculovirus expression of a truncated version of HCMV gB (residues 1-692), 
that was secreted into the culture medium, thus aiding purification, has also been 
reported (Carlson et al, 1997). This secreted version of HCMV gB retained its 
functional activity in that it was dimeric, properly folded and able to bind to a heparin 
affinity matrix.
In order to clone the complete PCMV gB gene, a forward primer was designed to 
anneal upstream from, and in frame with the PCMV gB initiation codon ATG, while a 
reverse primer was designed to anneal just upstream from the PCMV gB stop codon. 
Primer binding sites are shown in Figure 5.IB. Since the complete PCMV gB contains a 
transmembrane anchor sequence it should be expressed on the surface of infected insect 
cells. In addition, a truncated version of PCMV gB (PCMV gBT) was cloned using the 
same forward primer, and a reverse primer designed to anneal in-between the AD-1- 
homologous region and the predicted transmembrane anchor sequences of PCMV gB. 
PCMV gBT should be secreted into the culture medium of infected insect cells from 
where it can be purified for use in the development of an ELISA for PCMV. The 
expression of PCMV gB and gBT was optimised in Sf9 and High Five insect cells. 
Insect cells expressing recombinant PCMV gB proteins were subsequently used as a 
substrate in the development of an IIF assay, such as has been used to measure antibody 
titres to HCMV gB (Deayton et al, 2002). Recombinant PCMV gBT was also used as a 
viral antigen in the development of an ELISA for PCMV.
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5.2 Results
5.2.1 PCR amplification of the complete and truncated PCMV gB ORFs and 
cloning into the baculovirus vector
Primers specific for the 3’ and 5’ ends of the PCMV gB gene were used to amplify the 
complete 2.6-kb ORF of PCMV gB (excluding the stop codon), from a TCS sample of 
PCMV strain B6-infected porcine alveolar macrophages (Figure 5.2, panel A). In 
addition, a 1.93-kb truncated sequence was amplified from the same sample (Figure 5.2, 
panel B). Both sequences were purified, and cloned into the baculovirus transfer vector 
pBlueBac4.5/V5 His TOPO TA, in frame with the carboxyl-terminal peptide. The 
presence of the both sequences, in the correct orientation within the vector, was 
confirmed by restriction enzyme analysis (Figure 5.3). Sequence analysis also 
confirmed that no mutations had been introduced into the gB and gBT sequences during 
PCR amplification with the proof-reading enzyme BIO-X-ACT DNA polymerase (data 
not shown).
5.2.2 Transfection of Sf9 insect cells and PCR analysis of recombinant baculovirus
Recombinant transfer vectors and Bac-N-Blue DNA were combined, and used to co­
transfect Sf9 insect cells. Recombinant baculovirus in the culture medium was 
harvested 3 dpi, while subsequent lysis and detachment of infected cells from the cell 
culture dish was observed 4-7 dpi. Recombinant baculovirus was purified from wild- 
type virus by plaque assay and screening for recombinant blue plaques following the 
addition of the chromogenic substrate X-Gal. Recombination between the 5’ portion of 
the lacZ gene in the transfer vector, and the 3’ portion of the lacZ gene in the Bac-N- 
Blue DNA, resulted in the expression of p-galactosidase, converting X-Gal to a blue 
product. Blue plaques were identified 6-7 dpi and used to generate a PI virus stock.
Purification of recombinant virus from wild-type virus was confirmed by PCR analysis 
of DNA extracted from Sf9 insect cells 6 dpi with Sf900II medium containing 
recombinant plaques. Viral DNA was amplified by PCR using baculovirus and PCMV 
gB-specific primers. The results in Figure 5.4 show that a sequence of approximately 3- 
kb in size was amplified from viral DNA from each of four recombinant plaques using
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Figure 5.2. PCR amplification of the complete and truncated ORFs of PCMV gB from 
a TCS sample of porcine alveolar macrophages infected with PCMV strain B6. Panel A 
shows the 2.6-kb full length PCMV gB sequence amplified from 1 pi of 1/10 (lane 2) 
and 1/20 (lane 3) dilutions of PCMV TCS, alongside HyperLadder I DNA markers (lane 
1). Panel B shows the 1.9-kb PCMV gBT sequence amplified from 1 pi of a 1/10 
dilution of PCMV TCS (lane 2), and 2 pg of the recombinant pBlueBac4.5/V5-His- 
TOPO transfer vector containing the complete PCMV gB ORF (lane 3), alongside 
HyperLadder I DNA markers (lane 1).
A
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Figure 5.3. Bam HI and Hind III restriction enzyme analysis of recombinant PCMV gB 
(A) and gBT (B) transfer vector DNA extracted from four recombinant clones (lanes 2- 
5). Ten microlitres of each digestion reaction were run on a 1 % agarose gel alongside 
HyperLadder I DNA markers (lane 1).
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the baculovirus primers. This sequence represents the 2.6-kb sequence of the PCMV gB 
gene flanked by the 839-bp sequence of the baculovirus genome. Since no sequence 
representing wild-type virus (as in lane 2) was amplified from these samples, the results 
suggest that these plaques contained pure recombinant virus. In addition, a 2.6-kb 
sequence was amplified from each plaque using the PCMV gB-specific primers, again 
confirming that plaques contained recombinant virus. Since plaque 1 contained the most 
recombinant virus, high-titre virus stocks were prepared from the PI stock derived from 
this plaque. The results in Figure 5.5 show that a sequence of approximately 2.7-kb in 
size was amplified from the viral DNA from each of ten recombinant plaques using the 
baculovirus primers. This sequence represents the 1.9-kb truncated sequence of the 
PCMV gB gene flanked by the 839-bp sequence of the baculovirus genome. Since no 
sequence representing wild-type virus was amplified from these samples, the results 
suggest that these plaques contained pure recombinant virus. High-titre stocks of PCMV 
gBT recombinant baculovirus were prepared from the PI stock derived from 
recombinant plaque 1.
5.2.3 Preparation of high-titre virus stocks and calculation of virus titre
The small-scale, low-titre PI virus stocks were used to generate large-scale, high-titre 
P2 and P3 virus stocks of recombinant PCMV gB and gBT baculoviruses, by infection 
of larger numbers of insect cells. The titre of the P3 virus stocks was then determined by 
plaque assay, performed in triplicate, from plates containing 50-100 plaques. Titres of 
7.5 xlO7 pfu/ml and 9.8 xlO7 pfu/ml were obtained for PCMV gB and gBT P3 virus 
stocks respectively.
5.2.4 Determining optimal recombinant protein expression
The time-course of the expression of recombinant PCMV gB and gBT in High Five 
insect cells was analysed 1, 2, 3 and 4 dpi. Cell lysates from infected cells harvested at 
these time points were analysed by SDS-PAGE followed by coomassie staining and 
western blotting. The results in Figure 5.6, show that maximal recombinant protein 
expression in High Five insect cells was achieved 2-4 dpi, with minimal recombinant 
protein production at 1 dpi. The western blot results show that recombinant PCMV gB 
comprised a large amount of protein of approximately 100-150 kDa in size and a
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Figure 5.4. PCR analysis of recombinant PCMV gB baculovirus following purification 
by plaque assay, using baculovirus (lanes 2-10) and PCMV gB-specific primers (lanes 
11-19). Analysis of four recombinant plaques 1-4 (lanes 3-6 & 12-15) shows 
recombinant baculovirus was purified from wild-type virus (lane 2). DNA extracted 
from uninfected Sf9 insect cells (lanes 7 & 16), and SDW (lanes 9, 10, 18 & 19), were 
used as negative controls, while recombinant transfer vector DNA was used as a 
positive control (lanes 8 & 17).
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Figure 5.5. PCR analysis of recombinant PCMV gBT baculovirus following 
purification by plaque assay, using baculovirus primers. Analysis of ten recombinant 
plaques 1-10 (lanes 2-11) shows recombinant baculovirus was purified from wild-type 
virus. DNA extracted from uninfected Sf9 insect cells (lanes 12 & 13), and SDW (lanes 
15-18), were used as negative controls, while recombinant transfer vector DNA was 
used as a positive control (lane 14).
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Figure 5.6. Coomassie stain (A) and western blot (B) showing the time-course of 
recombinant protein production in High Five insect cells. Cell lysates from PCMV gB- 
(lanes 2-5) and PCMV gBT- (lanes 7-10) infected High Five cells harvested 1-4 dpi 
were analysed by SDS-PAGE, alongside uninfected High Five cells (lane 6), Rainbow 
markers (lane 1) and 6xHis Protein Ladder (lane 11) using non-reducing conditions.
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smaller protein of approximately 45 kDa. Recombinant PCMV gBT comprised a large 
protein band of approximately 70-100 kDa in size and a smaller protein of 
approximately 20 kDa in size. Neither of these proteins were detected in the uninfected 
cell lysate (lane 6). The expression of recombinant PCMV gB and gBT 2 dpi was 
subsequently compared in Sf9 and High Five insect cells. The results in Figure 5.7 show 
that there was no significant difference in the amount of recombinant protein produced 
in Sf9 and High Five cells at this time point.
Secretion of recombinant PCMV gBT in the culture supernatant of infected High Five 
cells was analysed and compared with cell lysate samples harvested 2 and 3 dpi (Figure 
5.8). While there was a significant amount of recombinant PCMV gBT in the cell lysate 
harvested 2 and 3 dpi, no protein was detected in the culture supernatant, suggesting 
that the truncated form of PCMV gB was not being secreted from High Five insect 
cells. In addition, the culture supernatant harvested from PCMV gBT infected Sf9 and 
High Five cells 4 dpi was concentrated by centrifugation through an Amicon Ultra-15 
Centrifugal Filter Device with a 10 kDa cut-off. The results in Figure 5.9 show that 
again, while there was a significant amount of recombinant PCMV gBT in the cell 
lysate harvested from Sf9 and High Five cells 4 dpi, no protein was detected in the 
filter-concentrated culture supernatant from these cells.
5.2.5 Analysis of recombinant protein by IIF
In order to analyse the recombinant PCMV gB proteins by IIF, and to assess the utility 
of these proteins in an IIF assay for PCMV, High Five insect cells were harvested 2 dpi 
with recombinant PCMV gB and gBT baculoviruses at an MOI of 10, and used to 
prepare immunofluorescence slides. A range of porcine serum samples from PCMV 
DNA PCR-positive and -negative pigs (as tested in Chapter 4), were used in an IIF 
assay to detect PCMV gB-specific antibodies. PCMV gB-specific antibodies bound to 
recombinant PCMV gB proteins expressed in infected High Five cells, were detected 
using FITC-Conjugated Rabbit Anti-Swine IgG antibodies.
The immunofluorescence of recombinant baculovirus PCMV gB and gBT-infected 
High Five insect cells was significantly increased when compared with uninfected cells 
(Figure 5.10). Since glycoproteins are membrane-bound proteins, recombinant PCMV
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Figure 5.7. Coomassie stain (A) and western blot (B) showing the comparison of 
recombinant protein production in High Five vs. Sf9 insect cells 2 dpi. Cell lysates from 
PCMV gB- (lane 2) and PCMV gBT- (lane 6) infected Sf9 cells, and PCMV gB- (lane 
4) and PCMV gBT- (lane 8) infected High Five insect cells, were analysed by SDS- 
PAGE, alongside uninfected Sf9 (lanes 3 & 7) and High Five cells (lanes 5 & 9) using 
non-reducing conditions. Rainbow markers (lane 1) and 6xHis Protein Ladder (lane 11) 
were also run on the gel.
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Figure 5.8. Coomassie stain (A) and western blot (B) showing the analysis of 
supernatant and cell lysate samples from PCMV gBT-infected High Five insect cells 
harvested 2 and 3 dpi following SDS-PAGE, using non-reducing conditions. Culture 
supernatant samples from PCMV gBT-infected High Five cells were run in lanes 2 (2 
dpi) and 6 (3 dpi), while supernatant samples from uninfected cells were run in lanes 3 
and 7. Cell lysate samples from PCMV gBT-infected High Five cells were run in lanes 
4 (2 dpi) and 8 (3 dpi), while cells lysate samples from uninfected cells were run in 
lanes 5 and 9. Rainbow markers (lane 1) and 6xHis Protein Ladder (lane 10) were also 
run on the gel.
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Figure 5.9. Coomassie stain (A) and western blot (B) showing the analysis of filter 
concentrated supernatant and cell lysate samples from PCMV gBT-infected Sf9 and 
High Five cells 4 dpi, by SDS-PAGE, using non-reducing conditions. Concentrated 
supernatant samples from PCMV gBT-infected Sf9 and High Five cells were in run 
lanes 2 & 6 respectively, while concentrated supernatant samples from uninfected cells 
were run in lanes 3 & 7. Cell lysate samples from PCMV gBT-infected Sf9 and High 
Five cells were run in lanes 4 & 8 respectively, while cells lysate samples from 
uninfected cells were run in lanes 5 & 9. Rainbow markers (lane 1) and 6xHis Protein 
Ladder (lane 10) were also run on the gel.
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A B
Figure 5.10. IIF assay of PCMV seropositive J176 porcine serum, diluted 1/20, using 
PCMV gB (B) and PCMV gBT (D) -infected High Five insect cells compared with 
uninfected cells (panels A & C).
A B
Figure 5.11. Recombinant PCMV gB (A) and PCMV gBT (B) proteins are expressed in 
the cytoplasm of infected High Five insect cells. The IIF assay was performed using 
serum from piglet J176, diluted 1/20. Cells were fixed in 100 % acetone.
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gB should be expressed on the surface of infected insect cells. However, the 
immunofluorescence results showed that the protein was found in the cytoplasm of 
infected High Five cells (Figure 5.11, panel A). Recombinant PCMV gBT also appeared 
to be expressed in the cytoplasm of infected insect cells (Figure 5.11, panel B).
The IIF assay results in Table 5.1 show that porcine serum samples from 
conventionally-reared adult pigs D681, E765, G473, F800, F934, and piglets J147, 
J159, J176 and J184, tested positive for PCMV gB-specific antibodies, while the serum 
sample from gnotobiotic piglet 193 tested negative for PCMV gB-specific antibodies. 
These results are consistent with those obtained following qualitative PCR detection of 
PCMV DNA in a range of samples from the same animals (see Chapter 4, Tables 4.1,
4.2 and 4.6). However, in those results piglet J176 tested negative for PCMV, 
suggesting that maternally-derived PCMV gB-specific antibodies were detected by IIF.
In order to assess the potential for cross-reactivity of human serum with recombinant 
PCMV gB and porcine serum with recombinant HCMV gB, IIF was additionally 
performed using mouse anti-HCMV gB monoclonal antibodies and 
immunofluorescence slides prepared from Sf9 insect cells infected with recombinant 
HCMV gB baculovirus. Immunofluorescence results showed that while PCMV- 
seropositive porcine serum bound recombinant PCMV gB, and mouse anti-HCMV gB 
monoclonal antibodies bound recombinant HCMV gB, antibodies did not cross-react 
with recombinant gB of a different species (data not shown). These results also confirm 
that porcine serum does not cross-react with baculovirus proteins
5.2.6 Analysis of cell lysis methods for the preparation of recombinant protein for 
use in a PCMV ELISA
Since it was not possible to purify PCMV gBT, as it had not been secreted into the 
culture medium of infected insect cells, an ELISA was set up using a crude lysate 
preparation of PCMV gBT-infected High Five insect cells. In order to determine the 
best method for preparing this lysate, PCMV gBT-infected High Five cell pellets were 
resuspended in 1 ml of TNE Buffer and lysed by either four cycles of freeze-thawing, or 
by sonication on ice. Lysates were then clarified by centrifugation to pellet the cell 
debris, and the supernatant was transferred to a clean tube. Centrifuged and non-
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Table 5.1. Qualitative PCMV IIF assay results of porcine serum samples, using slides 
prepared from PCMV gB-infected High Five insect cells.
Porcine serum
IIF result PCMV DNA PCR 
result (spleen)
Adult pig D681 (conventionally reared) + +
E765 + +
G473 + +
F800 + +
F894 + +
F934 + +
Piglet J147 + +
J159 + +
J176 + -
J184 + +
Adult pig 193 (gnotobiotic) - -
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centrifuged cell lysate samples were analysed by SDS-PAGE and western blot. The 
results in Figures 5.12 and 5.13 show that little or no recombinant protein was detected 
in the clarified cell lysate samples prepared by either freeze-thawing or sonication. 
Recombinant protein was however detected in all non-centrifuged cell lysate samples, 
suggesting that either PCMV gBT-infected High Five cells were not properly lysed, or 
that the recombinant protein was insoluble.
5.2.7 Preliminary PCMV ELISA
Since clarified lysates prepared from PCMV gBT-infected High Five cells did not 
contain PCMV gBT, whole and filtered lysate samples from PCMVgBT-infected High 
Five cells were tested in an ELISA format for reactivity with porcine serum. Protein 
lysates from PCMV gBT-infected (2 dpi) and uninfected (control) High Five insect cells 
were prepared by lysis in TNE buffer, followed by sonication. A portion of each cell 
lysate sample was partially clarified by filtration through a 0.8 pm filter, and 5 pg/ml of 
filtered and non-filtered samples were adsorbed onto each well of a 96-well Maxisorp 
immuno-plate. Following blocking, wells were incubated with serial dilutions of pooled 
sera from PCMV-positive and negative pigs, and pooled high-titre HCMV-positive and 
negative human serum, diluted 1/5000. HRP conjugate antibody, diluted 1/7000, 
followed by TMB substrate, were added to wells and the absorbance determined at 450 
and 630 nm. As shown in Figure 5.14, PCMV-negative porcine serum, and both 
HCMV-positive and negative human serum gave absorbance values below 0.4 for all 
protein lysates tested. PCMV-positive porcine serum gave high absorbance values 
(within range 1.9-2.4 when diluted 1/50) to both filtered and non-filtered lysates 
prepared from PCMV gBT-infected and control High Five cells, but a much lower 
absorbance in the wells containing buffer only. These results suggest non-specific 
reactions between porcine antibodies in PCMV-positive serum and proteins within the 
insect cell lysate.
5.2.8 Optimisation of the PCMV ELISA
Checker-board titration experiments were performed to optimise the PCMV ELISA and 
to try to reduce the non-specific reactions described above. Protein lysates were 
adsorbed onto plates at concentrations of between 0.1 and 20 pg/ml, and the ELISA
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Figure 5.12. Coomassie stain (A) and western blot (B) of PCMV gBT-infected and 
uninfected High Five insect cells lysed in TNE buffer by four ffeeze-thaw cycles. 
PCMV gBT-infected cell lysates with and without protease inhibitor were run in lanes 3 
& 5 respectively. Uninfected cell lysate containing protease inhibitor was run in lane 7. 
Cell lysates, cleared by centrifugation at 15,000 xg for 30 min, were run in lanes 2, 4, 
and 6 respectively. Rainbow markers (lane 1) and 6xHis protein ladder (lane 8) were 
also run on the gel.
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Figure 5.13. Coomassie stain (A) and western blot (B) analysis of PCMV gBT-infected 
High Five insect cells lysed in TNE buffer by increasing levels of sonication, following 
SDS-PAGE using non-reducing conditions. Cells were sonicated at a peak-to-peak 
power of 8 microns for 10 s (lane 3) and 20 s (lane 5), a peak-to-peak power 10 microns 
for 10 s (lane 7), and 12 microns for 10 s (lane 9), while the cell lysate in lane 11 was 
not sonicated. Each cell lysate was then cleared by centrifugation at 15,000 xg for 30 
min and run in lanes 2, 4, 6, 8 and 10 respectively. Rainbow markers (lane 1) and 6xHis 
protein ladder (lane 12) were also run on the gel.
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Figure 5.14. Preliminary PCMV ELISA. Filtered (F) and non-filtered protein lysates (5 
jxg/ml) from PCMV gBT-infected and uninfected (control) High Five insect cells, 2 dpi, 
were adsorped onto a 96-well Maxisorp reaction plate. An ELISA was performed using 
pooled sera from PCMV-positive (+) and negative (-) pigs diluted to 1/50, 1/100 and 
1/500, while high-titre HCMV-positive and negative human serum diluted to 1/5000 
was tested as a negative control.
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performed using pooled PCMV-positive and negative porcine serum serially diluted 
from 1/50 to 1/1000. When 10 and 20 pg/ml of each protein lysate was tested, the 
greatest absorbance values were measured with PCMV-positive pig serum to the 
uninfected control lysate samples (Figure 5.15), indicating strong non-specific 
reactions. When 0.1 and 0.5 |ig/ml of each protein lysate was tested, the greatest 
absorbance values were measured with PCMV-positive pig serum to both PCMV gBT- 
infected and uninfected control lysate samples (Figure 5.16), with no significant 
discrimination between the different lysate samples. When 1 fig/ml of each protein 
lysate was tested, the absorbance values of PCMV-positive pig serum to the PCMV 
gBT-infected protein lysates were significantly higher than those to the control lysates 
(Figure 5.16). However, non-specific reactions of porcine antibodies in PCMV-positive 
serum with insect proteins within the control lysate still contributed to high background 
absorbance values.
In a further optimisation experiment, the HRP conjugate antibody concentration used in 
the PCMV ELISA was altered. Plates were prepared using 1 pg/ml of each protein 
lysate sample, and following the removal of porcine serum, plates were incubated with 
HRP conjugate antibody diluted to either 1/5000, 1/10000 or 1/15000 in sterile PBS. 
Varying the HRP conjugate concentration used in the PCMV ELISA, did not reduce 
non-specific reactions, but simply altered the degree of absorbance measured in each 
reaction, such that high absorbance values were measured at the highest concentration 
of HRP conjugate tested, while low absorbance values were measured at the lowest 
concentration of HRP conjugate tested (Figure 5.17).
Finally, the plate washing procedure between the serum incubation and HRP conjugate 
antibody incubation steps was altered to reduce the non-specific reactions observed in 
the PCMV ELISA. Plates were washed 3 or 6 times, using either 0.05 % or 0.1 % 
Tween in PBS on an automated plate washer. As shown in Figure 5.18, the most 
significant reduction in non-specific reactions was measured in the plate washed 3 times 
with 0.05 % Tween in PBS. Therefore, increasing the number of washes, and the 
concentration of Tween 20 in the wash, did not prevent non-specific reactions as might 
have been expected.
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Figure 5.15. The effect of increasing the concentration of protein lysate in the PCMV 
ELISA. Filtered (F) and non-filtered protein lysates from PCMV gBT-infected and 
uninfected (control) High Five insect cells, 2 dpi, were diluted to 10 pg/ml (A) and 20 
pg/ml (B), and were adsorped onto a 96-well Maxisorp reaction plate. An ELISA was 
performed using pooled sera ffom PCMV-positive (+) and negative (-) pigs, serially 
diluted ffom 1/50 to 1/1000.
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Figure 5.16. The effect of decreasing the concentration of protein lysate in the PCMV 
ELISA. Filtered (F) and non-filtered protein lysates ffom PCMV gBT-infected and 
uninfected (control) High Five insect cells, 2 dpi, were diluted to 0.1 (ig/ml (A), 0.5 
pg/ml (B) and 1 |iig/ml (C), and were adsorped onto a 96-well Maxisorp reaction plate. 
An ELISA was performed using pooled sera ffom PCMV-positive (+) and negative (-) 
pigs, serially diluted from 1/50 to 1/1000.
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Figure 5.17. The effect of altering the concentration of HRP conjugate in the PCMV 
ELISA. Filtered (F) and non-filtered protein lysates (1 pg/ml), from PCMV gBT- 
infected and uninfected (control) High Five insect cells, 2 dpi, were adsorped onto a 96- 
well Maxisorp reaction plate. An ELISA was performed using pooled sera ffom PCMV- 
positive (+) and negative (-) pigs, serially diluted ffom 1/50 to 1/1000, while HRP 
congugate was diluted to 1/5000 (A), 1/10000 (B) and 1/15000 (C).
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Figure 5.18. The effect of altering the washing procedure in the PCMV ELISA. Filtered 
(F) and non-filtered protein lysates (1 pg/ml) ffom PCMV gBT-infected and uninfected 
(control) High Five insect cells, 2 dpi, were adsorped onto a 96-well Maxisorp reaction 
plate. An ELISA was performed using pooled sera ffom PCMV-positive (+) and 
negative (-) pigs, serially diluted ffom 1/50 to 1/1000. Following incubation with 
porcine serum, each well was washed either 3 or 6 times, using 0.05 % or 0.1 % Tween 
in PBS (PBS-T).
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5.3 Discussion
The use of pigs as a source of organs for xenotransplantation requires the development 
of simple yet effective assays, to screen pigs for the presence of porcine infectious 
agents within readily available samples such as blood or serum. Currently, no such test 
exists for the detection of PCMV. Serological assays that have previously been 
developed rely on the in vitro culturing of PCMV, which can be time consuming 
(Rondhuis et al, 1980; Tajima et al, 1993).
HCMV gB is an abundant constituent of the viral envelope and the major 
immunodominant protein, being the target of 40-70 % of virus-neutralising antibodies 
in human serum (Britt et al, 1990). HCMV gB is synthesised as a single polypeptide 
chain with a molecular weight of 165-170 kDa when fully glycosylated. However, this 
is proteolytically cleaved in the Golgi apparatus into two fragments of 116 kDa and 55 
kDa, which appear covalently linked on the surface of virions and infected cells (Britt & 
Vugler, 1989). Baculoviruses are commonly used to produce recombinant eukaryotic 
proteins in insect cells since the appropriate posttranslational modifications take place 
(van Oers & Vlak, 2000). Important applications of the baculovirus expression system 
include the production of antigens for serological assays and the development of subunit 
vaccines. A recombinant baculovirus expressing HCMV gB has been used as an antigen 
in IIF to detect and measure antibody titres to HCMV gB (Deayton et al, 2002), while a 
baculovirus-expressed recombinant guinea pig CMV gB vaccine has been shown to 
protect against congenital CMV infection and disease in guinea pigs (Schleiss et al, 
2004).
This chapter describes the development of a recombinant protein-based serological 
assay for PCMV, using the viral protein glycoprotein B as an antigenic target for the 
detection of PCMV-specific antibodies in porcine serum. The complete ORF of PCMV 
gB and a truncated sequence excluding the predicted transmembrane regions were 
cloned and expressed in Sf9 insect cells using a baculovirus expression system. Western 
blot analysis confirmed the expression of the recombinant proteins in Sf9 and High Five 
insect cells. The western blot of PCMV gB-infected insect cells identified His-tagged 
recombinant proteins of approximately 100-150 kDa and 45 kDa in size, while the 
western blot of PCMV gBT-infected insect cells identified His-tagged recombinant
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proteins of approximately 70-100 kDa and 20 kDa in size. The larger proteins are likely 
to correspond to the uncleaved PCMV gB and gBT proteins, while the smaller proteins 
are likely to correspond to the proteolytically-cleaved carboxyl-terminal His-tagged 
fragments of these proteins. These visualised proteins correspond well with those 
predicted for PCMV gB and gBT proteins using the internet-based protein analysis 
website ExPASy (http://ca.expasy.org). Theoretical molecular weights for PCMV gB 
and gBT, including the proteolytically-cleaved carboxyl-terminal His-tagged fragments, 
were calculated by the addition of the average isotopic masses of amino acids in the 
protein sequence. The predicted masses of the uncleaved PCMV gB and gBT proteins 
were 101 kDa and 76 kDa respectively, while the predicted masses of the 
proteolytically-cleaved carboxyl-terminal His-tagged PCMV gB and gBT fragments 
were 50 kDa and 25 kDa respectively.
The time-course for recombinant protein expression showed maximum protein 
expression 2-4 dpi, with little protein expressed at 1 dpi. This was expected since 
polydera-derived virus particles are normally produced in the nucleus of infected cells at 
~ 18 hrs postinfection and continue to accumulate as late as 72 hrs postinfection, or until 
the cells lyse (Murphy et al, 1997). There was no significant difference in the yield of 
recombinant proteins produced in Sf9 and High Five insect cells, despite the fact that 
the expression of certain secreted proteins has been reported to be up to 28-fold greater 
in Tn5 (High Five) insect cells compared with Sf9 cells (Wickham & Nemerow, 1993).
The truncation of recombinant baculovirus-expressed HCMV gB at amino acid 692, to 
remove the transmembrane anchor region, was reported to result in the secretion of the 
recombinant protein into the culture medium of infected Tn 5 (High Five) insect cells 
(Carlson et al, 1997). A similar truncation of PCMV gB at amino acid 634 did not result 
in secretion of the recombinant protein into the culture supernatant of infected Sf9 or 
High Five insect cells. This may have been due to problems in the secretory pathways 
from the ER to the cell surface. A region of the carboxyl-terminal hydrophobic 
sequence of HCMV gB (amino acids 714-750) was shown to be involved in 
transporting HCMV gB through the exocytic pathway, while amino acids 751-771 were 
found to function as a membrane anchor. Mutated recombinant HCMV gB proteins with 
deletions in either amino acids 717-747 or a substitution at amino acid 748 were 
reported to be blocked from cell surface expression, while wild-type protein was not
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(Zheng et al, 1996). Additionally, these mutated proteins were found to form stable 
complexes with some molecular chaperones, causing their retention in the ER. 
However, in the same study a HCMV gB mutant with a deletion in the entire region 
from amino acids 717 to 772 was secreted into the culture medium.
The IIF assay of recombinant PCMV gB and gBT-infected High Five insect cells 
demonstrated the immunogenic nature of PCMV gB and again confirmed expression of 
the recombinant proteins. IIF showed recombinant proteins to be only located in the 
cytoplasm of infected High Five cells, suggesting that PCMV gB especially, was not 
being targeted to the appropriate destination within the cell. This may additionally be a 
result of improper posttranslational modifications or folding which may affect transport 
within the cell. N-glycosylation is sometimes required for the transport of recombinant 
glycoproteins through the Sf9 secretory pathway (Jarvis et al, 1990). Lepidopteran 
insect cells have been shown to add mannose, fucose and probably N-acetylglucose 
groups onto native glycoproteins, but not galactose or sialic acid groups as in 
mammalian cells (Jarvis & Finn, 1995). Recently, a new transgenic insect cell line, 
expressing N-acetylglucosaminyltransferase II has been produced, and could be used to 
produce more authentic recombinant glycoproteins by baculovirus expression vectors 
(Hollister et ah 2002).
The IIF assay of porcine serum samples showed that the expression of recombinant 
PCMV gB in insect cells could effectively be used to detect antibody to PCMV. The 
positive IIF result of piglet J176 was misleading about the true PCMV status of that 
piglet, since all samples (total of 15) obtained from that piglet, including spleen, tested 
negative for PCMV DNA by PCR. PCMV-specific antibodies are likely to have been 
passed from the sow to her offspring in milk secretions. Piglets are bom with almost no 
serum antibody and absorb IgG, IgM and IgA from sow colostrum, with subsequent 
milk from 3 days of age until the end of lactation containing predominantly IgA 
immunoglobulins (Roth, 1999). All three classes of immunoglobulins are absorbed from 
the colostrum into the circulation of newborn pigs, however, IgA is absorbed less 
frequently than the other classes of antibody (Roth, 1999). Since pigs being bred for 
xenograft organs will not receive colostrum or milk from the sow (Onions et aly 2000), 
false-positive results such as this are unlikely to occur during pre-transplant screening 
of herds.
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An ELISA using purified PCMV gBT could not be established since this truncated 
protein was not secreted from infected insect cells. Therefore, an attempt was made to 
set up an ELISA using a crude lysate preparation of PCMV gBT-infected High Five 
insect cells. Control lysates were prepared from uninfected High Five insect cells. Since 
lysate samples clarified by centrifugation did not contain PCMV gBT, possibly because 
it was insoluble and removed in the cell pellet, whole lysates and those partially 
clarified by filtration were adsorbed onto immuno-plates. Despite altering lysate and 
HRP conjugate concentrations, and altering the washing step between serum and HRP 
conjugate incubations, non-specific reactions between PCMV-positive pig sera and 
insect cell proteins, remained a frequent problem in this PCMV ELISA. These non­
specific reactions are an inherent problem with using crude lysates, since they contain a 
large number of non-specific targets. Another problem is that a significantly greater 
number of insect cell proteins were likely to be present within the uninfected control 
lysate, compared with the PCMV gBT-infected lysate. Since the proportion of 
recombinant protein within the PCMV gBT-infected lysate was unknown, it was not 
possible to ensure that equal quantities of control insect cell proteins were present in 
infected and uninfected lysates. For example, if recombinant PCMV gBT made up 50 % 
of the total protein content of infected cell lysates, and 1 pg/ml of each lysate was added 
to wells, then twice the amount of insect proteins were present in control wells, than in 
infected wells, which would undoubtedly have resulted in increased background 
absorbance in the control well. The only feasible method of preventing non-specific 
reactions would be to use purified recombinant protein in the assay, however, time 
constraints did not allow for the purification of recombinant PCMV gBT from infected 
lysate samples.
A further problem with this PCMV ELISA was the absence of an appropriate negative 
control porcine serum. The only PCMV-negative porcine serum samples available were 
from gnotobiotic pigs which have lower serum antibody levels, compared with 
conventionally-reared pigs (Tucker et al, 2002b). The use of such a serum as a negative 
control in a clinical ELISA may give rise to false-positive results, since, a PCMV- 
negative serum from a conventionally-reared pig might be expected to produce a higher 
non-specific absorbance, than the gnotobiotic serum, and could be confused with a 
positive result for PCMV.
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In summary, this chapter describes the production of recombinant PCMV gB using a 
baculovirus expression system, and the development of a recombinant PCMV gB IIF 
assay for the detection of PCMV-specific antibodies. It is hoped that this assay will 
provide a useful tool for the detection of PCMV in pigs being bred for xenograft organs. 
Recombinant PCMV gB could also potentially be used in the development of a subunit 
vaccine for PCMV. Clinical trials using a HCMV gB subunit vaccine combined with 
MF59 adjuvent, developed by CHIRON, are underway. Phase 1 studies showed that the 
immunisation of seronegative individuals with the HCMV gB/MF59 vaccine resulted in 
high levels of neutralising antibodies (Pass et al, 1999; Frey et al, 1999).
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Chapter 6: The susceptibility of PCMV to 
established antiherpetic agents in vitro
199
Chapter 6: Susceptibility o f PCMV to antiviral drugs
6.1 Introduction
The results obtained in Chapter 4 show that PCMV can be eliminated from pigs by 
caesarian delivery and barrier-rearing. These methods could therefore be used to 
generate PCMV-free pig herds for use in xenotransplantation. The SPF status of these 
herds would need to be quality controlled by testing spleen samples from sentinel 
animals, and from individual donor animals at the time of harvesting of the xenograft. 
The transmission of PCMV to human xenograft recipients should thus be preventable, 
however, knowledge of the antiviral susceptibility of PCMV is also important as it 
would provide therapeutic options should this screening procedure fail.
This chapter describes the investigations into the in vitro effect on PCMV replication of 
antiviral drugs (Fryer et al, 2004), including ganciclovir (GCV), foscamet (PFA), 
cidofovir (HPMPC) and aciclovir (ACV) (Figure 6.1), currently licensed for use in the 
treatment and/or prophylaxis of human herpesvirus infections. GCV is the first choice 
therapy for life-threatening or sight-threatening HCMV infections in the 
immunocompromised including AIDS and transplant patients, while foscamet and 
cidofovir are used to treat CMV retinitis in ADDS patients (BNF, 2004). ACV is 
predominantly used for the treatment of HSV and VZV infections, but has also 
demonstrated activity against HCMV (Meyers et al, 1988; Prentice et al, 1994). These 
antiviral agents are all nucleoside or nucleotide analogue inhibitors of the viral DNA 
polymerase, apart from foscamet, which is a pyrophosphate analogue.
Antiviral susceptibility is conventionally determined by plaque reduction assay relying 
on the development of CPE. Currently, there is very little information on the ability to 
culture PCMV in vitro. The vims is slow growing in pig fallopian tube (PFT) cells, an 
adherent fibroblast-like cell line, replicating to produce CPE approximately 11 days post 
infection (Kawamura et al, 1992). It has otherwise only been shown to grow in porcine 
alveolar macrophages, which are difficult to obtain and potentially compromised by 
other infectious agents.
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Figure 6.1. Chemical stmctures of some of the antiviral agents currently licensed for 
use in the treatment and/or prophylaxis of human herpesvirus infections.
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The first aim of this chapter was to establish PCMV infection in PFT cells, although a 
porcine peripheral blood T cell line, L45, was also investigated for it’s susceptibility to 
PCMV infection. PCMV (laboratory adapted strain) and the PFT cell line were kindly 
provided by Dr Clive Patience (Immerge BioTherapeutics Inc.). The effect of TPA on 
the growth of PCMV in PFT cells was also investigated since PCMV has previously 
been shown to replicate more rapidly in medium containing 5-60 ng/ml of TPA, with 
CPE observed 2 dpi (Kawamura & Matsuzaki, 1996). TPA is a mitogen which induces 
cell replication, particularly nuclear division. It has also been shown to induce EBV 
reactivation via nuclear factor (NF) -kB and activator protein (AP) -1 in vitro (Gao et al, 
2001).
As an alternative to the use of plaque reduction assays, the antiviral inhibition of PCMV 
DNA production by PFT cells was determined by quantification of viral DNA in the cell 
culture supernatant using real-time PCR. Real-time PCR provides an alternative and 
favourable method for quantifying DNA compared to QC PCR, by the detection and 
quantitation of a fluorescent reporter. A dual-labelled probe, containing a 5’ fluorescent 
dye and a 3’ quenching dye, is designed to anneal to an internal region of the PCR 
product. The close proximity of the quencher to the fluorescent dye prevents any 
emission of fluorescence. During the PCR, the DNA polymerase cleaves the fluorescent 
dye from the probe, resulting in an increased emission of fluorescence with the 
formation of PCR product. This fluorescence is then quantified and used to determine 
the quantity of DNA target present in the original sample. For the PCMV real-time 
PCR, primers and probe were designed using Primer Express software from a region of 
the DNA polymerase gene of PCMV (Widen et al, 1999). The primers and probe were 
shown by BLAST analysis to share 100 % nucleotide identity with sequence data for the 
DNA polymerase of all three PCMV strains (55b, B6, and OF-1), deposited in 
GenBank, suggesting their ability to amplify different isolates. A similar real-time PCR 
approach was recently used to measure the antiviral susceptibility of HSV (Stranska et 
al, 2002). In addition, PCMV IIF was used to determine the effect of each antiviral on 
PCMV-infected cells.
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6.2 Results
6.2.1 Establishing PCMV infection in PFT cells
PCMV infection of PFT cells was initially established by mixing infected and 
uninfected cells and culturing in complete MEM. Propagation and replication of PCMV 
in PFT cells was confirmed by RT PCR of total RNA extracted from PFT-PCMV cells 
following 8 days of culture, and by nested qualitative PCMV PCR of TCS harvested 
from PFT-PCMV cultures at 3, 4, 7, and 8 days following initial mixing of cells. The 
results in Figure 6.2, panel A, show that PCMV mRNA was detected in PFT-PCMV 
cells following 8 days of culture, while PCMV DNA was detected in TCS harvested 
from PFT-PCMV cells up to 8 days following culture, despite several complete changes 
of medium. Propagation and replication of PCMV was also confirmed by IIF assay of 
slides prepared from PFT-PCMV cells following 10 days of culture (Figure 6.2, panel 
B). The photographs of a section of a well on the IIF slide show a number of 
fluorescing, PCMV-infected cells, present in the culture.
6.2.2 The effect of TPA on the growth of PCMV in PFT cells
The effect of TPA on the growth of PCMV in PFT cells was investigated by IIF of PFT- 
PCMV cells following 3, 7 and 11 days of culture, with or without incubation with 5 
ng/ml of TPA. The IIF assay results (Figure 6.3) show that the number of fluorescing, 
PCMV-infected PFT cells increased following culture with 5 ng/ml of TPA (panel B), 
compared to the culture containing no TPA (panel A), such that by day 11 there was a 
dramatic increase in the number of fluorescing PFT-PCMV cells seen by IIF.
In addition, the effect of various concentrations of TPA on uninfected PFT cells was 
assessed by observing cells under a light microscope following 3 days of incubation 
with 0, 1,2, and 5 ng/ml of TPA. It was noted that at the highest concentration of TPA 
tested, cells were less confluent and there were significantly more floating cells 
compared to those incubated with no TPA. At the lower concentrations of TPA tested 
fewer floating cells were seen and cells looked more confluent, however, the 
morphology of the cells was altered from those incubated with no TPA (data not 
shown).
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Figure 6.2. Confirmation of PCMV infection in PFT cells. Panel A shows first round 
(lanes 2-10), and nested round (lanes 12-20), qualitative PCMV PCR products of the RT 
reaction of RNA harvested 8 dpi, and TCS, harvested from PCMV-infected PFT cells. 
Positive PCMV PCR controls comprised 103 copies of PCMVpol control plasmid (lanes 
4 and 14), while negative controls comprised SDW (lanes 9-10 and 19-20). PCR 
products were electrophoresed on a 3 % agarose gel, alongside HyperLadder IV DNA 
markers. PCMVpol sequences were amplified from the RT reaction (lanes 2 and 12), 
but not from the RNA control (lanes 3 and 13) showing the absence of contaminating 
DNA in the purified RNA. Meanwhile, PCMVpol sequences were amplified from TCS 
samples harvested 3, 4, 7 and 8 dpi (lanes 5-8 and 15-18), following several changes of 
medium. Panel B shows fluorescing PFT-PCMV cells harvested from the culture 10 
dpi.
L... 212-bp 
^  160-bp
B
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Figure 6.3. The effect of TPA on the growth of PCMV in PFT cells as determined by 
IIF. Panel A shows little or no increase in the number of fluorescing PFT-PCMV cells 
following 3, 7 and 11 days of incubation without TPA, whereas panel B shows a 
dramatic increase in the number of fluorescing PFT-PCMV cells following 3, 7 and 11 
days of incubation with 5 ng/ml of TPA.
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6.2.3 Preparation of PCMV inoculum
In order to determine the optimum method of infecting PFT cells with PCMV, two 
PCMV inoculums were prepared from a single culture of PFT-PCMV cells. A TCS 
inoculum was prepared by centrifugation of TCS to remove floating cells, and filtered 
through a 0.45 pm filter. Meanwhile, a cell lysate inoculum was prepared by freeze- 
thawing of cells harvested from the culture flask. An aliquot of each inoculum was then 
used to infect PFT cells with or without the presence of 5 ng/ml of TPA in the culture 
medium. In addition, the PCMV DNA load of each inoculum was determined by QC 
PCR. The effect of each inoculum on the resulting PCMV-infection of PFT cells was 
determined by IIF at 21 dpi. The results in Figure 6.4 show that more PCMV-infected 
PFT cells were present in cultures infected with TCS inoculum compared with the cell 
lysate inoculum. In contrast, the PCMV DNA load was significantly higher in the cell 
lysate inoculum (PCMV DNA viral load of 3.4 xlO7 genome copies/pl), than in the 
TCS inoculum (PCMV DNA viral load of 1.32 xlO6 genome copies/pl), suggesting that 
although more viral DNA was detected, less infectious virus was present in PFT-PCMV 
cells than was present in the TCS.
The effect of using freshly harvested TCS compared with TCS inoculum that had been 
stored at -80 °C, to infect PFT cells was also investigated by IIF at 17 and 27 dpi. 
Figure 6.5 shows that at both 17 and 27 dpi there were more PCMV-infected PFT cells 
present in cultures infected with fresh compared to frozen TCS inoculum. These results 
were found despite the fact that the PCMV DNA load was higher in the TCS inoculum 
that had been stored at -80 °C (PCMV DNA viral load of 9.6 xlO5 genome copies/pl), 
compared with the PCMV DNA load in the TCS that was freshly harvested (PCMV 
DNA viral load of 1.24 xlO5 genome copies/pl). These results suggest that the PCMV 
infectious titre was reduced by storing TCS inoculum at -80 °C.
It was next investigated whether 70 % sorbitol could be used to preserve virus titre 
when storing PCMV inoculum at -80 °C. TCS inoculum was prepared from PFT-PCMV 
cells, and stored at -80 °C in either an equal volume of 70 % sorbitol (inoculum 1), an 
equal volume of complete MEM (inoculum 2), or neat (inoculum 3). Each inoculum 
was subsequently used to infect PFT cells and IIF was performed at 14 dpi. The effect 
of each inoculum on subsequent PCMV infection in PFT cells was determined by
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without TPA
Figure 6.4. IIF of PFT-PCMV cells 21 dpi with 1 ml of either cell lysate inoculum 
(PCMV DNA viral load of 3.4 xlO7 genome copies/pl) (A), or TCS inoculum (PCMV 
DNA viral load of 1.32 xlO6 genome copies/pl) (B), with or without incubation with 5 
ng/ml of TPA.
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Figure 6.5. Comparison of using fresh vs. frozen PCMV TCS to infect PFT cells as 
determined by IIF. Panel A shows PFT-PCMV cells infected with PCMV TCS 
inoculum that had been stored at -80 °C (PCMV DNA viral load of 9.6 xlO5 genome 
copies/pi) 17 and 27 dpi. Panel B shows PFT-PCMV cells infected with freshly 
harvested PCMV TCS inoculum (PCMV DNA viral load of 1.24 xlO5 genome 
copies/pl) 17 and 27 dpi.
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counting the total number of fluorescing, PCMV-infected PFT cells in each well of the 
IIF slide. In cultures infected with inoculum 1 no fluorescing PCMV-PFT cells were 
detected by IIF assay at 14 dpi, while in cultures infected with inoculums 2 and 3, an 
average (total of four wells) of 19 and 26 fluorescing PCMV-PFT cells were detected 
respectively by IIF assay at 14 dpi. These results indicate that freezing PCMV TCS in 
70 % sorbitol was not effective in preserving the titre of infectious PCMV, and in fact 
dramatically reduced the number of PCMV-infected cells seen by IIF.
6.2.4 The PCMV plaque assay
A plaque assay was performed using PFT cells in order to determine the infectious titre 
of PCMV inoculum prepared in section 2.4.7. Initially, the plaque assay was performed 
according to the protocol used by Kawamura et al (Kawamura et al, 1992). In this 
method, the infected PFT cell monolayer was overlaid with 0.8 % bacteriological agar 
in complete MEM. Fresh overlay medium was added following every 5 days of 
incubation, with a 0.005 % neutral red overlay added after 10 and 15 days of culture, 
and plates examined for plaques up to 20 dpi. Neutral red dye is taken up by living cells, 
but not by dead cells, such that plaques appear as clear areas on a red monolayer of 
cells. However in this study, PFT monolayers only partially stained red with neutral red 
dye even in uninfected control wells, suggesting that the cells were dying, perhaps 
because of insufficient nutrients in the overlay. In the areas of living cells, which stained 
red with neutral red dye, no plaques were identified.
An alternative method was then used in order to determine the infectious titre of the 
PCMV inoculum. In this method, the infected PFT cell monolayer was overlaid with 
methyl cellulose containing concentrated nutrients. This method has previously been 
used in our department to determine the titre of HCMV virus stocks using human 
embryonic lung fibroblast cells. Thirteen days postinfection PFT cells were stained with 
methylene blue which stains dead cells but not living cells. Although monolayers 
remained healthy in all wells (i.e. did not stain blue) no plaques were visible.
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6.2.5 Experimental PCMV infection of L45 cells
The continuous cell line, L45, a porcine T-cell lineage, grown in suspension culture, 
was experimentally infected with PCMV TCS inoculum in order to determine whether 
they could be better used, rather than PFT cells, to determine the susceptibility of 
PCMV to antiviral agents. IIF of L45 cells 10, 20 and 30 dpi with PCMV TCS showed 
that only a small proportion of cells (approximately 1-10 cells/well, <1 % of total cells) 
were infected with PCMV (Figure 6.6). These results suggest that although L45 cells 
may be permissive for PCMV infection, it is likely that the nature of PCMV replication 
in these cells and the fact that these cells were grown in suspension meant that few 
infected cells were detected by IIF. L45 cells are grown in suspension culture and need 
to be passaged at a ratio of 1:5 every 5 days. Since PCMV may have been slow growing 
in these cells, regular passaging like this would mean that PCMV-infected cells would 
be diluted out, hindering virus spread.
6.2.6 Establishing chronic PCMV infection in PFT cells
Since PCMV was found to be slow growing in PFT cells when passaged approximately 
every 5-6 days, the potential for establishing chronic infection by not passaging cells 
was investigated. PCMV CPE in PFT cells was first detected 7 dpi with PCMV TCS, 
while the development of CPE in unpassaged cells was observed under a light 
microscope up to 20 dpi (Figure 6.8), and suggests that virus is spread between adjacent 
cells. The proportion of PCMV-infected cells determined by IIF was comparable to the 
proportion of cells exhibiting CPE (data not shown).
Electron microscopy was used to directly visualise PCMV in TCS harvested from 
chronically-infected PFT cells. PCMV virus particles were pelleted by 
ultracentrifugation and resuspended in EM stain. Figure 6.7, panel A, shows the typical 
CMV ‘fried-egg’ appearance of a negatively stained PCMV dense body, with visible 
clusters of viral glycoproteins protruding from the viral envelope, while Figure 6.7, 
panel B, shows the viral capsids.
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Figure 6.6. IIF of L45 cells 20 dpi with PCMV TCS. 
A
B
Figure 6.7. Electron microscopy of PCMV. Panel A shows the typical CMV ‘ffied-egg’ 
appearance of a negatively stained dense body, with visible clusters of viral 
glycoproteins protruding from the viral envelope. Panel B shows PCMV viral capsids.
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x200
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Figure 6.8. The development of CPE in PFT cells over 20 days following infection with 
PCMV TCS. Chronic infection was established in PFT cells by culturing PCMV for 20 
days without passaging of cells. CPE was observed by phase-contrast microscopy.
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6.2.7 Design of the antiviral study
The design of the investigation into the antiviral susceptibility of PCMV was based on 
the experiences learned from PCMV culture in PFT cells thus far. PCMV infection in 
PFT cells was established by inoculation of sub-confluent PFT cells with freshly 
harvested PCMV TCS in 25 cm2 cell culture flasks. Chronic infections were then 
established by incubating cells for two weeks unpassaged, whilst changing the culture 
medium weekly. PFT-PCMV cells were then transferred to larger 75 cm2 flasks and 
incubated for a further week. TPA was not used to increase PCMV replication since it 
appeared to have a detrimental effect on the growth of PFT cells. Since it had not been 
possible to determine the virus titre of PCMV inoculum by plaque assay, chronically- 
infected PFT cells were divided between four 25 cm2 cell culture flasks; one flask for 
each of three concentrations of antiviral drug tested, and one control flask containing no 
antiviral drug (day -2). Once cells had adhered to the flasks, the culture medium was 
replaced to remove unattached cells (day 0). In order to ensure that cells had been 
equally divided between the four flasks, the medium was again replaced two days later 
and an aliquot of TCS stored for PCMV DNA quantitation by real-time PCR (day 2). 
The effect of each antiviral drug on PCMV DNA load in TCS was then monitored from 
day 2 until day 14 by real-time PCR of TCS harvested from each culture prior to total 
medium replacement including antiviral drug. Following this two week period, cells 
were harvested for the preparation of IIF slides and DNA extraction.
6.2.8 Establishing a real-time PCR assay for the quantification of PCMV DNA
Target sequences were quantified by real-time PCR using an ABI PRISM 7700 
Sequence Detection System. The ability of the real-time PCMV PCR primers to amplify 
target sequences was tested using 106-0.1 copies of wild-type PCMVpol plasmid 
standard per reaction. Reaction products were analysed using Taqman software (Figure 
6.9, panels A and B), and in addition, were run on 3 % agarose to show that real-time 
PCMV PCR primers were consistently able to amplify 10 copies of target sequence 
(Figure 6.9, panel C). In addition, Figure 6.9, panel C, shows that 0.1 copies of wild- 
type PCMVpol plasmid were not amplified, indicating correct dilution of the standards. 
Figure 6.9, panels A and B, show the standard curve and amplification plot of the 
PCMV standards as analysed using Taqman software. Subsequently, samples were
213
AChapter 6: Susceptibility of PCMV to antiviral drugs
B
50 00
20.00
10-1 10-2  10- *  10-4  10-5  10- *  10-7
Standards
.82-bp
Figure 6.9. Standard curve (A) and amplification plot (B) of 106-0.1 copies of wild-type 
PCMVpol standard amplified by real-time PCMV PCR. PCR products were 
electrophoresed on a 3 % agarose gel, alongside HyperLadder IV DNA markers, to 
confirm the sensitivity of the real-time PCMV PCR (C).
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amplified alongside 109-103 copies of standard, since PCMV DNA loads fell within this 
range.
6.2.9 Monitoring PCMV antiviral susceptibility in TCS over 14 days
PCMV DNA load was monitored in supernatant from day 2 of culture and then every 
second day until day 14 by real-time PCR. PCMV cultures were sub-confluent at the 
start of the experiment, replicating to confluency during the 14 day period. Antivirals at 
the highest concentrations used in this study did not inhibit the activity of the Taq 
polymerase in the real-time PCR assay (data not shown). The real-time PCMV PCR of 
culture supernatant harvested on day 2 (prior to addition of antiviral), shows that equal 
numbers of infected cells were present in each flask (Figure 6.10). In all cultures 
containing no antiviral drug, PCMV viral load in the supernatant increased at a steady 
rate over 14 days. At the lower concentrations of ganciclovir, foscamet and aciclovir 
tested, the viral load increased at a lesser rate over the 14 days. At the highest 
concentrations of these antivirals tested, there was little or no evident increase in viral 
load over 14 days. At all concentrations of cidofovir tested, there was no increase in 
PCMV viral load in supernatant over 14 days.
The effect of each antiviral on PCMV in PFT cells was determined by quantifying the 
viral load in DNA extracted from cells after the 14 day period. The results in Figure
6.11 show a dramatic reduction in the PCMV viral load in cells incubated with all 
concentrations of cidofovir tested, and the higher concentrations of ganciclovir and 
foscamet tested, compared with no drug controls. There was a slight reduction in the 
PCMV viral load in cells incubated with the higher concentrations of aciclovir tested, 
however, overall aciclovir and foscamet had a much less dramatic effect on PCMV 
replication than the other chugs.
Figure 6.12 shows the percentage reduction in PCMV viral load in PFT-PCMV cells 
following incubation with antiviral agents. Antiviral susceptibility is often represented 
as the 50 % effective concentration (EC50), or the concentration of antiviral which 
inhibits vims replication by 50 %. The antiviral susceptibilities of PCMV in PFT cells 
were calculated from the real-time PCR results of DNA extracted from PFT-PCMV 
cells following the 14 day period and are shown in Table 6.1. Ganciclovir and cidofovir
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PCR of viral DNA in infected cell extracts, harvested at day 14.
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Figure 6.12. The percentage reduction in PCMV viral load in PFT-PCMV cells 
following antiviral incubation, by real-time PCR of viral DNA in infected cells extracts, 
harvested at day 14.
Table 6.1. Antiviral susceptibilities of PCMV in PFT cells. EC50 values were calculated 
from the real-time PCR results of DNA extracted from PFT-PCMV cells at day 14.
Antiviral EC50 (ng/ml) EC50 ftiM)
GCV <1 <4
PFA 25-50 83-167
HPMPC <1 <4
ACV >25 >111
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both had EC50 values of <1 (ig/ml (<4 while foscamet had an EC50 value within 
the range of 25-50 |ig/ml (83-167 fiM). Aciclovir had an EC50 value of >25 |ig/ml 
(>111
6.2.10 Immunofluorescence results
In order to complement the results determined by real-time PCR, IIF was used to assess 
the number of PCMV-infected PFT cells at day 14, following treatment with the 
antiviral agents. Following the IIF assay, the average number of fluorescing PFT- 
PCMV cells in each well was calculated by counting the total number of fluorescing 
cells in each of four wells on the IIF slide. Consistent with the results shown in Figure 
6.11, the IIF data shows a dramatic reduction in the number of fluorescing PCMV-PFT 
cells in those cultures incubated with all concentrations of cidofovir tested, and the 
higher concentrations of ganciclovir and foscamet tested, compared with no drug 
controls (Figure 6.13). There was a slight reduction in the number of fluorescing cells in 
cultures incubated with varying concentrations of aciclovir tested, compared with the no 
drug control. Representative examples of these results are shown in Figures 6.14-6.17. 
These photographs show sections of wells on IIF slides, prepared using PFT-PCMV 
cells incubated with varying concentrations of antiviral agent.
6.2.11 Determining the cytotoxicity of antiviral agents
The toxicity of the antiviral drugs used in this study to PFT-PCMV cells was 
determined by counting the total number of remaining adherent cells harvested from 
cultures at day 14. Less than 5 % of adherent cells stained with trypan blue. A 
significant reduction (-50 %) in the total cell count was only found in the culture of 
PFT-PCMV cells incubated with 10 fig/ml of cidofovir (Table 6.2). No significant 
cytotoxicity was noted at the lower concentrations of cidofovir tested, or at any 
concentration of the other antivirals tested.
In a parallel study, the toxicity of the antiviral chugs to uninfected PFT cells was 
determined, using cellular DNA extracted from the remaining adherent uninfected cells 
at day 14, as a marker of the total cell count. Again, the results in Table 6.3 show that 
evidence for cytotoxicity was only observed in PFT cells incubated with the highest
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Figure 6.13. Determining the susceptibility of PCMV to antiviral drugs by IIF assay, 
following a 14 day period. Values represent the average number of fluorescing (PFT- 
PCMV) cells counted in each of four wells on the IIF slide.
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D
Figure 6.14. The effect of ganciclovir (GCV) on PFT-PCMV cells by IIF assay, following 
a 14 day period. Panels A-D show the centre of a well on an IIF slide, prepared using 
PFT-PCMV cells incubated with no GCV (A), 1 pg/ml of GCV (B), 5 pg/ml of GCV (C), 
and 10 pg/ml of GCV (D).
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Figure 6.15. The effect of foscamet (PFA) on PFT-PCMV cells by IIF assay, following a 
14 day period. Panels A-D show the centre of a well on an IIF slide, prepared using PFT- 
PCMV cells incubated with no PFA (A), 25 of ng/ml PFA (B), 50 pg/ml of PFA (C), and 
100 jig/ml of PFA (D).
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Figure 6.16. The effect of cidofovir (HPMPC) on PFT-PCMV cells by IIF assay, 
following a 14 day period. Panels A-D show the centre of a well on an IIF slide, prepared 
using PFT-PCMV cells incubated with no HPMPC (A), 1 pg/ml of HPMPC (B), 5 pg/ml 
of HPMPC (C), and 10 pg/ml of HPMPC (D).
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Figure 6.17. The effect of aciclovir (ACV) on PFT-PCMV cells by IIF assay, following a 
14 day period. Panels A-D show the centre of a well on an IIF slide, prepared using PFT- 
PCMV cells incubated with no ACV (A), 5 pg/ml of ACV (B), 10 jig/ml of ACV (C), and 
25 pg/ml of ACV (D).
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Table 6.2. Determining the toxicity of each antiviral to PFT-PCMV cells. Numbers 
represent the total number of remaining adherent cells, counted using a 
haemocytometer, in each flask at day 14.
GCV 0 (ig/ml
5.84 xlO6
1 (ig/ml
5.32 x10s
5 (ig/ml
6.08 xlO6
10 (ig/ml
6.48 x10s
PFA 0 (ig/ml
3.92 xlO6
25 (ig/ml
3.92 x10s
50 (ig/ml
5.28 x10s
100 (ig/ml
4.52 xlO6
HPMPC 0 (ig/ml
5.44 xlO6
1 (ig/ml
5.60 x10s
5 (ig/ml
4.44 x10s
10 (ig/ml
2.49 x10s
ACV 0 (ig/ml
5.24 x10s
5 (ig/ml
5.40 x10s
10 (ig/ml
5.56 x10s
25 (ig/ml
5.84 xlO6
Table 6.3. Determining the toxicity of each antiviral to uninfected PFT cells. Numbers 
represent the total cellular DNA harvested from remaining adherent PFT cells in each 
flask at day 14, as a marker of the total cell count.
GCV 0 (ig/ml 1 (ig/ml 5 (ig/ml 10 (ig/ml
37.2 42.0 41.0 40.2
PFA 0 (ig/ml 25 (ig/ml 50 (ig/ml 100 (ig/ml
32.4 37.8 41.1 37.3
HPMPC 0 (ig/ml 1 (ig/ml 5 (ig/ml 10 (ig/ml
51.0 46.2 41.5 23.3
ACV 0 (ig/ml 5 (ig/ml 10 (ig/ml 25 (ig/ml
38.4 37.7 43.6 43.3
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concentration of cidofovir tested. In addition, only the cell extract of detached cells 
removed in the culture medium from PFT cells incubated with 10 |xg/ml of cidofovir 
yielded a detectable quantity of DNA (data not shown).
6.2.12 Investigating the dynamics of PCMV replication in vivo
In order to estimate the doubling time of PCMV in pigs, PCMV viral load was 
determined in blood collected from piglets, derived from sow P49M, on days 35, 49 and 
82 after birth, by real-time PCR. The results in Figure 6.18 show that between days 35 
and 49, the PCMV viral load in the blood of the majority of piglets examined had 
reached a plateau, while between days 49 and 82, virus was being cleared in all piglets. 
From these results it was not possible to determine the doubling time of PCMV 
replication since samples were not taken sufficiently early or frequently.
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Figure 6.18. Investigating the dynamics of PCMV replication in vivo by monitoring 
PCMV viral loads in the blood of piglets (J443-J453) derived from sow P49M. The 
viral load in each blood sample was quantified in triplicate by real-time PCR. Each 
value represents the mean of three results with the standard deviation of the mean 
shown in error bars.
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6.3 Discussion
HCMV is an important pathogen in the human allograft recipient, where viral 
transmission from the donor and reactivation are common occurrences, and a major 
cause of disease and graft failure. Similarly, in xenotransplantation, reactivation of 
PCMV is a concern, as it has been shown to cause invasive disease and possibly 
contribute to consumptive coagulopathy in pig-to-baboon models (Mueller et al, 2002; 
Gollackner et al, 2003). Whether PCMV would be transmitted to human cells outside 
the xenograft is unclear, as previous studies have failed to provide evidence for PCMV 
infection of human cells in vitro (Tucker et al, 1999), although only two cell lines were 
tested, while no in vivo studies have been performed to date. In order to avoid the 
potential zoonotic transmission of porcine viruses in xenotransplantation, it is ideal to 
eliminate as many potential pathogens as possible from pigs being bred for xenograft 
organs. For this, defined breeding methods to eliminate infectious agents from pigs and 
stringent testing of donor animals are required. It is possible to exclude most pathogens 
by caesarian delivery and barrier-rearing of donor animals (Tucker et al, 2002a). For the 
first time, the results obtained in Chapter 4 show that PCMV can be eliminated from 
pigs by these methods. If zoonotic transmission could not be prevented, through the 
failure of screening methods, knowledge of the antiviral susceptibility of PCMV would 
be essential, as PCMV would undoubtedly be reactivated under the strong 
immunosuppressive conditions (Mueller et al, 2002; Gollackner et al, 2003; Mueller et 
al, 2003).
In this chapter, the efficacy of anti-herpetic agents currently licensed for use in the 
treatment of human herpesvirus infections to prevent PCMV replication in vitro was 
determined. PCMV infection was established in PFT cells, an adherent, fibroblast-like 
cell line. PCMV was very slow growing in these cells with CPE detected 7 dpi with 
PCMV TCS. In addition, the continuous porcine T cell line, L45, was also investigated 
for susceptibility to PCMV infection, since PCMV is closely related to HHV-6 and -7, 
which are T cell-tropic viruses. Although L45 cells were susceptible to PCMV 
infection, chronic infection could not be established due to the slow growth of PCMV in 
this suspension culture. Since virus titre could not be determined by plaque assay using 
PFT cells, chronically-infected PFT-PCMV cells were divided between culture flasks 
and incubated with each concentration of antiviral tested. Real-time PCMV PCR was
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used to calculate the effect of each antiviral, at three different concentrations, on PCMV 
viral load in supernatant over a 14 day period, and in DNA extracted from cells at day
14. In this cell culture system, ganciclovir and cidofovir (both EC50 <1 (ig/ml) were the 
most effective against PCMV replication, however, some cytotoxicity was associated 
with the highest concentration of cidofovir tested. Foscamet (EC50 within range 25-50 
fig/ml) and aciclovir (EC50 >25 pl/ml) were the least effective antivirals.
The activity of ganciclovir and to a lesser extent aciclovir suggests the presence of a 
HCMV UL97 gene homologue in the PCMV genome, as these drugs require initial 
phosphorylation by viral-encoded protein kinases. Such a gene has yet to be identified 
and characterised in PCMV.
It is possible that the long intracellular half-life of cidofovir contributed to its antiviral 
activity against PCMV in this study. The long half-life of cidofovir (Ho et al, 1992) 
permits the drug to be administered once weekly in induction therapy, and twice weekly 
for maintenance therapy for HCMV infection. In this study, the replacement of 
cidofovir in the cell culture flasks every two days meant that high levels of the drug may 
have built up in the cells thus exaggerating its antiviral effect, and potentially 
contributing to the cytotoxicity found at the highest concentration tested. Ganciclovir 
and aciclovir have much shorter intracellular half-lives of approximately 1 day and 1-2 
hours respectively (Lietman & Laskin, 1997), and are therefore less likely to accumulate 
within the cells.
In a recent study, similar antiviral susceptibilities for PCMV were reported to those 
identified in this chapter (Mueller et al, 2003). In that preliminary investigation, the 
level of PCMV infection in the culture system was presented only as a percentage 
reduction in viral load. The results obtained in this chapter confirm and extend those 
from this previous study.
Comparison of the antiviral EC50 values for PCMV determined in this study, with those 
previously obtained for HCMV is difficult, as differing methodologies have been used. 
Several studies have tried to compare the antiviral susceptibilities of different viruses 
obtained by plaque reduction assays and modem molecular methods (Underwood et al,
229
Chapter 6: Susceptibility o f PCMV to antiviral drugs
1998; Stranska et al, 2002), but have produced varying results suggesting that there is 
not a consistent relationship between the two methods.
In the case of antiviral agents that interfere with DNA replication, there is a delicate 
balance between cytotoxicity and efficacy. Cytotoxicity in vitro is often determined by 
trypan blue exclusion. However in this study, since PFT cells are adherent, and the 
culture medium was replaced at regular intervals throughout the study, this method was 
not feasible. Cytotoxicity was therefore best determined by counting the total number of 
remaining, adherent PFT-PCMV cells harvested following incubation with the antiviral 
agents. Trypan blue staining of cells showed that most adherent cells (>95 %) were 
living. Cytotoxicity results were confirmed in a parallel study, using cellular DNA 
extracted at day 14 from uninfected adherent cells, cultured with each concentration of 
antiviral, as a marker of the total cell count.
Although only one isolate of PCMV was tested, it is highly probable that it is 
representative of the antiviral activity of agents against PCMV. In particular, the DNA 
polymerase genes of PCMV strains B6 and OF-1, and isolate 55b are >99.3 % identical 
at the amino acid level (Goltz et al, 2000).
Following retrospective PCMV DNA real-time PCR analysis of the viral load in the 
blood of piglets monitored from birth, it was not possible to determine the doubling 
time of PCMV replication in vivo due to late and infrequent sampling. The dynamics of 
HCMV replication in vivo has previously been determined in our laboratory (Emery et 
al, 1999). In this study, a direct estimate of the doubling time of HCMV in BMT 
recipients was obtained by measuring the viral load in blood, sampled on average once 
per week. Previously, HCMV had been described as a slowly replicating virus, based on 
the slow development of CPE in virus culture, however, the results of this study 
demonstrated that the doubling time of HCMV in blood during active infection is ~1 
day, when frequent samples are collected, showing that HCMV DNA replication in vivo 
is in fact a highly dynamic process. These results have significant implications for the 
treatment of HCMV infections. Similarly, should PCMV be transmitted to humans 
following xenotransplantation, knowledge of the dynamics of PCMV replication in vivo 
would have implications for it’s treatment in these patients.
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In solid-organ allograft recipients either ganciclovir prophylaxis or pre-emptive therapy 
is used to treat HCMV infections posttransplant. Although in vivo studies in a porcine 
model are needed to confirm the results obtained in this chapter, they suggest that 
ganciclovir may also be used to treat any potential PCMV infections that may arise 
following xenotransplantation, with cidofovir providing an alternative drug for 
management.
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Xenotransplantation of porcine tissues and organs has been proposed to alleviate the 
current shortfall in human donor organs available for transplant. For clinical 
xenotransplantation to be feasible, several significant immunological hurdles need to be 
overcome. One of these is HAR, mediated by antibodies against glycoproteins 
containing terminal aGal sugar residues, which activate complement and lead to 
vascular graft loss within hours. Molecular approaches used to abrogate this response 
include the genetic modification of pig endothelium to express human complement 
control factors CD55 (Bhatti et al, 1999; Cozzi et al, 2000), CD46 (Diamond et al, 
2001; Adams et al, 2001) and CD59 (Fodor et al, 1994; Diamond et al, 1996). Porcine 
xenografts expressing these proteins have been shown to prevent HAR in nonhuman 
primate models of xenotransplantation. In addition, it has recently been possible to 
knockout the al,3G T gene, which adds these terminal aGal sugars onto the surface of 
porcine cells, in pigs (Phelps et al, 2003), however, extensive studies of these knockout 
animals to reduce donor immunogenicity have yet to be reported.
While advances have been made in overcoming immune rejection, xenotransplantation 
has raised considerable safety concerns regarding the potential for the transmission of 
porcine infectious agents, particularly viruses, to humans, and pigs being bred for use in 
xenotransplantation will need to be free from a long list of porcine infectious agents 
(Onions et al, 2000). Viruses of particular concern include those transmitted in the 
germline or in utero, such as members of the retrovirus or herpesvirus families (Magre 
et al, 2003), since they will potentially be difficult to eliminate from pigs being bred for 
xenograft organs. Much of the recent research in this area has focused on the porcine 
endogenous retroviruses which have been shown to be capable of infecting human cells 
in vitro (Patience et al, 1997a; Wilson et al, 1998; Martin et al, 1998; Martin et al,
2000), and crossing the species barrier in vivo into mice (van der Laan et al, 2000). 
However, retrospective analysis of human recipients of porcine xenografts, has revealed 
no evidence of PERV transmission to humans, despite long-term microchimerism in 
some patients (Heneine et al, 1998; Patience et al, 1998; Paradis et al, 1999; Pitkin & 
Mullon, 1999; Schumacher et al, 2000; Dinsmore et al, 2000; Levy et al, 2000). These 
patients were however, never tested for the presence of other porcine infectious agents 
such as herpesviruses. So far, five herpesviruses have been identified in pigs: these 
being PRV, PCMV, and three recently identified PLHVs, -1,-2 and -3 (Ehlers et al, 
1999; Chmielewicz et al, 2003b).
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PCMV is a betaherpesvirus which is endemic in the world pig population, with over 90 
% of pigs being seropositive in the UK, many of which are from well-managed high 
health status farms (Edington, 1999). Although PCMV was originally classified as a 
betaherpesvirus, genus Cytomegalovirus, based on the formation of characteristic 
cytomegalic inclusions in infected cells, recent sequence analysis of the DNA 
polymerase gene (Goltz et al, 2000), the major capsid protein gene (Rupasinghe et al,
2001), and the glycoprotein B gene (Widen et al, 2001), has revealed that the virus is in 
fact more closely related to HHV-6 and -7, which are classified into the genus 
Roseolovirus. Since PCMV does not have a major economic impact on pig farming, 
much of what we know about the epidemiology of PCMV is based on studies carried 
out by Edington et al in the 1970s. PCMV causes generalised infection in newborn 
piglets, leading to foetal and piglet deaths, ranting, rhinitis and pneumonia, while 
infection in adults is generally silent. Virus was thought to be transmitted horizontally 
and in utero, with a common mode of transmission being through infected nasal 
droplets (Plowright et al, 1976).
PCMV represents a potential zoonotic risk in xenotransplantation since its human 
counterpart, HCMV, is frequently transmitted from the donor organ and reactivates 
posttransplant where it is associated with end-organ disease and graft rejection 
(Fishman & Rubin, 1998). In addition, BCMV is the only infectious virus which has 
been transmitted to humans following xenotransplantation, when it was isolated from 
the peripheral blood of a human recipient of a baboon liver (Michaels et al, 2001). As a 
herpesvirus, PCMV has the ability to remain in the host life-long, following primary 
infection, including a latent phase, and may reactivate periodically to produce infectious 
virus and potentially cause disease. Indeed, reactivation of latent PCMV has been 
demonstrated following the administration of immunosuppressive agents in pigs 
(Edington et al, 1976b; Narita et al, 1985). The major theoretical concern associated 
with PCMV in the xenotransplantation setting is the possibility that PCMV, transplanted 
in a latent form within the xenograft, might reactivate and result in graft rejection or 
direct damage to the organ. Recent evidence has shown that PCMV is often reactivated 
and is associated with invasive disease in porcine organs transplanted into baboons, 
although reactivation appears to be limited to the porcine organ (Mueller et al, 2002; 
Mueller et al, 2004). PCMV reactivation in the xenograft may also contribute to
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consumptive coagulopathy observed in pig-to-nonhuman primate xenotransplantation, a 
condition that could only be reversed by removal of the xenograft (Gollackner et al, 
2003). Whether PCMV would subsequently spread to human cells outside the xenograft 
is unclear as previous studies have failed to provide evidence for PCMV infection of 
human cells in vitro (Tucker et al, 1999), although only two cell lines have been tested, 
while no in vivo studies have been performed to date. Co-culture of PCMV-infected 
macrophages with human B cells (Raji cells) and HEK293 cells, did not facilitate 
transmission. However, these in vitro cell culture experiments do not provide the same 
degree of chronic cell-to-cell contact that would be present following 
xenotransplantation, which includes intimate connection of the graft to the human 
vascular system, coupled with inflammatory up-regulation of multiple genes including 
those of herpesviruses. Even in the absence of transmission to the human recipient, the 
results of Mueller et al suggest that reactivation of PCMV in the xenograft could 
potentially compromise graft function and survival.
The initial aim of this thesis was to develop qualitative and QC PCR assays for the 
detection and quantification of PCMV DNA. Primers were designed from a region of 
the DNA polymerase gene of PCMV (Widen et al, 1999), and were shown by BLAST 
analysis to share 100 % nucleotide identity with sequence data for the DNA polymerase 
gene of all three PCMV strains (55b, B6 and OF-1), deposited in Genbank, suggesting 
their ability to amplify different isolates. The qualitative PCR was found to be sensitive 
to 5 genome copies per reaction and did not amplify HCMV, HHV-6 or -7 sequences. 
The QC PCR is based on the coamplification of the test sample with an internal 
competitor, which differs from the wild-type sequence by the presence of a unique 
restriction endonuclease site in the middle of the amplicon. The Sma I restriction 
endonuclease site was introduced into the middle of the PCMV amplicon by PCR- 
mediated, site-directed mutagenesis, similar to the method described by Fox et al (Fox 
et al, 1992). The PCMV QC PCR was shown to be accurate and reproducible over a 
broad dynamic range (Fryer et al, 2001).
These assays were subsequently used to investigate the epidemiology of PCMV in pigs 
being bred for xenograft organs at Imutran Ltd, and in particular, to investigate the 
prevalence, quantity and organ distribution of PCMV in immunocompetent and 
immunosuppressed pigs, to investigate when vims is acquired and examine methods to
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eliminate PCMV from these animals (Clark et al, 2003). A range of porcine organs and 
clinical samples were tested from conventionally-reared CD55 transgenic Large White 
pigs. The results showed that the virus was persistent in a range of organs from adult 
pigs aged > 15  months, including those intended as potential xenografts, namely the 
heart, kidney and liver. Viral loads in these tissues were low indicating either latent or 
low-level active infection. Meanwhile, in 3-5 week old weaned piglets infection was 
widely disseminated, with high viral loads detected in tissues. This suggested that 
infection was occurring early in life possibly in the early post-weaning period following 
mixing of animals.
The next aim was to further investigate when virus is acquired, by testing foetal spleen 
samples from PCMV-positive sows and by monitoring piglets for PCMV viraemia 
following birth. The results showed that piglets monitored from birth acquired PCMV 
post-natally at 2-5 weeks of age. Although the precise source of virus was not 
determined in the two litters examined, the timing of infection correlated with their 
movement to a building with shared air space with other pigs. In addition, there was no 
evidence of infection in utero when foetal spleen was sampled at day 86 out of an 
average full-term gestation of 114 days. These results suggest that acquisition of the 
virus predominantly occurred in the post-natal period rather than in utero. These results 
were in agreement with the epidemiology of PCMV in commercial pig herds (Plowright 
et al, 1976). Importantly, the results showed that hysterotomy-derived, barrier-reared 
animals did not acquire PCMV in the post-natal period, up to the age of 21 weeks, and 
that transplacental infection from PCMV-positive sows did not occur. These results 
suggest that although transplacental transmission of PCMV can occur following the 
experimental infection of pregnant sows with or without the presence of circulating 
antibody (Edington et al, 1977; Edington et al, 1988a; Edington et al, 1988b), it is 
however uncommon in the conventional setting, if it occurs at all. These findings 
suggest that PCMV can realistically be targeted for eradication from pigs being bred for 
xenograft organs.
In order to determine the potential for PCMV reactivation in the transplant setting, the 
effect of standard immunosuppressive therapy on PCMV viral loads in treated and 
control pigs was investigated. Gnotobiotic, SEW and conventionally-reared pigs (with 
appropriate control groups) were subjected to a 2 month period of oral
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immunosuppression including Cyclosporin A, azathioprine and prednisolone. In this 
study, such immunosuppression did not appear to affect the PCMV viral load in the 
tissues investigated, although the study was limited by the small number of pigs tested, 
and by the fact that the pigs were not examined throughout the period of 
immunosuppression.
The proposed method for the large-scale production of pigs for xenotransplantation 
involves caesarian delivery followed by barrier-rearing of source animals in closed 
cohorts (Onions et al, 2000). The results from this thesis suggest that PCMV could be 
eliminated from pigs being bred for xenograft organs by these methods. In addition, 
these methods have recently been demonstrated to exclude a number of other porcine 
infectious agents such as porcine circoviruses (Tucker et al, 2003). However, the 
prevalence of PLHV was only reduced by SPF breeding, suggesting that PLHV transfer 
in utero is rare. It should therefore be feasible to derive animals that are free from 
PLHVs and porcine circoviruses.
If xenotransplantation is to proceed, PCMV-free breeding stocks will need to be 
established in al,3GT knockout pigs. The transmission of PCMV should then be 
preventable, first in nonhuman primate models of xenotransplantation, and then in 
humans if clinical trials proceed. Routine monitoring of these source pig cohorts for the 
presence of specific porcine infectious agents such as PCMV will be necessary at 
intervals throughout the life of the source pig. This will include extensive analysis of 
sentinel animals, representative of the entire cohort, at two months of age and prior to 
approval of the organs from the cohort for human clinical use (Onions et al, 2000). The 
results obtained in this thesis suggest that the spleen of these sentinel animals should be 
tested by PCMV PCR, meanwhile, at the time of transplant rapid PCR testing of this 
non-xenograft organ, should be performed in order to confirm the SPF status of the 
individual donor animal, with an appropriate quantity of input DNA added.
The fact that PCMV was not always detected in readily available samples such as blood 
or serum from seropositive pigs in chapter 4, highlights the need for a reliable 
serological assay for PCMV. Serological assays that have been developed for PCMV 
rely on the in vitro culturing of the virus in either primary alveolar macrophages or pig 
fallopian tube cells (Plowright et al, 1976; Rhonduis et al, 1980; Tajima et al, 1993).
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Since the virus is slow growing in these cells, these assays can be time consuming. The 
use of baculovirus expression systems to produce recombinant viral immunogenic 
proteins in insect cells provides an alternative approach to these in vitro cultivation 
systems. Since glycoprotein B is the major immunodominant protein of HCMV, being 
the target of 40-70 % of virus-neutralising antibodies (Britt et al, 1990), PCMV gB was 
cloned and expressed in insect cells using a baculovirus expression system, and used to 
develop a recombinant protein-based serological assay for PCMV. In addition to the 
full-length ORF of PCMV gB, a truncated version of the protein, excluding the 
proposed transmembrane anchor regions, was cloned into the baculovirus vector. Both 
PCMV gB proteins were found to be expressed in Sf9 and High Five insect cells 2-4 
dpi, however, the truncated protein was not secreted into the culture medium as 
expected. Both proteins were found to be immunogenic by PCMV IIF assay, and did not 
cross-react with anti-HCMV gB monoclonal antibodies. This fact is important when 
screening human recipients of porcine xenografts for the presence of PCMV, although 
the cross-reactivity of PCMV gB with anti-HCMV, HHV-6 and -7 polyclonal antibodies 
remains to be determined. The IIF assay of porcine serum samples from adult pigs and 
piglets from Imutran Ltd, corresponded well with the PCMV PCR results of DNA 
extracted from a range of organs and clinical samples from these animals in chapter 4. 
These results highlight the potential use of recombinant PCMV gB in a serological 
assay for PCMV. Although time constraints did not allow further development of the 
PCMV ELISA using recombinant PCMV gB, this assay would allow the screening of a 
large number of samples.
If zoonotic transmission of PCMV in xenotransplantation could not be prevented, 
presumably through the failure of screening methods, then knowledge of the antiviral 
susceptibility of PCMV would be essential, as the virus would undoubtedly be 
reactivated under the strong immunosuppressive conditions (Mueller et al, 2002; 
Mueller et al, 2004). Therefore, the final aim of this thesis was to determine the efficacy 
of anti-herpetic agents, currently licensed for use in the treatment and/or prophylaxis of 
human herpesvirus infections, to prevent PCMV replication in vitro (Fryer et al, 2004). 
The antiviral agents used in this study, included ganciclovir, foscamet, cidofovir and 
aciclovir, which are all nucleoside/nucleotide analogue inhibitors of the viral DNA 
polymerase, apart from foscamet which is a pyrophosphate analogue. Ganciclovir is the 
first choice therapy for HCMV infections in the immunocompromised, and in solid-
238
Chapter 7: General discussion
organ allograft recipients, with either prophylactic or pre-emptive strategies employed. 
It has also been used in the treatment of suspected HHV-6 -associated diseases (Johnston 
et al, 1999). PCMV infection was established in PFT cells, an adherent, fibroblast-like 
cell line, in which it has previously been shown to be slow-growing, producing CPE 
approximately 14 dpi (Kawamura et al, 1992). Real-time PCR was used to calculate the 
effect of each antiviral, at three different concentrations, on the PCMV viral load in 
supernatant over a 14 day period, and in DNA extracted from cells at day 14. In 
addition, PCMV IIF was used to determine the effect of each antiviral on PCMV- 
infected cells. In this cell culture system, ganciclovir and cidofovir (both EC50 < 1 
jig/ml) were the most effective against PCMV replication; however, some toxicity was 
associated with the highest concentration of cidofovir tested. Foscamet (EC50 within 
range 25-50 (ig/ml) and aciclovir (EC50 > 25 pg/ml) were the least effective antivirals. 
The antiviral activity of ganciclovir, and to a lesser extent aciclovir, suggests the 
presence of a HCMV UL97 gene homologue in the genome of PCMV. This may need 
to be further investigated in order to determine the mechanism of action of ganciclovir 
against PCMV.
The proposed breeding methods for producing pigs for xenotransplantation should 
eliminate the majority of porcine infectious agents, however, certain viruses such as the 
porcine endogenous vimses will prove more difficult to eliminate. Recent research 
suggests that pigs possess few copies of the HTRC PER Vs, and that these could 
potentially be removed through selective breeding and knockout technologies. If they 
could not be removed, siRNA technology has been suggested as a means of preventing 
PERV expression in xenograft recipients (Karlas et al, 2004). In addition, knowledge of 
the susceptibility of porcine vimses to available antiviral therapies would be useful as it 
would provide therapeutic options should the screening procedure of xenografts fail. 
The results in this thesis show that should it prove necessary, ganciclovir should be 
considered as the first-line therapy for any PCMV infections that may arise following 
xenotransplantation, and that cidofovir provides an alternative chug for management. 
Other studies have suggested that PER Vs are sensitive to AZT and ddGTP (Qari et al, 
2001; Wilhelm et al, 2002).
Recently, five novel herpesviruses were identified in suid species from Africa and 
South-East Asia (Ehlers & Lowden, 2004), highlighting the risk that previously
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unidentified viruses may pose in xenotransplantation. Three of these viruses were 
closely related to known porcine beta and gammaherpesviruses, while two species were 
more closely related to bovine herpesvirus 4. Although these results suggest that there 
are likely to be unidentified porcine herpesviruses present in pig species worldwide, 
pigs being bred for xenograft organs will most likely be derived from well 
characterised, inbred herds. The screening of commercial, experimental and wild pigs 
from Germany, Spain, Sweden, France and the USA by pan-herpes PCR failed to 
identify further porcine herpesviruses (Chmielewicz et al, 2003a).
Whether xenotransplantation becomes a clinical reality is unknown at present. The 
ultimate decision will depend on weighing the potential for new human pathogens 
against the benefit of an unlimited supply of organs.
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